2023

Khanna, D., Denton, C.P., Furst, D.E., Mayes, M.D., Matucci-Cerinic, M., Smith, V., ...Randall, M.J. (2023). A 24-Week, Phase IIa, Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA).. Arthritis and Rheumatology, doi:10.1002/art.42477
Griffiths-Jones, D.J., Garcia, Y.S., Ryder, W.D., Pauling, J.D., Hall, F., Lanyon, P., ...Akil, M. (2023). A Phase II randomised controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).. Rheumatology, doi:10.1093/rheumatology/kead012
Ramyead, S., Denton, C.P., Orteu, C.H., Swale, V., Mayor-Jerez, J., Gardette, E. (2023). A purple plaque in a patient with systemic sclerosis. Journal of Scleroderma and Related Disorders, doi:10.1177/23971983231152342
Werner, F., Prentki Santos, E., Michel, K., Schrader, H., Völker, K., Potapenko, T., ...Schlattjan, M. (2023). Ablation of C-type natriuretic peptide/cGMP signaling in fibroblasts exacerbates adverse cardiac remodeling in mice. JCI Insight, doi:10.1172/jci.insight.160416
Denton, C.P., del Galdo, F., Khanna, D., Vonk, M.C., Chung, L., Johnson, S.R., ...Zecchin, C. (2023). Biological and clinical insights from a randomised phase II study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/keac300
Bruni, C., Buch, M.H., Djokovic, A., De Luca, G., Dumitru, R.B., Giollo, A., ...Suliman, Y.A. (2023). Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment. Journal of Scleroderma and Related Disorders, doi:10.1177/23971983231163413
Khanna, D., Maher, T.M., Volkmann, E.R., Allanore, Y., Smith, V., Assassi, S., ...Stock, C. (2023). Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression. RMD Open, 9 (1), doi:10.1136/rmdopen-2022-002859
Tornling, G., Batta, R., Salvail, D., Raud, J., Denton, C.P. (2023). Effects of the Oral Angiotensin II Type 2 Receptor Agonist C21 in Sugen-Hypoxia Induced Pulmonary Hypertension in Rats. International Journal of Molecular Sciences, 24 (8), doi:10.3390/ijms24087478
Spiera, R., Kuwana, M., Khanna, D., Hummers, L., Frech, T.M., Stevens, W., ...Jun, J.-.B. (2023). Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, doi:10.1002/art.42510
S. Rapoport, C., Choi, A.K., Kwakkenbos, L., Carrier, M.E., Henry, R.S., Mouthon, L., ...Fortuné, C. (2023). Evaluation of Measurement Properties and Differential Item Functioning in the English and French Versions of the University of California, Los Angeles, Loneliness Scale-6: A Scleroderma Patient-Centered Intervention Network (SPIN) Study. Arthritis Care and Research, doi:10.1002/acr.25115
Denton, C.P., De Lorenzis, E., Roblin, E., Goldman, N., Alcacer-Pitarch, B., Blamont, E., ...Del Galdo, F. (2023). Management of systemic sclerosis: British Society for Rheumatology guideline scope. Rheumatology Advances in Practice, 7 (1), doi:10.1093/rap/rkad022
Papaioannou, I., Dritsoula, A., Baliga, R., Trinder, S., Cook, E., Xu, S., ...Ponticos, M. (2023). NKX2-5 is a critical regulator of vessel remodelling in scleroderma-associated pulmonary arterial hypertension. JCI Insight,
Maclean, R.H., Ahmed, F., Ong, V.H., Murray, C.D., Denton, C.P. (2023). Phenome-Wide Association Study of Drugs and Co-morbidities Associated with Gastrointestinal Dysfunction in Systemic Sclerosis. The Journal of Rheumatology, jrheum.220990. doi:10.3899/jrheum.220990
Ghuman, A., Khanna, D., Lin, C.J.F., Furst, D.E., Raghu, G., Martinez, F.J., ...Nihtyanova, S.I. (2023). Prognostic and predictive markers of systemic sclerosis-interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology, doi:10.1093/rheumatology/kead234
Teles, C., Liyanage, C.K., Chow, G., Denton, C.P., Ong, V. (2023). Relapsing polychondritis in systemic sclerosis: A rare vasculitic mimic. Journal of Scleroderma and Related Disorders, 239719832211415. doi:10.1177/23971983221141599
Clark, K.E.N., Gak, N., Orteu, C.H., Ong, V.H., Derrett-Smith, E.C., Denton, C.P. (2023). Skin biopsy analysis of concurrent keloidal morphoea and systemic sclerosis confirms overlapping pathogenic pathways.. Clin Exp Rheumatol, doi:10.55563/clinexprheumatol/dvxhgc
Pope, J.E., Denton, C.P., Johnson, S.R., Fernandez-Codina, A., Hudson, M., Nevskaya, T. (2023). State-of-the-art evidence in the treatment of systemic sclerosis. Nature Reviews Rheumatology, 1-15. doi:10.1038/s41584-023-00909-5
Yu, L., Domsic, R.T., Saketkoo, L.-.A., Withey, J., Frech, T.M., Herrick, A.L., ...Khanna, D. (2023). The Assessment of Systemic sclerosis-associated RAynaud's Phenomenon (ASRAP) questionnaire: Item Bank and Short Form Development.. Arthritis Care and Research, doi:10.1002/acr.25038
Distler, J.H.W., Riemekasten, G., Denton, C.P. (2023). The Exciting Future for Scleroderma: What Therapeutic Pathways Are on the Horizon?. Rheumatic Disease Clinics of North America, doi:10.1016/j.rdc.2023.01.014
Saracino, A.M., Kelberman, D., Otto, G.W., Gagunashvili, A., Abraham, D.J., Denton, C.P. (2023). Unravelling morphoea aetiopathogenesis by next-generation sequencing of paired skin biopsies.. Arch Dermatol Res, doi:10.1007/s00403-023-02541-5

2022

Flurey, C.A., Pauling, J.D., Saketkoo, L.A., Denton, C.P., Galdas, P., Khanna, D., ...Hughes, M. (2022). "I turned in my man card": A qualitative study of the experiences, coping styles and support needs of men with systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/keac585
Franks, J.M., Toledo, D.M., Martyanov, V., Wang, Y., Huang, S., Wood, T.A., ...Derrett-Smith, E. (2022). A Genomic Meta-Analysis of Clinical Variables and Their Association with Intrinsic Molecular Subsets in Systemic Sclerosis. Rheumatology (Oxford), keac344. doi:10.1093/rheumatology/keac344
Griffiths-Jones, D., Garcia, Y.S., Ryder, D., Pauling, J., Hall, F., Lanyon, P., ...Herrick, A. (2022). A PHASE II RANDOMISED CONTROLLED TRIAL OF ORAL PREDNISOLONE IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (PREDSS).
Ahmed, F., Maclean, R.H., Nihtyanova, S.I., Ong, V.H., Murray, C.D., Denton, C.P. (2022). Autoantibody Predictors of Gastrointestinal Symptoms in Systemic Sclerosis. Rheumatology, doi:10.1093/rheumatology/keab395
Cole, A., Denton, C.P. (2022). Biomarkers in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD). Current Treatment Options in Rheumatology, doi:10.1007/s40674-022-00196-3
Clark, K.E.N., Campochiaro, C., Host, L.V., Sari, A., Harvey, J., Denton, C.P., Ong, V.H. (2022). Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes. Scientific Reports, 12 doi:10.1038/s41598-022-15062-4
Kerick, M., Acosta-Herrera, M., Pilar Simeon-Aznar, C., Luis Callejas, J., Assassi, S., Proudman, S.M., ...de Vries-Bouwstra, J.K. (2022). Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis. npj Genomic Medicine, 7 doi:10.1038/s41525-022-00327-8
Clark, K., Cole, A., Shiwen, X., Ong, V., Buckley, C.D., Denton, C.P. (2022). DEFINING DISTINCT RESIDENT AND MIGRATORY FIBROBLAST POPULATIONS FROM SKIN BIOPSIES IN SYSTEMIC SCLEROSIS.
Cole, A., Thomas, R., Goldman, N., Howell, K., Chakravarty, K., Denton, C.P., Ong, V.H. (2022). Diffuse cutaneous systemic sclerosis following SARS-Co V-2 vaccination. Journal of Autoimmunity, 102812. doi:10.1016/j.jaut.2022.102812
Knight, D.S., Karia, N., Cole, A.R., Maclean, R.H., Brown, J.T., Masi, A., ...Venneri, L. (2022). Distinct cardiovascular phenotypes are associated with prognosis in systemic sclerosis: a cardiovascular magnetic resonance study. European Heart Journal - Cardiovascular Imaging, doi:10.1093/ehjci/jeac120
Nihtyanova, S.I., Schreiber, B.E., Ong, V.H., Wells, A.U., Coghlan, J.G., Denton, C.P. (2022). Dynamic prediction of pulmonary hypertension in systemic sclerosis using landmark analysis. Arthritis and Rheumatology, doi:10.1002/art.42349
Volkmann, E.R., Kreuter, M., Hoffmann-Vold, A.M., Wijsenbeek, M., Smith, V., Khanna, D., ...Alves, M. (2022). Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology, doi:10.1093/rheumatology/keac091
Beesley, C.F., Goldman, N.R., Taher, T.E., Denton, C.P., Abraham, D.J., Mageed, R.A., Ong, V.H. (2022). Dysregulated B cell function and disease pathogenesis in systemic sclerosis. Frontiers in Immunology, 13 doi:10.3389/fimmu.2022.999008
Khanna, D., Maher, T., Volkmann, E., Allanore, Y., Smith, V., Assassi, S., ...Stock, C. (2022). EFFECT OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND RISK FACTORS FOR RAPID DECLINE IN FORCED VITAL CAPACITY: FURTHER ANALYSES OF THE SENSCIS TRIAL.
Kuster, S., Jordan, S., Elhai, M., Held, U., Steigmiller, K., Bruni, C., ...Rednic, S. (2022). Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD open, 8 (2), doi:10.1136/rmdopen-2022-002477
Assassi, S., Kuwana, M., Denton, C.P., Maher, T., Diefenbach, C., Ittrich, C., ...Distler, O. (2022). EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD).
Cantanhede, I.G., Liu, H., Liu, H., Balbuena Rodriguez, V., Shiwen, X., Ong, V.H., ...Lima-Filho, J.L. (2022). Exploring metabolism in scleroderma reveals opportunities for pharmacological intervention for therapy in fibrosis. Frontiers in Immunology, 13 doi:10.3389/fimmu.2022.1004949
Denton, C.P., Goh, N.S., Humphries, S.M., Maher, T.M., Spiera, R., Devaraj, A., ...Alves, M. (2022). Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology, doi:10.1093/rheumatology/keac535
Wasson, C.W., Caballero-Ruiz, B., Gillespie, J., Derrett-Smith, E., Mankouri, J., Denton, C.P., ...Del Galdo, F. (2022). Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF-β/Wnt3a Is Mediated by GLI2 Upregulation. Cells, 11 (3), doi:10.3390/cells11030530
Clark, K.E.N., Csomor, E., Campochiaro, C., Galwey, N., Nevin, K., Morse, M.A., ...Derrett-Smith, E. (2022). Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. The Lancet Rheumatology, 4 (7), e507-e516. doi:10.1016/S2665-9913(22)00094-7
Khanna, D., Lin, C.J.F., Furst, D.E., Wagner, B., Zucchetto, M., Raghu, G., ...Denton, C.P. (2022). Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.202103-0714OC
Al-Adwi, Y., Westra, J., Van Goor, H., Burgess, J.K., Denton, C.P., Mulder, D.J. (2022). Macrophages as determinants and regulators of fibrosis in systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/keac410
Vanhaecke, A., Cutolo, M., Distler, O., Riccieri, V., Allanore, Y., Denton, C.P., ...Avouac, J. (2022). Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. Rheumatology, doi:10.1093/rheumatology/keac079
Kuwana, M., Allanore, Y., Denton, C.P., Distler, J.H., Steen, V., Khanna, D., ...Miede, C. (2022). Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. Arthritis & Rheumatology, 74 (3), 518-526. doi:10.1002/art.41965
Campochiaro, C., Suliman, Y.A., Hughes, M., Schoones, J., Giuggioli, D., Moinzadeh, P., ...Chung, L. (2022). NON-SURGICAL LOCAL TREATMENTS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW.
Kreuter, M., Denton, C.P., Ho, L.A., Hoyles, R.K., Glaspole, I., Suda, T., ...Maher, T.M. (2022). Progression of systemic sclerosis-associated ILD (SSc-ILD) and effect of nintedanib in subgroups by monocyte and neutrophil counts.
Hughes, M., Allanore, Y., Baron, M., Del Galdo, F., Denton, C.P., Frech, T., ...Herrick, A.L. (2022). Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. The Lancet Rheumatology, doi:10.1016/S2665-9913(22)00183-7
Kwakkenbos, L., Carrier, M.E., Welling, J., Levis, B., Levis, A.W., Sauve, M., ...Carboni-Jiménez, A. (2022). Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial. Trials, 23 doi:10.1186/s13063-022-06923-4
Cole, A., Ong, V.H., Denton, C.P. (2022). Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis. Clinical Reviews in Allergy and Immunology, doi:10.1007/s12016-022-08945-x
Mehta, P., Hoyles, R.K., Gunawardena, H., Gooptu, B., Choudhary, N., Heightmann, M.J., ...Hamdulay, S. (2022). Rheumatologists have an important role in the management of interstitial lung disease (ILD): a cross-speciality, multi-centre, U.K. perspective.. Rheumatology (Oxford), doi:10.1093/rheumatology/keac061
Bjorkekjaer, H.J., Bruni, C., Carreira, P., Airo, P., Simeon-Aznar, C.P., Truchetet, M.E., ...Denton, C.P. (2022). RISK STRATIFICATION APPROACHES PERFORM DIFFERENTLY IN SSC-ASSOCIATED PAH IN EUSTAR.
Maher, T.M., Tudor, V., Saunders, P., Gibbons, M., Fletcher, S., Parfrey, H., ...Wells, A.U. (2022). Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease ( RECITAL): A Multi-Centre Randomised Controlled Trial.
Maher, T.M., Tudor, V.A., Saunders, P., Gibbons, M.A., Fletcher, S.V., Denton, C.P., ...Kokosi, M. (2022). Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00359-9
Shah, S., Denton, C.P. (2022). Scleroderma autoantibodies in guiding monitoring and treatment decisions. Current Opinion in Rheumatology, Publis doi:10.1097/BOR.0000000000000904
De Lorenzis, E., Kakkar, V., Ross, R., Di Donato, S., Barnes, T., Saleem, B., ...Douglas, K. (2022). SERUM INTERFERON SCORE PREDICTS SEVERITY OF PATIENT REPORTED HAND DISABILITY IN SYSTEMIC SCLEROSIS.
Herrick, A.L., Assassi, S., Denton, C.P. (2022). Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need.. Nature Reviews Rheumatology, doi:10.1038/s41584-022-00765-9
Suliman, Y.A., Campochiaro, C., Hughes, M., Schoones, J., Giuggioli, D., Maltez, N., ...Allanore, Y. (2022). SURGICAL MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW..
Maltez, N., Ross, L., Hughes, M., Schoones, J., Baron, M., Chung, L., ...Moinzadeh, P. (2022). SYSTEMIC PHARMACOLOGICAL TREATMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW.
Gordon, J.K., Showalter, K., Wu, Y., Kwakkenbos, L., Carrier, M.-.E., Henry, R.S., ...Cañedo-Ayala, M. (2022). Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study.. Lancet Rheumatol, doi:10.1016/S2665-9913(21)00416-1
Roofeh, D., Brown, K.K., Kazerooni, E.A., Tashkin, D., Assassi, S., Martinez, F., ...Chung, L. (2022). Systemic Sclerosis Associated Interstitial Lung Disease: A Conceptual Framework for Subclinical, Clinical, and Progressive Disease.. Rheumatology (Oxford), doi:10.1093/rheumatology/keac557
Jerjen, R., Nikpour, M., Krieg, T., Denton, C.P., Saracino, A.M. (2022). Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.. Journal of the American Academy of Dermatology, doi:10.1016/j.jaad.2021.10.065
Jerjen, R., Nikpour, M., Krieg, T., Denton, C.P., Saracino, A.M. (2022). Systemic sclerosis in adults. Part II: Management and therapeutics.. J Am Acad Dermatol, doi:10.1016/j.jaad.2021.10.066
Hoffmann-Vold, A.M., Distler, O., Bruni, C., Denton, C.P., de Vries-Bouwstra, J., Matucci Cerinic, M., ...Gabrielli, A. (2022). Systemic sclerosis in the time of COVID-19. The Lancet Rheumatology, 4 (8), e566-e575. doi:10.1016/S2665-9913(22)00130-8
Hughes, M., Denton, C.P. (2022). The critical need for patient-reported outcome measures to assess the severity and impact of systemic sclerosis. British Journal of Dermatology, doi:10.1111/bjd.20777
Villanueva-Martin, G., Acosta-Herrera, M., Kerick, M., López-Isac, E., Simeón, C.P., Callejas, J.L., ...Australian Scleroderma Interest Group, (.A.S.I.G.). (2022). The Effect of Body Fat Distribution on Systemic Sclerosis. Journal of Clinical Medicine, 11 (20), doi:10.3390/jcm11206014
Orlandi, M., Landini, N., Sambataro, G., Nardi, C., Tofani, L., Bruni, C., ...Hughes, M. (2022). The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, doi:10.1093/rheumatology/keab615
Spierings, J., Ong, V.H., Denton, C.P. (2022). Three Cases of Systemic Sclerosis Within One Family With Different Antibodies and Clinical Features.. Journal of Rheumatology, doi:10.3899/jrheum.211139
Kakkar, V., Assassi, S., Allanore, Y., Kuwana, M., Denton, C.P., Khanna, D., Del Galdo, F. (2022). Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Current Opinion in Rheumatology, 34 (6), 357-364. doi:10.1097/BOR.0000000000000907
Ong, V.H., Denton, C.P. (2022). When the game changes: efficacy of rituximab in systemic sclerosis. The Lancet Rheumatology, 4 (8), e527-e529. doi:10.1016/S2665-9913(22)00161-8
Stern, E.P., Host, L.V., Wanjiku, I., Escott, K.J., Gilmour, P.S., Ochiel, R., ...Cadiou, H. (2022). Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. Arthritis Research and Therapy, 24 doi:10.1186/s13075-022-02818-6

2021

Hughes, M., Allanore, Y., El Aoufy, K., Denton, C.P., Khanna, D., Krieg, T., Matucci-Cerinic, M. (2021). A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review. JAMA Dermatology, doi:10.1001/jamadermatol.2021.1463
Spiera, R., Khanna, D., Kuwana, M., Furst, D.E., Frech, T.M., Hummers, L., ...Distler, O. (2021). A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clinical and Experimental Rheumatology, 39 (4), S124-S133.
Hughes, M., Kahaleh, B., Denton, C.P., Mason, J.C., Matucci-Cerinic, M. (2021). ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies.. Rheumatology, doi:10.1093/rheumatology/keab278
Hughes, M., Allanore, Y., Chung, L., Pauling, J.D., Denton, C.P., Matucci-Cerinic, M. (2021). Author Correction: Raynaud phenomenon and digital ulcers in systemic sclerosis. Nature Reviews Rheumatology, 17 (4), 246. doi:10.1038/s41584-021-00591-5
Langridge, B.J., Jeon, F.H.K., Almadori, A., Griffin, M.F., Denton, C.P., Butler, P.E.M. (2021). Autologous lipotransfer can improve the outcomes of localised scleroderma. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 39 (4), S159.
Langridge, B.J., Jeon, F.H.K., Almadori, A., Griffin, M.F., Denton, C.P., Butler, P.E.M. (2021). Autologous lipotransfer canimprove the outcomes of localised scleroderma. Clinical and Experimental Rheumatology, 39 (4), S159-.
Mehta, P., Bunker, C.B., Ciurtin, C., Porter, J.C., Chambers, R.C., Papdopoulou, C., ...Howell, K.J. (2021). Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. The Lancet Infectious Diseases, doi:10.1016/s1473-3099(21)00133-x
Denton, C.P., Spierings, J. (2021). Combining datasets as well as therapies shows improved outcome in connective tissue disease associated pulmonary hypertension. Arthritis and Rheumatology, doi:10.1002/art.41670
Acosta-Herrera, M., Kerick, M., Lopéz-Isac, E., Assassi, S., Beretta, L., Simeón-Aznar, C.P., ...Moroncini, G. (2021). Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-219884
Kreuter, M., Volkmann, E.R., Hoffmann-Vold, A., Wijsenbeek, M.S., Smith, V., Khanna, D., ...Alves, M. (2021). Decline in Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and without Cough: Data from the SENSCIS Trial.
Becker, M.O., Dobrota, R., Garaiman, A., Debelak, R., Fligelstone, K., Tyrrell Kennedy, A., ...Czirják, L. (2021). Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-220702
Highland, K.B., Distler, O., Kuwana, M., Allanore, Y., Assassi, S., Azuma, A., ...Hoffmann-Vold, A.M. (2021). Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. LANCET RESPIRATORY MEDICINE, 9 (1), 96-106.
Stern, E.P., Unwin, R., Burns, A., Ong, V.H., Denton, C.P. (2021). Exploring molecular pathology of chronic kidney disease in systemic sclerosis by analysis of urinary and serum proteins. Rheumatology Advances in Practice, 5 (1), doi:10.1093/rap/rkaa083
Host, L.V., Campochiaro, C., Afonso, A., Nihtyanova, S.I., Denton, C.P., Ong, V.H. (2021). High proton pump inhibitor exposure increases risk of calcinosis in systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/keaa332
Clark, K.E., Campochiaro, C., Csomor, E., Taylor, A., Nevin, K., Morse, M.A., ...Flint, S. (2021). HIGH-DENSITY PROTEOMIC ANALYSIS OF SKIN BLISTER FLUID AND PLASMA IN SYSTEMIC SCLEROSIS IDENTIFIES LOCAL AND SYSTEMIC DIFFERENCES FOR KEY PROTEINS.
Fayed, H., Schreiber, B.E., Denton, C.P., Coghlan, J.G. (2021). Impact of routine screening on detection, severity and outcome of pulmonary arterial hypertension in systemic sclerosis.
Clark, K.E., Campochiaro, C., Csomor, E., Taylor, A., Nevin, K., Galwey, N., ...Wisniacki, N. (2021). INTEGRATED MOLECULAR ANALYSIS OF SYSTEMIC SCLEROSIS SKIN AND BLOOD SHOWS SIGNIFICANT DIFFERENCES BETWEEN MAJOR AUTOANTIBODY SUBGROUPS.
Khanna, D., Denton, C.P. (2021). Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00163-6
Clark, K.E.N., Campochiaro, C., Csomor, E., Taylor, A., Nevin, K., Galwey, N., ...Ong, V.H. (2021). Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2021-220402
Spierings, J., Nihtyanova, S.I., Derrett-Smith, E., Clark, K.E.N., van Laar, J.M., Ong, V., Denton, C.P. (2021). Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/keab604
Lee, Y.C., Fox, R.S., Kwakkenbos, L., Levis, B., Carrier, M.E., Welling, J., ...Bartlett, S.J. (2021). Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. The Lancet Rheumatology, 3 (12), e844-e854. doi:10.1016/S2665-9913(21)00318-0
Spierings, J., Ong, V., Denton, C.P. (2021). PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-219775
Kouranos, V., Host, L.V., Campochiaro, C., Wells, A., Denton, C.P., Ong, V.H., Renzoni, E. (2021). POTENTIAL BENEFIT OF INTRAVENOUS IMMUNOGLOBULIN IN CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASES.
Khanna, D., Lin, C.J.F., Furst, D.E., Zucchetto, M., Raghu, G., Martinez, F.J., Denton, C.P. (2021). Preservation of Lung Function with Tocilizumab in Patients with Systemic Sclerosis Interstitial Lung Disease: Analysis from the Double-Blind Period of a Phase 3 Trial.
Bruni, C., Buch, M.H., Furst, D.E., De Luca, G., Djokovic, A., Dumitru, R.B., ...Bratis, K. (2021). Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, doi:10.1177/23971983211053246
Denton, C.P., Khanna, D. (2021). Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. Lancet Rheumatology, 3 (5), E321-E323. doi:10.1016/S2665-9913(21)00111-9
Suleman, Y., Clark, K.E.N., Cole, A.R., Ong, V.H., Denton, C.P. (2021). Real-world experience of Tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase (ATA) positive patients.. Rheumatology (Oxford), doi:10.1093/rheumatology/keab273
Brown, J.T., Kotecha, T., Steeden, J.A., Fontana, M., Denton, C.P., Coghlan, J.G., ...Muthurangu, V. (2021). Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. Journal of Cardiovascular Magnetic Resonance, 23 (1), doi:10.1186/s12968-021-00817-1
Hughes, M., Denton, C.P., Khanna, D. (2021). Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology, 60 (2), 489-491. doi:10.1093/rheumatology/keaa675
Tam, A.Y.Y., Horwell, A.L., Trinder, S.L., Khan, K., Xu, S., Ong, V., ...Bou-Gharios, G. (2021). Selective deletion of Connective Tissue Growth Factor attenuates experimentally -induced pulmonary fibrosis and pulmonary arterial hypertension.. Int J Biochem Cell Biol, 105961. doi:10.1016/j.biocel.2021.105961
Spierings, J., Ong, V.H., Denton, C.P. (2021). SELF-ASSESSMENT OF SCLERODERMA SKIN THICKNESS: DEVELOPMENT AND EVALUATION OF THE PASTUL QUESTIONNAIRE.
Stock, C.J.W., Hoyles, R.K., Daccord, C., Kokosi, M., Visca, D., De Lauretis, A., ...George, P.M. (2021). Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. Respirology, doi:10.1111/resp.13988
Khanna, D., Tashkin, D.P., Wells, A.U., Seibold, J.R., Wax, S., Vazquez-Mateo, C., ...Denton, C.P. (2021). STRATUS, a Phase II Study of Abituzumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease. Journal of Rheumatology, doi:10.3899/jrheum.191365
Nevskaya, T., Pope, J.E., Turk, M.A., Shu, J., Marquardt, A., van den Hoogen, F., ...Baron, M. (2021). Systematic analysis of the literature in search of defining systemic sclerosis subsets. The Journal of Rheumatology, doi:10.3899/jrheum.201594
Khanna, D., Lescoat, A., Roofeh, D., Bernstein, E.J., Kazerooni, E.A., Roth, M.D., ...Denton, C.P. (2021). Systemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice. Arthritis and Rheumatology, doi:10.1002/art.41933
Lazzaroni, M.-.G., Marasco, E., Campochiaro, C., DeVries-Bouwstra, J., Gonzalez-Perez, M.-.I., Rojas-Serrano, J., ...Furini, F. (2021). The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.. Rheumatology (Oxford), doi:10.1093/rheumatology/keab152
Derrett-Smith, E., Clark, K.E.N., Shiwen, X., Abraham, D.J., Hoyles, R.K., Lacombe, O., ...Ong, V.H. (2021). The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. Arthritis Research and Therapy, 23 doi:10.1186/s13075-021-02592-x
Nordlund, J., Henry, R.S., Kwakkenbos, L., Carrier, M.E., Levis, B., Nielson, W.R., ...Fedoruk, C. (2021). The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 22 (1), doi:10.1186/s13063-021-05827-z
Khanna, D., Linz, C.J.F., Furst, D.E., Zucchetto, M., Raghu, G., Martinez, F.J., Denton, C.P. (2021). Tocilizumab in Systemic Sclerosis Interstitial Lung Disease: Safety and Efficacy in the Double-Blind and Open-Label Periods of a Randomized Controlled Phase 3 Trial.
Khanna, D., Lin, C.J.F., Furst, D.E., Goldin, J., Kim, G., Kuwana, M., ...Shima, Y. (2021). Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg 963, 2020). The Lancet Respiratory Medicine, 9 (3), E29.
Roofeh, D., Lin, C.J.F., Goldin, J., Kim, G.H., Furst, D.E., Denton, C.P., ...focuSSced, i.n.v.e.s.t.i.g.a.t.o.r.s. (2021). Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease. Arthritis and Rheumatology, doi:10.1002/art.41668
Clark, K.E.N., Denton, C.P. (2021). Unravelling extracellular matrix biomarkers in systemic sclerosis. The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30412-4

2020

Hughes, M., Pauling, J.D., Jones, J., Denton, C.P., Domsic, R.T., Frech, T.M., ...McKenzie, L. (2020). A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis.. Arthritis Care Res (Hoboken), doi:10.1002/acr.24127
Allanore, Y., Wung, P., Soubrane, C., Esperet, C., Marrache, F., Bejuit, R., ......I.n.v.e.s.t.i.g.a.t.o.r.s. (2020). A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.. Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218447
Khanna, D., Spino, C., Johnson, S., Chung, L., Whitfield, M., Denton, C.P., ...Molitor, J. (2020). Abatacept in Early Diffuse Cutaneous Systemic Sclerosis - Results of a Phase 2 Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial.. Arthritis Rheumatol, doi:10.1002/art.41055
Bütikofer, L., Varisco, P.A., Distler, O., Kowal-Bielecka, O., Allanore, Y., Riemekasten, G., ...Walker, U.A. (2020). ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis - A EUSTAR analysis. Arthritis Research & Therapy, 22 (1), doi:10.1186/s13075-020-2141-2
Sari, A., Nihtyanova, S.I., Schreiber, B.E., Coghlan, G., Denton, C.P., Ong, V.H. (2020). ALTERED IRON HOMEOSTASIS AND PULMONARY HAEMODYNAMICS IN SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION.
Stern, E.P., Guerra, S.G., Chinque, H., Acquaah, V., González-Serna, D., Ponticos, M., ...Nihtyanova, S.I. (2020). Analysis of anti-RNA polymerase III antibody positive systemic sclerosis suggests altered GPATCH2L and CTNND2 expression in scleroderma renal crisis. Journal of Rheumatology, doi:10.3899/jrheum.190945
Denton, C.P., Ong, V.H. (2020). Challenges in evidence-based therapy for systemic sclerosis associated interstitial lung disease. The Lancet Respiratory Medicine, 8 (3), 226-227. doi:10.1016/S2213-2600(20)30012-6
Denton, C.P., Laird, B., Moros, L., Flores, J.L.L. (2020). Challenges in physician-patient communication for optimal management of systemic sclerosis-associated interstitial lung disease: a discourse analysis.. Clin Rheumatol, doi:10.1007/s10067-020-05063-x
Herrick, A.L., Griffiths-Jones, D.J., Ryder, W.D., Mason, J.C., Denton, C.P. (2020). Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). Journal of Scleroderma and Related Disorders, doi:10.1177/2397198320957552
Campochiaro, C., Clark, K.E.N., Host, L., Sari, A., Denton, C.P., Ong, V.H. (2020). CO-EXISTENCE OF SCLERODERMA HALLMARK AUTOANTIBODIES ASSOCIATES WITH DISTINCT CLINICAL PHENOTYPE.
Oláh, C., Schwartz, N., Denton, C., Kardos, Z., Putterman, C., Szekanecz, Z. (2020). Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Research & Therapy, 22 (1), doi:10.1186/s13075-020-02180-5
Saracino, A.M., George, C., Nihtyanova, S.I., Denton, C.P. (2020). Comparing paediatric- and adult-onset linear morphoea in a large tertiary-referral scleroderma centre. Journal of Scleroderma and Related Disorders, doi:10.1177/2397198320925684
Griffin, M.F., Jeon, F.H.K., Chew, B.J.W., Sherief, A., Denton, C.P., Butler, P.E.M. (2020). Comparison of non-invasive methodologies to assess mouth opening following lipotransfer techniques to reverse oral fibrosis. Clinical and Experimental Rheumatology, 38 Suppl 125 (3), 184.
Lescoat, A., Murphy, S.L., Roofeh, D., Pauling, J.D., Hughes, M., Sandler, R., ...Chung, L. (2020). Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, doi:10.1177/2397198320961967
Denton, C.P., Campochiaro, C., Bruni, C., Distler, O., Iagnocco, A., Matucci Cerinic, M. (2020). COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. Journal of Scleroderma and Related Disorders, doi:10.1177/2397198320963393
Nagaraja, V., Cerinic, M.-.M., Furst, D.E., Kuwana, M., Allanore, Y., Denton, C.P., ...Seibold, J.R. (2020). Current and future outlook on disease modification and defining low disease activity in systemic sclerosis. Arthritis and Rheumatology, doi:10.1002/art.41246
Arbore, G., Ong, V.H., Costantini, B., Denton, C.P., Abraham, D., Placais, L., ...Heck, S. (2020). Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis.. Cellular and Molecular Immunology, doi:10.1038/s41423-019-0360-8
Stock, C.J.W., De Lauretis, A., Visca, D., Daccord, C., Kokosi, M., Kouranos, V., ...Nihtyanova, S. (2020). Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clinical Rheumatology, doi:10.1007/s10067-019-04922-6
Giannakopoulos, I., Griffin, M., Denton, C.P., Butler, P. (2020). Developing a quantitative tool to evaluate dermal fibrosis in systemic sclerosis patients. A case-control study. Clinical and Experimental Rheumatology,
Hughes, M., Alcacer-Pitarch, B., Allanore, Y., Baron, M., Boin, F., Bruni, C., ...Matucci-Cerinic, M. (2020). Digital ulcers: should debridement be a standard of care in systemic sclerosis?. The Lancet Rheumatology, 2 (5), e302-e307. doi:10.1016/S2665-9913(19)30164-X
Goh, N., Denton, C.P., Lynch, D.A., Maher, T.M., Smith, V., Prasse, A., ...Gahlemann, M. (2020). Effect of Nintedanib in Patients with Limited and Extensive Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS Trial.
Jouneau, S., Lescoat, A., Crestani, B., Riemekasten, G., Kondoh, Y., Smith, V., ...Gahlemann, M. (2020). Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Body Mass Index (BMI) at Baseline: Subgroup Analysis of the SENSCIS Trial.
Jeon, F.H.K., Griffin, M., Denton, C.P., Butler, P.E.M. (2020). Feasibility study of stem-cell enriched autologous lipotransfer to treat oro-facial fibrosis in systemic sclerosis (Sys-Stem): Protocol for open-label randomised controlled trial. International Journal of Surgery Protocols, 23 6-10. doi:10.1016/j.isjp.2020.07.002
Nihtyanova, S.I., Derrett-Smith, E.C., Fonseca, C., Ong, V.H., Denton, C.P. (2020). FORCED VITAL CAPACITY IN PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY FIBROSIS: PREDICTORS OF MEANINGFUL DECLINE.
Hughes, M., Pauling, J.D., Armstrong-James, L., Denton, C.P., Galdas, P., Flurey, C. (2020). Gender-related differences in systemic sclerosis. Autoimmunity Reviews, 102494. doi:10.1016/j.autrev.2020.102494
Bossini-Castillo, L., Villanueva-Martin, G., Kerick, M., Acosta-Herrera, M., López-Isac, E., Simeón, C.P., ...Australian Scleroderma Interest Group, (.A.S.I.G.). (2020). Genomic Risk Score impact on susceptibility to systemic sclerosis.. Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218558
Allanore, Y., Bozzi, S., Terlinden, A., Huscher, D., Amand, C., Soubrane, C., ...Hachulla, E. (2020). Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. Arthritis Research and Therapy, 22 (1), doi:10.1186/s13075-020-02329-2
Moezinia, C.J., Ji-Xu, A., Azari, A., Horlick, S., Denton, C., Stratton, R. (2020). Iloprost for COVID-19-related vasculopathy. The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30232-0
Ngcozana, T., Ong, V.H., Denton, C.P. (2020). Improving access to digital ulcer care through nurse-led clinic: a service evaluation. Musculoskeletal Care, doi:10.1002/msc.1433
Stock, C.J., Conti, C., Montero-Fernandez, Á., Caramori, G., Molyneaux, P.L., George, P.M., ...Chua, F. (2020). Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. Thorax, doi:10.1136/thoraxjnl-2020-214579
Yaseen, B., Lopez, H., Taki, Z., Zafar, S., Rosario, H., Abdi, B.A., ...Black, S. (2020). Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology, doi:10.1093/rheumatology/keaa195
Denton, C.P., Yee, P., Ong, V.H. (2020). News and failures from recent treatment trials in systemic sclerosis. Eur J Rheumatol, doi:10.5152/eurjrheum.2020.19187
Nihtyanova, S.I., Derrett-Smith, E.C., Fonseca, C., Ong, V.H., Denton, C.P. (2020). P152 SKIN SCORE TRAJECTORY ASSOCIATES WITH SURVIVAL AND PULMONARY OUTCOME IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
Nihtyanova, S.I., Denton, C.P. (2020). Pathogenesis of systemic sclerosis associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 5 (2_suppl), 6-16. doi:10.1177/2397198320903867
Stratton, R., Taki, Z., Denton, C., Ahmed Abdi, B. (2020). Pathogenic Activation of Mesenchymal Stem Cells is induced by the Disease Microenvironment in Systemic Sclerosis. Arthritis and Rheumatology,
Hughes, M., Pauling, J.D., Jones, J., Denton, C.P., Domsic, R.T., Frech, T.M., ...McKenzie, L. (2020). Patient experiences of digital ulcer development and evolution in systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/keaa037
Distler, O., Assassi, S., Cottin, V., Cutolo, M., Danoff, S.K., Denton, C.P., ...Müller Ladner, U. (2020). Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, doi:10.1183/13993003.02026-2019
Weibel, L., Theiler, M., Howell, K.J., Denton, C.P., Waelchli, R., Atherton, D., ...Harper, J.I. (2020). Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imaging. Journal of the European Academy of Dermatology and Venereology, doi:10.1111/jdv.16308
Jaeger, V.K., Tikly, M., Xu, D., Siegert, E., Hachulla, E., Airò, P., ...Cozzi, F. (2020). Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.. Rheumatology, doi:10.1093/rheumatology/kez486
Hughes, M., Allanore, Y., Chung, L., Pauling, J.D., Denton, C.P., Matucci-Cerinic, M. (2020). Raynaud phenomenon and digital ulcers in systemic sclerosis. Nature Reviews Rheumatology, doi:10.1038/s41584-020-0386-4
Khanna, D., Allanore, Y., Denton, C.P., Kuwana, M., Matucci-Cerinic, M., Pope, J.E., ...Hachulla, E. (2020). Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.. Ann Rheum Dis, 79 (5), 618-625. doi:10.1136/annrheumdis-2019-216823
Chung, L., Spino, C., McLain, R., Johnson, S.R., Denton, C.P., Molitor, J.A., ...Kafaja, S. (2020). Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30237-X
Orteu, C.H., Ong, V.H., Denton, C.P. (2020). Scleroderma mimics – Clinical features and management. Best Practice and Research: Clinical Rheumatology, 101489. doi:10.1016/j.berh.2020.101489
Clark, K.E.N., Campochiaro, C., Nevin, K., Csomor, E., Galwey, N., Morse, M., ...Derrett-Smith, E. (2020). STAGE AND SUBSET SPECIFIC PROFILES OF FIBROGENESIS HIGHLIGHTED THROUGH ANALYSIS OF SERUM MARKERS ACROSS THE SCLERODERMA SPECTRUM.
Smith, V., Herrick, A.L., Ingegnoli, F., Damjanov, N., A.n.g.e.l.i.s., Denton, C.P., ...Frech, T. (2020). Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.. Autoimmun Rev, 102458. doi:10.1016/j.autrev.2020.102458
Matucci-Cerinic, M., Bruni, C., Allanore, Y., Clementi, M., Dagna, L., Damjanov, N.S., ...Fox, D. (2020). Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217407
Clark, K.E.N., Denton, C.P. (2020). The patient knows best: a new self‐reported outcome measure for systemic sclerosis. British Journal of Dermatology, doi:10.1111/bjd.19033
Denton, C.P., Laird, B., Moros, L., Luna Flores, J.L. (2020). Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionals-a discourse analysis.. Clin Rheumatol, doi:10.1007/s10067-020-05371-2
Khanna, D., Lin, C.J.F., Furst, D.E., Goldin, J., Kim, G., Kuwana, M., ...Shima, Y. (2020). Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30318-0
Clark, K.E.N., Suleman, Y., Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2020). TOCILIZUMAB IN SYSTEMIC SCLEROSIS: REAL WORLD EXPERIENCE FROM A SINGLE CENTRE COHORT SUPPORTS POTENTIAL BENEFIT ON LUNG FUNCTION FOR ANTI-TOPOISOMERASE (SCL-70) POSITIVE SUBGROUP.
Roofeh, D., Distler, O., Allanore, Y., Denton, C.P., Khanna, D. (2020). Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials. Journal of Scleroderma and Related Disorders, 5 (2 Suppl), 61-71. doi:10.1177/2397198320903208
Roofeh, D., Distler, O., Allanore, Y., Denton, C.P., Khanna, D. (2020). Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. Journal of scleroderma and related disorders, 5 (2 Suppl), 61-71. doi:10.1177/2397198320903208
Ahmed, F., Nihtyanova, S.I., Chatzinikolaou, S., Ong, V.H., Murray, C.D., Denton, C.P. (2020). UNDERSTANDING THE ASSOCIATIONS AND IMPACT OF SEVERE GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: A STRUCTURED APPROACH.
Nihtyanova, S.I., Sari, A., Harvey, J.C., Leslie, A., Derrett-Smith, E.C., Fonseca, C., ...Denton, C.P. (2020). Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis Rheumatol, doi:10.1002/art.41153
Moinzadeh, P., Frommolt, P., Franitza, M., Toliat, M.R., Becker, K., Nürnberg, P., ...Hunzelmann, N. (2020). Whole blood gene expression profiling distinguishes systemic sclerosis-overlap syndromes from other subsets.. J Eur Acad Dermatol Venereol, doi:10.1111/jdv.16198

2019

Khanna, D., Tashkin, D.P., Denton, C.P., Renzoni, E.A., Desai, S.R., Varga, J. (2019). Aetiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.. Am J Respir Crit Care Med, doi:10.1164/rccm.201903-0563CI
Baron, M., Kahaleh, B., Bernstein, E.J., Chung, L., Clements, P.J., Denton, C., ...Frech, T. (2019). An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 4 (1), 17-27. doi:10.1177/2397198318783926
Campochiaro, C., Atay, S., Clark, K.E.N., Ong, V., Denton, C.P. (2019). Autoimmunity and immunodeficiency at the crossroad: autoimmune disorders as the presenting feature of selective IgM deficiency.. BMJ Case Reports, 12 (1), doi:10.1136/bcr-2017-223180
Denton, C.P., Murray, C. (2019). Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis. Arthritis Research & Therapy, 21 (1), 81. doi:10.1186/s13075-019-1872-4
Denton, C.P. (2019). Challenges in systemic sclerosis trial design.. Semin Arthritis Rheum, 49 (3S), S3-S7. doi:10.1016/j.semarthrit.2019.09.019
Blagojevic, J., Bellando-Randone, S., Abignano, G., Avouac, J., Cometi, L., Czirjak, L., ...Guiducci, S. (2019). Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey. Arthritis Research & Therapy, 21 (1), doi:10.1186/s13075-019-1822-1
Clark, K.E.N., Campochiaro, C., Host, L.V., Harvey, J., Denton, C.P., Ong, V.H. (2019). CLINICAL SIGNIFICANCE OF GAINING ADDITIONAL SPECIFIC AUTOANTIBODIES DURING FOLLOW-UP IN CONNECTIVE TISSUE DISEASE.
Clark, K.E.N., Gak, N., Campochiaro, C., Ong, V.H., Denton, C.P., Derrett-Smith, E. (2019). DEVELOPING A MOLECULAR CLASSIFIER FOR SCLERODERMA SPECTRUM DISORDERS TO AUGMENT CLINICAL CATEGORISATION.
Nihtyanova, S.I., Sari, A., Ong, V.H., Denton, C.P. (2019). DISEASE DURATION AND AUTOANTIBODIES DETERMINE DISTINCT SKIN SCORE TRAJECTORIES IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
Nihtyanova, S.I., Sari, A., Leslie, A., Ong, V.H., Denton, C.P. (2019). DISEASE-SPECIFIC AUTOANTIBODIES ASSOCIATE WITH REMARKABLY DIFFERENT RISK OF DEVELOPMENT OF SIGNIFICANT LUNG FIBROSIS IN SYSTEMIC SCLEROSIS.
Pan, Z., Marra, A.M., Benjamin, N., Eichstaedt, C.A., Blank, N., Bossone, E., ...Distler, O. (2019). Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Res Ther, 21 (1), 217. doi:10.1186/s13075-019-1981-0
Hemmrich, M., Distler, O., Allanore, Y., Denton, C.P., Kuwana, M., Matucci-Cerinic, M., ...Yao, Z. (2019). Efficacy and safety of riociguat in patients with early diffuse cutaneous systemic sclerosis: results from the RISE-SSc study, a randomized, double-blind, placebo-controlled phase IIb study.
Campochiaro, C., Lytton, S., Nihtyanova, S., Fuchs, D., Ong, V.H., Denton, C.P. (2019). Elevated kynurenine levels in diffuse cutaneous and anti-RNA polymerase III positive systemic sclerosis.. Clin Immunol, doi:10.1016/j.clim.2018.12.009
Derrett-Smith, E., Hoyles, R., Xu, S.-.W., Lacombe, O., Broqua, P., Junien, J.-.L., ...Denton, C.P. (2019). EVIDENCE FOR ALTERED PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) PATHWAY ACTIVITY IN A TRANSGENIC MOUSE MODEL OF SCLERODERMA (TBRIIDK-FIB): ANALYSIS OF MOUSE SKIN, LUNG AND EXPLANTED CELLS.
Smith, V., Vanhaecke, A., Herrick, A.L., Distler, O., Guerra, M.G., Denton, C.P., ...Hachulla, E. (2019). Fast track algorithm: How to differentiate a "scleroderma pattern" from a "non-scleroderma pattern".. Autoimmun Rev, 102394. doi:10.1016/j.autrev.2019.102394
Hemmings, K.E., Bageghni, S.A., Maqbool, A., Porter, K.E., Denton, C.P., Pinteaux, E., ...Turner, N.A. (2019). Fibroblast-Specific Deletion of Interleukin-1 Receptor 1 (IL-1R1) Is Cardioprotective in an Experimental Model of Myocardial Infarction.
Bageghni, S.A., Hemmings, K.E., Yuldasheva, N.Y., Maqbool, A., Gamboa-Esteves, F.O., Humphreys, N.E., ...Porter, K.E. (2019). Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction.. JCI Insight, 5 doi:10.1172/jci.insight.125074
Denton, C.P. (2019). FIBROSIS: STATUS OF PHASE II AND III CLINICAL TRIALS FOR SKIN AND LUNG IN SYSTEMIC SCLEROSIS.
Butler, E.A., Baron, M., Fogo, A.B., Frech, T., Ghossein, C., Hachulla, E., ...Mouthon, L. (2019). Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, doi:10.1002/art.40809
López-Isac, E., Acosta-Herrera, M., Kerick, M., Assassi, S., Satpathy, A.T., Granja, J., ...Carreira, P. (2019). GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways.. Nat Commun, 10 (1), 4955. doi:10.1038/s41467-019-12760-y
Derrett-Smith, E., Xu, S.-.W., Abraham, D., Lacombe, O., Broqua, P., Junien, J.-.L., ...Denton, C.P. (2019). IN VIVO ASSESSMENT OF PREVENTION OF LUNG FIBROSIS USING THE PAN-PPAR AGONIST LANIFIBRANOR IN THE TBRIIDK-FIB MOUSE MODEL OF SYSTEMIC SCLEROSIS.
Alyousef, A.A., Nihtyanova, S., Denton, C.P., Bosoni, P., Bellazzi, R., Tucker, A. (2019). Latent class multi-label classification to identify subclasses of disease for improved prediction.
Denton, C.P., Lin, C.J.F., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., ...Matucci-Cerinic, M. (2019). Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc).
Arbore, G., Kordasti, S., Kemper, C., Hourcade, D., Costantini, B., Placais, L., ...Abraham, D. (2019). MASS CYTOMETRY ANALYSIS REVEALS DYSREGULATED T CELL COMPLEMENT RESPONSES IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
Wells, A., Devaraj, A., Renzoni, E.A., Denton, C.P. (2019). Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.. Semin Respir Crit Care Med, 40 (2), 184-193. doi:10.1055/s-0039-1684020
Dhaliwal, K., Griffin, M.F., Salinas, S., Howell, K., Denton, C.P., Butler, P.E.M. (2019). Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series. Clinical Rheumatology, doi:10.1007/s10067-019-04762-4
Sobanski, V., Giovannelli, J., Allanore, Y., Riemekasten, G., Airo, P., Vettori, S., ...Denton, C. (2019). Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, doi:10.1002/art.40906
Becker, M., Graf, N., Sauter, R., Allanore, Y., Curram, J., Denton, C.P., ...Pope, J.E. (2019). Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.. Ann Rheum Dis, doi:10.1136/annrheumdis-2019-215145
Bruni, C., Ngcozana, T., Braschi, F., Pucci, T., Piemonte, G., Benelli, L., ...Bellando-Randone, S. (2019). Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis.. J Rheumatol, doi:10.3899/jrheum.171486
Khanna, D., Lin, C.J.F., Goldin, J., Kim, G., Kuwana, M., Allanore, Y., ...Matucci-Cerinic, M. (2019). Preservation of Lung Function Observed in a Phase 3 Randomized Controlled Trial of Tocilizumab for the Treatment of Early Systemic Sclerosis.
Clark, K.E.N., Beynon, H.L.C., Denton, C.P., Ong, V.H. (2019). PREVALENCE AND DISTINCT CLINICAL PHENOTYPE OF CONCOMITANT SARCOIDOSIS WITH OTHER AUTOIMMUNE RHEUMATIC DISEASES.
Wijsenbeek, M., Kreuter, M., Olson, A., Fischer, A., Bendstrup, E., Wells, C.D., ...Quaresma, M. (2019). Progressive Fibrosing Interstitial Lung Diseases: Current Practice in Diagnosis and Management.. Curr Med Res Opin, 1. doi:10.1080/03007995.2019.1647040
Wu, W., Jordan, S., Graf, N., de Oliveira Pena, J., Curram, J., Allanore, Y., ...Khanna, D. (2019). Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.. Ann Rheum Dis, doi:10.1136/annrheumdis-2018-213455
Wells, A., Denton, C.P. (2019). Pulmonary Complications of Connective Tissue Disease.. Semin Respir Crit Care Med, 40 (2), 145-146. doi:10.1055/s-0039-1688716
Wollin, L., Distler, J.H.W., Denton, C.P., Gahlemann, M. (2019). Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of Scleroderma and Related Disorders, doi:10.1177/2397198319841842
Nagel, C., Marra, A.M., Benjamin, N., Blank, N., Cittadini, A., Coghlan, G., ...Fiehn, C. (2019). Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. Arthritis and Rheumatology, doi:10.1002/art.40814
Krogmannova, K.L., Tan, S.S., Abdi, B.A., Etomi, O., Abraham, D., Denton, C.P., Stratton, R.J. (2019). ROLE OF MECHANOSENSING IN MACROPHAGE ACTIVATION IN SYSTEMIC SCLEROSIS.
Stock, C.J.W., Visca, D., DeLauretis, A., Daccord, C., Kokosi, M., Alfieri, V., ...Molyneaux, P.L. (2019). SERUM BIOMARKERS IN SSC-ILD: ASSOCIATION WITH PRESENCE, SEVERITY AND PROGNOSIS.
Sha, M., Griffin, M., Denton, C.P., Butler, P.E. (2019). Sidestream Dark Field (SDF) imaging of oral microcirculation in the assessment of systemic sclerosis.. Microvasc Res, 126 103890. doi:10.1016/j.mvr.2019.103890
Almadori, A., Griffin, M., Ryan, C.M., Hunt, D.F., Hansen, E., Kumar, R., ...Butler, P.E.M. (2019). Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis.
Almadori, A., Griffin, M., Ryan, C.M., Hunt, D.F., Hansen, E., Kumar, R., ...Butler, P.E.M. (2019). Stem cell enriched lipotransfer reverses the effects of fibrosis in systemic sclerosis.. PLoS One, 14 (7), e0218068. doi:10.1371/journal.pone.0218068
Blagojevic, J., Abignano, G., Avouac, J., Cometi, L., Frerix, M., Bellando-Randone, S., ...Jaeger, V.K. (2019). Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.. Clin Rheumatol, doi:10.1007/s10067-019-04564-8
Fayed, H., Ahmad, M., Abdelkhalek, R., Kotecha, T., Brown, J., Okonkwo, N., ...Handler, C. (2019). Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH).
Valentini, G., Huscher, D., Riccardi, A., Fasano, S., Irace, R., Messiniti, V., ...Maurer, B. (2019). Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.. Ann Rheum Dis, doi:10.1136/annrheumdis-2019-215486
Stock, C.J.W., DeLauretis, A., Visca, D., Daccord, C., Kokosi, M., Kouranos, V., ...Chua, F. (2019). VERIFICATION OF GENETIC ASSOCIATIONS WITH SCLERODERMA ASSOCIATED INTERSTITIAL LUNG DISEASE.
Clark, K.E.N., Gak, N., Campochiaro, C., Ong, V.H., Denton, C.P., Derrett-Smith, E. (2019). WHOLE GENOME EXPRESSION ANALYSIS FROM PAIRED SAMPLES OF KELOIDAL MORPHEA AND SYSTEMIC SCLEROSIS SKIN IDENTIFIES KEY SCLERODERMA CANDIDATE GENES.

2018

Wilkinson, J.D., Leggett, S.A., Marjanovic, E.J., Moore, T.L., Allen, J., Anderson, M.E., ...Denton, C.P. (2018). A multicentre study of validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's phenomenon.. Arthritis & rheumatology (Hoboken, N.J.), doi:10.1002/art.40457
Nihtyanova, S.I., Derrett-Smith, E.C., Fonseca, C.M., Ong, V.H., Denton, C.P. (2018). A Practical Classification of Systemic Sclerosis Using Subset and Autoantibodies for the Purpose of Early Risk Stratification.
Nihtyanova, S.I., Derrett-Smith, E.C., Fonseca, C., Ong, V.H., Denton, C.P. (2018). A SIMPLE CLASSIFICATION OF SYSTEMIC SCLEROSIS USING SUBSET AND AUTOANTIBODIES CAN DISCRIMINATE WELL BETWEEN DISTINCT OUTCOME GROUPS.
Hughes, M., Bhushan, M., Chakravarty, K., Denton, C.P., Dubey, S., Guiducci, S., ...Pauling, J. (2018). A STUDY EXAMINING THE RELIABILITY OF DIGITAL ULCER DEFINITIONS AS PROPOSED BY THE UK SCLERODERMA STUDY GROUP: CHALLENGES AND INSIGHTS FOR FUTURE CLINICAL TRIAL DESIGN.
González-Serna, D., Carmona, E.G., Ortego-Centeno, N., Simeón, C.P., Solans, R., Hernández-Rodríguez, J., ...Martinez-Valle, F. (2018). A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility.. PLoS One, 13 (12), e0209343. doi:10.1371/journal.pone.0209343
Khanna, D., Spino, C., Bush, E., Johnson, S., Chung, L., Molitor, J., ...Denton, C.P. (2018). Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis-Results of a Phase 2 Investigator Initiated, Double- Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study.
Coghlan, J.G., Denton, C.P. (2018). Aggressive combination therapy for treatment of systemic sclerosis-associated pulmonary hypertension. Journal of Scleroderma and Related Disorders, 3 (1), 30-38. doi:10.1177/2397198318758422
Taher, T.E., Ong, V.H., Bystrom, J., Hillion, S., Simon, Q., Denton, C.P., ...Mageed, R.A. (2018). Association of Defective Regulation of Autoreactive Interleukin‐6–Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis. Arthritis and Rheumatology, doi:10.1002/art.40390
Mura, S., Fin, A., Parodi, P.C., Denton, C.P., Howell, K.J., Cordaro, E.R. (2018). Autologous fat transfer in the successful treatment of upper limb linear morphoea. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 36 (4), S183.
Bageghni, S.A., Hemmings, K.E., Zava, N., Denton, C.P., Porter, K.E., Ainscough, J.F.X., ...Turner, N.A. (2018). Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, fj201701455RR. doi:10.1096/fj.201701455rr
Schreiber, B.E., Parish, V., Knight, D.S., Bell, A.D., Denton, C.P., Banner, N., Coghlan, G. (2018). Cardiac transplantation in a 20-year-old woman with scleroderma.. Journal of scleroderma and related disorders, 3 (1), NP1-NP4. doi:10.1177/2397198318758417
Moreno-Moral, A., Bagnati, M., Koturan, S., Ko, J.-.H., Fonseca, C., Harmston, N., ...Abraham, D.J. (2018). Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2017-212454
Campochiaro, C., Host, L.V., Ong, V.H., Denton, C.P. (2018). Development of systemic sclerosis in transgender females: a case series and review of the literature. Clinical and experimental rheumatology, 36 (4), 50-52.
Suliman, Y.A., Bruni, C., Johnson, S., Kafaja, S., Praino, E., Khanna, D., ...Krieg, T. (2018). Discriminant Validity and Reliability of World Scleroderma Foundation (WSF) Definition of Skin Ulcers in Systemic Sclerosis.
Nihtyanova, S.I., Sari, A., Ong, V.H., Denton, C.P. (2018). Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis.
Nihtyanova, S.I., Sari, A., Leslie, A., Ong, V.H., Denton, C.P. (2018). Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis.
Sari, A., Nihtyanova, S.I., Gill, A., Ong, V.H., Denton, C.P. (2018). DISEASE-SPECIFIC AUTOANTIBODIES ASSOCIATE WITH REMARKABLY DIFFERENT RISK OF DEVELOPMENT OF SIGNIFICANT LUNG FIBROSIS IN SYSTEMIC SCLEROSIS.
Caetano, J., Nihtyanova, S.I., Harvey, J., Denton, C.P., Ong, V.H. (2018). Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis. Rheumatology Advances in Practice, 2 (1), doi:10.1093/rap/rky002
Allanore, Y., Distler, O., Jagerschmidt, A., Illiano, S., Ledein, L., Boitier, E., ...Khanna, D. (2018). Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis.. Arthritis & rheumatology, doi:10.1002/art.40547
Pope, J.E., Lee, J.J., Denton, C.P. (2018). Editorial: Bench to Bedside—and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe. Arthritis and Rheumatology, doi:10.1002/art.40373
Khanna, D., Lin, C.J.F., Kuwana, M., Allanore, Y., Batalov, A., Butrimiene, I., ...Kaliterna, D.M. (2018). Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled Trial.
Abignano, G., Blagojevic, J., Bissell, L.-.A., Dumitru, R.B., Eng, S., Allanore, Y., ...Distler, O. (2018). European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis.. Rheumatology (Oxford), doi:10.1093/rheumatology/key271
Khanna, D., Lin, C.J.F., Spotswood, H., Siegel, J., Jahreis, A., Denton, C.P., Furst, D.E. (2018). Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis (ACR CRISS) in a Phase 3 Randomized Controlled Trial.
Derrett-Smith, E.C., Xu, S., Hoyles, R.K., Lacombe, O., Broqua, P., Junien, J.-.L., ...Denton, C.P. (2018). Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (T beta RII Delta k-fib): Analysis of Mouse Skin, Lung and Explanted Cells.
Distler, O., Allanore, Y., Denton, C.P., Matucci-Cerinic, M., Pope, J.E., Hinzmann, B., ...Khanna, D. (2018). Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatology, doi:10.1093/rheumatology/kex504
Denton, C.P. (2018). FIBROBLAST-MATRIX-VESSEL: THE UNHAPPY TRIAD.
Clark, K.E.N., Campochiaro, C., Host, L.V., Sari, A., Nihtyanova, S.I., Fonseca, C., ...Ong, V.H. (2018). Frequency and Clinical Associations of Rare Antibodies in a Large Connective Tissue Disease Cohort.
Jaeger, V.K., Distler, O., Maurer, B., Czirják, L., Lóránd, V., Valentini, G., ...Denton, C. (2018). Functional disability and its predictors in systemic sclerosis: A study from the DeSScipher project within the EUSTAR group. Rheumatology (United Kingdom), 57 (3), 441-450. doi:10.1093/rheumatology/kex182
Parkes, J.E., Rothwell, S., Oldroyd, A., Chinoy, H., Lamb, J.A., Lundberg, I.E., ...Gregersen, P.K. (2018). Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-γ autoantibodies in adult patients with myositis. Arthritis Research and Therapy, 20 (1), doi:10.1186/s13075-018-1617-9
Simonneau, G., Montani, D., Celermajer, D.S., Denton, C.P., Gatzoulis, M.A., Krowka, M., ...Souza, R. (2018). Haemodynamic definitions and updated clinical classification of pulmonary hypertension.. Eur Respir J, doi:10.1183/13993003.01913-2018
Fayed, H., Kotecha, T., Ahmad, M., Nihtyanova, S., Schreiber, B., Handler, C., ...Coghlan, J.G. (2018). Improved ten-year survival of systemic sclerosis-associated pulmonary arterial hypertension in the contemporary treatment era: a single centre retrospective study of 451 patients.
Derrett-Smith, E.C., Xu, S., Abraham, D., Lacombe, O., Broqua, P., Junien, J.-.L., ...Denton, C.P. (2018). In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the T beta rii delta k-Fib Mouse Model of Systemic Sclerosis.
Coghlan, G., Wolf, M., Distler, O., Denton, C.P., Doelberg, M., Harutyunova, S., ...Grünig, E. (2018). Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.. The European respiratory journal, doi:10.1183/13993003.01197-2017
Tam, A., Reinke-Breen, L., Trujillo, G., Xu, S., Denton, C.P., Abraham, D.J., ...Ong, V.H. (2018). INCREASED FREQUENCY OF CIRCULATING CD163+NON-CLASSICAL MONOCYTES IN SCLERODERMA AND ENHANCED DUAL POLARISATION TOWARDS M1 AND M2-LIKE PHENOTYPES IN MONOCYTE-DERIVED MACROPHAGES.
Denton, C.P. (2018). LIGHT AT THE LOWER GASTROINTESTINAL TRACT IN SYSTEMIC SCLEROSIS.
Denton, C.P., Wells, A.U., Coghlan, J.G. (2018). Major lung complications of systemic sclerosis. Nature Reviews Rheumatology, 14 511-527. doi:10.1038/s41584-018-0062-0
Denton, C.P., Wells, A.U., Coghlan, J.G. (2018). Major lung complications of systemic sclerosis (vol 14, pg 511, 2018). NATURE REVIEWS RHEUMATOLOGY, 14 (11), 682. doi:10.1038/s41584-018-0108-3
Arbore, G., Kordasti, S., Kemper, C., Hourcade, D., Costantini, B., Placais, L., ...Abraham, D. (2018). Mass Cytometry Analysis Detects Dysregulated T Cell Complement Responses in Diffuse Cutaneous Systemic Sclerosis.
Alyousef, A.A., Nihtyanova, S., Denton, C., Bosoni, P., Bellazzi, R., Tucker, A. (2018). Nearest Consensus Clustering Classification to Identify Subclasses and Predict Disease. Journal of Healthcare Informatics Research, 2 (4), 402-422. doi:10.1007/s41666-018-0029-6
Lopez-Isac, E., Acosta-Herrera, M., Assassi, S., Simeon, C.P., Carreira, P.E., Castellvi, I., ...Gabrielli, A. (2018). NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY.
Abdi, B.A., Lopez, H., Martin, G., Garvin, C., Jaynes, J., Stanway, J., ...Morris, S. (2018). Novel Therapeutic Peptides Which Target CD206 Inhibit Macrophage Dependent Fibroblast Activation in Scleroderma.
Khanna, D., Tashkin, D.P., Denton, C.P., Lubell, M.W., Vazquez-Mateo, C., Wax, S. (2018). Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.. Rheumatology (Oxford, England), doi:10.1093/rheumatology/key151
Herrick, A.L., Peytrignet, S., Lunt, M., Pan, X., Hesselstrand, R., Mouthon, L., ...Czirják, L. (2018). Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2017-211912
Hsu, V.M., Denton, C.P., Domsic, R.T., Furst, D.E., Rischmueller, M., Stanislav, M., ...Cooper, A. (2018). Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. The Journal of Rheumatology, doi:10.3899/jrheum.161040
Clarks, K.E.N., Beynon, H., Denton, C.P., One, V.H. (2018). Prevalence and Distinct Clinical Phenotype of Concomitant Sarcoidosis in Other Autoimmune Rheumatic Diseases.
Host, L.V., Campochiaro, C., Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2018). PROLONGED PROTON PUMP INHIBITOR EXPOSURE IS ASSOCIATED WITH DEVELOPMENT OF CALCINOSIS IN SYSTEMIC SCLEROSIS.
Host, L.V., Campochiaro, C., Nihtyanova, S.I., Denton, C.P., Ong, V.H. (2018). Prospective Confirmation of Potential Link between Proton Pump Inhibitor Exposure and Calcinosis in Systemic Sclerosis.
Chaigne, B., Clary, G., Le Gall, M., Dumoitier, N., Fernandez, C., Lofek, S., ...Denton, C.P. (2018). Proteomic Analysis of Human Scleroderma Fibroblasts Response to Transforming Growth Factor-ß.. Proteomics Clin Appl, e1800069. doi:10.1002/prca.201800069
Host, L.V., Campochiaro, C., Nihtyanova, S., Ong, V., Denton, C.P. (2018). PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH CALCINOSIS IN SYSTEMIC SCLEROSIS.
Carrier, M.E., Kwakkenbos, L., Boutron, I., Welling, J., Sauve, M., van den Ende, C., ...Mouthon, L. (2018). Randomized feasibility trial of the Scleroderma patient-centered intervention network hand exercise program (SPIN-HAND): Study protocol. Journal of Scleroderma and Related Disorders, 3 (1), 91-97. doi:10.5301/jsrd.5000263
Hughes, M., Tracey, A., Bhushan, M., Chakravarty, K., Denton, C.P., Dubey, S., ...Parker, L. (2018). Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design.. Journal of scleroderma and related disorders, 3 (2), 170-174. doi:10.1177/2397198318764796
Denton, C.P., Herrick, A.L. (2018). Reply: Pauling, et al., Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis.. Arthritis and Rheumatology, doi:10.1002/art.40480
Allanore, Y., Distler, O., Matucci-Cerinic, M., Denton, C.P. (2018). Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. Arthritis and Rheumatology, doi:10.1002/art.40377
Distler, O., Allanore, Y., Denton, C.P., Kuwana, M., Matucci-Cerinic, M., Pope, J.E., ...Khanna, D. (2018). Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc).
Khanna, D., Denton, C.P., Jahreis, A.A. (2018). Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (vol 387, pg 2630, 2016). LANCET, 391 (10128), 1356. doi:10.1016/S0140-6736(18)30807-9
Stock, C.J.W., Hoyles, R., D'accord, C., Kokosi, M., Alfieri, V., Campochiaro, C., ...Kouranos, V. (2018). SERUM CYFRA 21-1 AS A PROGNOSTIC MARKER IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE.
Stock, C., Hoyles, R., D'Accord, C., Kokosi, M., Alfieri, V., Campochiaro, C., ...Kouranos, V. (2018). Serum KL-6 as a marker of disease progression in SSc-ILD.
Hughes, M., Murray, A., Denton, C.P., Herrick, A.L. (2018). Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?. Medical Hypotheses, 116 101-104. doi:10.1016/j.mehy.2018.04.024
Jaeger, V.K., Valentini, G., Hachulla, E., Cozzi, F., Distler, O., Airo, P., ...Rosato, E. (2018). Smoking Behaviour and the Severity and Progression of Organ Manifestations in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study.
Jaeger, V.K., Valentini, G., Hachulla, E., Cozzi, F., Distler, O., Airó, P., ...Rosato, E. (2018). Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study. Arthritis and Rheumatology, doi:10.1002/art.40557
Papaioannou, I., Xu, S., Denton, C.P., Abraham, D.J., Ponticos, M. (2018). STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation. Molecular Biology of the Cell, 29 (2), 84-95. doi:10.1091/mbc.E17-06-0342
Adler, S., Huscher, D., Siegert, E., Allanore, Y., Czirják, L., DelGaldo, F., ...Matucci-Cerinic, M. (2018). Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.. Arthritis research & therapy, 20 (1), 17. doi:10.1186/s13075-018-1517-z
Aringer, M., Denton, C.P. (2018). Systemic sclerosis phase III clinical trials: Hope on the horizon?. Journal of Scleroderma and Related Disorders, 3 (3), 193-200. doi:10.1177/2397198318775353
Gillespie, J., Ross, R.L., Corinaldesi, C., Esteves, F., Derrett-Smith, E., McDermott, M.F., ...Del Galdo, F. (2018). TGFβ activation primes canonical Wnt signaling through the downregulation of AXIN2. Arthritis and Rheumatology, doi:10.1002/art.40437
Khanna, D., Allanore, Y., Denton, C.P., Kuwana, M., Matucci-Cerinic, M., Pope, J.E., ...Distler, O. (2018). The Effects of Riociguat on Raynaud's Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study.
Lilleker, J.B., Vencovsky, J., Wang, G., Wedderburn, L.R., Diederichsen, L.P., Schmidt, J., ...Danko, K. (2018). The EuroMyositis registry: an international collaborative tool to facilitate myositis research.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2017-211868
Dritsoula, A., Papaioannou, I., Guerra, S.G., Fonseca, C., Martin, J., Herrick, A.L., ...Ponticos, M. (2018). The molecular basis for dysregulated activation of NKX2-5 in vascular remodelling of systemic sclerosis.. Arthritis & rheumatology (Hoboken, N.J.), doi:10.1002/art.40419
Dhaliwal, K., Griffin, M., Denton, C.P., Butler, P.E.M. (2018). The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes. BMJ case reports, 2018 doi:10.1136/bcr-2017-219348
Dougherty, D.H., Kwakkenbos, L., Carrier, M.E., Salazar, G., Assassi, S., Baron, M., ...van den Hoogen, F. (2018). The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. Rheumatology (Oxford, England), 57 (9), 1623-1631. doi:10.1093/rheumatology/key139
Denton, C.P., Ong, V.H., Xu, S., Chen-Harris, H., Modrusan, Z., Lafyatis, R., ...Sornasse, T. (2018). Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2018-213031
Johnson, S.R., Soowamber, M.L., Fransen, J., Khanna, D., Van den Hoogen, F., Baron, M., ...Carreira, P.E. (2018). There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scandinavian Journal of Rheumatology, 47 (1), 62-70. doi:10.1080/03009742.2017.1299793
Sari, A., Gill, A., Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2018). UNEXPLAINED IRON DEFICIENCY IS FREQUENT IN SYSTEMIC SCLEROSIS.
Mills, S.D., Kwakkenbos, L., Carrier, M.E., Gholizadeh, S., Fox, R.S., Jewett, L.R., ...Malcarne, V.L. (2018). Validation of the Social Appearance Anxiety Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care and Research, 70 (10), 1557-1562. doi:10.1002/acr.23514
Gholizadeh, S., Kwakkenbos, L., Carrier, M.E., Mills, S.D., Fox, R.S., Jewett, L.R., ...Malcarne, V.L. (2018). Validation of the social interaction anxiety scale in scleroderma: A scleroderma patientcentered intervention network cohort study. Journal of Scleroderma and Related Disorders, 3 (1), 98-105. doi:10.5301/jsrd.5000264

2017

Murray, A.K., Manning, J., Moore, T., Wilkinson, J., Marjanovic, E., Leggett, S., ...Anderson, M.E. (2017). A MULTICENTRE RELIABILITY AND VALIDITY STUDY OF LASER SPECKLE CONTRAST IMAGING AND THERMOGRAPHY IN PATIENTS WITH RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS.
Taroni, J.N., Greene, C.S., Martyanov, V., Wood, T.A., Christmann, R.B., Farber, H.W., ...Pioli, P.A. (2017). A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.. Genome Med, 9 (1), 27. doi:10.1186/s13073-017-0417-1
López-Isac, E., Bossini-Castillo, L., Palma, A.B., Assassi, S., Simeón, C.P., Ortego-Centeno, N., ...Román-Ivorra, J.A. (2017). Analysis of ATP8B4 F436L missense variant in a large Systemic sclerosis cohort.. Arthritis Rheumatol, doi:10.1002/art.40058
Coghlan, J.G., Denton, C.P. (2017). Cardiac Involvement in Scleroderma. In Handbook of Systemic Autoimmune Diseases. (pp. 323-333). .
Griffin, M., Ryan, C.M., Pathan, O., Abraham, D., Denton, C.P., Butler, P.E. (2017). Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine.. Stem Cell Res Ther, 8 (1), 23. doi:10.1186/s13287-016-0444-7
Suliman, Y.A., Bruni, C., Johnson, S.R., Praino, E., Alemam, M., Borazan, N., ...Allanore, Y. (2017). Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.. J Scleroderma Relat Disord, 2 (2), 115-120. doi:10.5301/jsrd.5000236
Campochiaro, C., Fonseca, C., Derrett-Smith, E., Ong, V.H., Denton, C.P. (2017). DEVELOPMENT OF SYSTEMIC SCLEROSIS IN TRANSGENDERED FEMALES: A CASE SERIES.
Seibold, J.R., Wigley, F.M., Schiopu, E., Denton, C.P., Silver, R.M., Steen, V.D., ...Chatterjee, S. (2017). Digital ulcers in SSc treated with oral treprostinil: A randomized, double-blind, placebo-controlled study with open-label follow-up. Journal of Scleroderma and Related Disorders, 2 (1), 42-49. doi:10.5301/jsrd.5000232
Peytrignet, S., Denton, C.P., Lunt, M., Hesselstrand, R., Mouthon, L., Silman, A., ...Distler, J.H.W. (2017). Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.. Rheumatology (Oxford, England), doi:10.1093/rheumatology/kex410
Nihtyanova, S.I., Ong, V.H., Derrett-Smith, E.C., Schreiber, B.E., Coghlan, G.J., DeStavola, B.L., Denton, C.P. (2017). DYNAMIC PREDICTION OF PULMONARY HYPERTENSION DEVELOPMENT IN SYSTEMIC SCLEROSIS PATIENTS USING LANDMARK ANALYSIS.
Denton, C.P., Hachulla, É., Riemekasten, G., Schwarting, A., Frenoux, J.-.M., Frey, A., ...Raynaud Study, I.n.v.e.s.t.i.g.a.t.o.r.s. (2017). Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.. Arthritis & rheumatology (Hoboken, N.J.), 69 (12), 2370-2379. doi:10.1002/art.40242
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., ...Rudnicka, L. (2017). European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.. Journal of the European Academy of Dermatology and Venereology : JEADV, doi:10.1111/jdv.14458
Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., ...Rudnicka, L. (2017). European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.. Journal of the European Academy of Dermatology and Venereology, doi:10.1111/jdv.14466
Mihai, C., Antic, M., Dobrota, R., Bonderman, D., Chadha-Boreham, H., Coghlan, J.G., ...Khanna, D. (2017). Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2017-211480
Denton, C.P. (2017). HOT SESSION: SCLERODERMA TREATMENT.
Agueusop, I., Illiano, S., Rocher, C., Boitier, E., Murphy, J., Allanore, Y., ...Benderitter, F. (2017). IDENTIFICATION OF A TRANSCRIPTOMIC SIGNATURE CORRELATED WITH MODIFIED RODNAN SKIN SCORE (MRSS) IN PATIENTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
Rothwell, S., Cooper, R.G., Lundberg, I.E., Gregersen, P.K., Hanna, M.G., Machado, P.M., ...Roberts, M. (2017). Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. ARTHRITIS & RHEUMATOLOGY, 69 1090-1099. doi:10.1002/art.40045
Denton, C.P., Ong, V.H. (2017). Interleukin-6 and related proteins as biomarkers in systemic sclerosis. Journal of Scleroderma and Related Disorders, 2 S13-S19. doi:10.5301/jsrd.5000266
Derrett-Smith, E.C., Martyanov, V., Chighizola, C.B., Moinzadeh, P., Campochiaro, C., Khan, K., ...Ong, V.H. (2017). Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature.. Arthritis research & therapy, 19 (1), 156. doi:10.1186/s13075-017-1360-7
Derrett-Smith, E., Martyanov, V., Chighizola, C., Moinzadeh, P., Khan, K., Wood, T., ...Whitfield, M. (2017). LIMITED CUTANEOUS SYSTEMIC SCLEROSIS SKIN DEMONSTRATES MOLECULAR SUBSETS THAT INCLUDE A CARDIOVASCULAR DEVELOPMENT GENE EXPRESSION SIGNATURE.
Denton, C.P. (2017). MULTIFACTORIAL TISSUE GROWTH FACTORS.
Quillinan, N., Clark, K.E., Youl, B., Vernes, J., McIntosh, D., Haq, S., Denton, C.P. (2017). Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis.. Arthritis Research & Therapy, 19 (1), 45. doi:10.1186/s13075-017-1252-x
Derrett-Smith, E., Hoyles, R., Xu, S.-.W., Denton, C.P. (2017). MULTITISSUE GENE EXPRESSION PATHWAY ANALYSIS OF MERGING THERAPEUTICS IN A TRANSFORMING GROWTH FACTOR BETA-DEPENDENT MOUSE MODEL OF SYSTEMIC SCLEROSIS.
Denton, C.P. (2017). NEW APPROACHES BY TARGETING SOLUBLE MEDIATORS.
Schwaiger, J.P., Loder, C.D., Dobarro, D., Kaier, T., Reddecliffe, S., Schreiber, B.E., ...Coghlan, J.G. (2017). Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis.. Scientific Reports, 7 43304. doi:10.1038/srep43304
Fiandeiro, P.T., Saracino, A., Nihtyanova, S., Denton, C.P., Orteu, C. (2017). Panniculitis occurring in systemic sclerosis: a report of 16 cases from a large UK systemic sclerosis cohort.
Arnold, M.B., Khanna, D., Denton, C.P., van Laar, J.M., Frech, T.M., Anderson, M.E., ...Lakshminarayanan, S. (2017). Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.. Rheumatology (Oxford, England), doi:10.1093/rheumatology/kex396
Wu, W., Jordan, S., Graf, N., Pena, J., Curram, J., Allanore, Y., ...Khanna, D. (2017). Progression of Skin Fibrosis Is Associated with Decline in Lung Function in Patients with Diffuse Cutaneous Systemic Sclerosis: A European Scleroderma Trials and Research (EUSTAR) Analysis.
Schreiber, B.E., Denton, C.P., Robinson, G., Wells, A.U., Keir, G., Sverzelatti, N., ...Coghlan, G. (2017). PULMONARY ARTERY DIAMETER AND PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS.
Domsic, R.T., Nihtyanova, S.I., Wisniewski, S.R., Fine, M.J., Lucas, M., Kwoh, C.K., ...Medsger, T.A. (2017). Reply for "Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients with Early Diffuse Cutaneous Scleroderma".. Arthritis and Rheumatology, doi:10.1002/art.39853
Distler, O., Pope, J., Denton, C., Allanore, Y., Matucci-Cerinic, M., de Oliveira Pena, J., Khanna, D. (2017). RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. Respiratory Medicine, 122 S14-S17. doi:10.1016/j.rmed.2016.09.011
Tsipouri, V., Saunders, P., Keir, G.J., Ashby, D., Fletcher, S.V., Gibbons, M., ...Denton, C.P. (2017). Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): a randomised controlled trial.
Saunders, P., Tsipouri, V., Keir, G.J., Ashby, D., Flather, M.D., Parfrey, H., ...Wells, A.U. (2017). Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. TRIALS, 18 doi:10.1186/s13063-017-2016-2
Khanna, D., Denton, C.P., Lin, C.J., van Laar, J.M., Frech, T.M., Anderson, M.E., ...Lakshminarayanan, S. (2017). Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2017-211682
Liakouli, V., Elies Comez, J., El-Sherbiny, Y.M., Scarcia, M., Grant, G., Abignano, G., ...Emery, P. (2017). Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2017-212120
Nihtyanova, S.I., Denton, C.P. (2017). Scleroderma Lung Involvement, Autoantibodies, and Outcome Prediction: The Confounding Effect of Time. JOURNAL OF RHEUMATOLOGY, 44 (4), 404-406. doi:10.3899/jrheum.170055
Campochiaro, C., Lytton, S.D., Abdi, B.A., Ong, V.H., Denton, C.P. (2017). SERUM KYNURENINE/ TRYPTOPHAN (KYN/ TRP) RATIO AND NEOPTERIN (NEO) LEVELS ARE RAISED IN SYSTEMIC SCLEROSIS (SSC) AND ASSOCIATE WITH SPECIFIC CLINICAL AND AETIO-PATHOGENETIC FEATURES.
Goh, N.S., Hoyles, R.K., Denton, C.P., Hansell, D.M., Renzoni, E.A., Maher, T.M., ...Wells, A.U. (2017). Short term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis.. Arthritis & rheumatology (Hoboken, N.J.), doi:10.1002/art.40130
Khanna, D., Furst, D.E., Clements, P.J., Allanore, Y., Baron, M., Czirjak, L., ...Matucci-Cerinic, M. (2017). Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.. Journal of scleroderma and related disorders, 2 (1), 11-18. doi:10.5301/jsrd.5000231
Denton, C.P., Khanna, D. (2017). Systemic sclerosis.. Lancet (London, England), doi:10.1016/s0140-6736(17)30933-9
Galiè, N., Denton, C.P., Dardi, F., Manes, A., Mazzanti, G., Li, B., ...Palazzini, M. (2017). Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.. Int J Cardiol, 235 67-72. doi:10.1016/j.ijcard.2017.02.094
Caetano, J., Nihtyanova, S.I., Denton, C.P., Ong, V.H. (2017). THE DISTINCTIVE CLINICAL PHENOTYPE OF ANTI-CENTROMERE ANTIBODY-POSITIVE DIFFUSE SYSTEMIC SCLEROSIS.
Bruni, C., Ngcozana, T., Braschi, F., Guiducci, S., Bellando-Randone, S., Suliman, Y.A., ...Matucci-Cerinic, M. (2017). THE DUCAS: PROPOSAL FOR A DIGITAL ULCER ASSESSMENT SCORE IN SCLERODERMA.
Valentini, G., Iudici, M., Walker, U.A., Jaeger, V.K., Baron, M., Carreira, P., ...Hachulla, E. (2017). The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2016-209768
Ryerson, C.J., Denton, C.P. (2017). The Fine Line Between Success and Failure in Scleroderma Lung Fibrosis Trials. American Journal of Respiratory and Critical Care Medicine, doi:10.1164/rccm.201711-2268ED
Saracino, A.M., Denton, C.P., Orteu, C.H. (2017). The molecular pathogenesis of morphoea: from genetics to future treatment targets.. British Journal of Dermatology, doi:10.1111/bjd.15001
Hoa, S., Stern, E.P., Denton, C.P., Hudson, M., Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working, G.r.o.u.p., Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working, G.r.o.u.p. (2017). Towards developing criteria for scleroderma renal crisis: A scoping review.. Autoimmun Rev, doi:10.1016/j.autrev.2017.02.012
Herrick, A.L., Pan, X., Peytrignet, S., Lunt, M., Hesselstrand, R., Mouthon, L., ...Distler, J.H. (2017). Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2016-210503
Schwaiger, J.P., Knight, D.S., Kaier, T., Gallimore, A., Denton, C.P., Schreiber, B.E., ...Coghlan, J.G. (2017). Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension. Echocardiography, 34 (6), 817-824. doi:10.1111/echo.13541
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., ...Czirjak, L. (2017). Update of EULAR recommendations for the treatment of systemic sclerosis.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2016-209909
Stern, E.P., Ong, V.H., Burns, A., Khan, K., Unwin, R.J., Denton, C.P. (2017). URINARY CELL ADHESION MOLECULES AS MARKERS OF RENAL INVOLVEMENT IN SYSTEMIC SCLEROSIS.
Ahmed Abdi, B., Lopez, H., Karrar, S., Renzoni, E., Wells, A., Tam, A., ...Shiwen, X. (2017). Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration.. Scientific reports, 7 (1), 2628. doi:10.1038/s41598-017-02621-3

2016

Elhai, M., Avouac, J., Walker, U.A., Matucci-Cerinic, M., Riemekasten, G., Airò, P., ...Cozzi, F. (2016). A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study. Annals of the Rheumatic Diseases, 75 (1), 163-169. doi:10.1136/annrheumdis-2014-206386
Hsu, V., Denton, C.P., Domsic, R.T., Furst, D.E., Rischmueller, M., Stanislav, M., ...Cooper, A. (2016). A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease.
Garthwaite, H.S., Holmes, V., Mikolasch, T., Azzopardi, G., Denton, C.P., Groves, A.M., Porter, J.C. (2016). A PROSPECTIVE COHORT STUDY TO MEASURE IN-VIVO CHANGES IN LUNG GLUCOSE METABOLISM IN PATIENTS WITH SSCL-ILD USING FDG-PET.
Tam, A., Lopez, H., Shiwen, X., Nikitorowicz-Buniak, J., Ahmed-Abdi, B., Denton, C.P., ...Stratton, R.J. (2016). A role for MRTF-A in mechanical stress-associated monocyte/macrophage activation.
Denton, C.P. (2016). Advances in pathogenesis and treatment of systemic sclerosis. Clinical Medicine, 16 (1), 55-60. doi:10.7861/clinmedicine.16-1-55
Fischer, A., Denton, C.P., Matucci-Cerinic, M., Gillies, H., Blair, C., Tislow, J., Nathan, S.D. (2016). Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.. Respiratory medicine, 117 254-263. doi:10.1016/j.rmed.2016.06.018
Betteridge, Z.E., Woodhead, F., Lu, H., Shaddick, G., Bunn, C.C., Denton, C.P., ...Wells, A.U. (2016). Anti-Eukaryotic Initiation Factor 2B Autoantibodies are Associated with Interstitial Lung Disease in Patients with Systemic Sclerosis.. Arthritis & rheumatology (Hoboken, N.J.), doi:10.1002/art.39755
Raja, J., Denton, C.P. (2016). Author's response. Indian Journal of Rheumatology, 11 (4), 239-. doi:10.4103/0973-3698.193591
Nihtyanova, S.I., Denton, C.P. (2016). Biologic therapies in systemic sclerosis. In Biologics in Rheumatology: New Developments, Clinical Uses and Health Implication. (pp. 83-108). .
López-Isac, E., Martín, J.E., Assassi, S., Simeón, C.P., Carreira, P., Ortego-Centeno, N., ...Alegre-Sancho, J.J. (2016). Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. Arthritis & rheumatology, doi:10.1002/art.39730
Denton, C.P., Hughes, M., Gak, N., Vila, J., Buch, M.H., Chakravarty, K., ...Herrick, A.L. (2016). BSR and BHPR guideline for the treatment of systemic sclerosis.. Rheumatology (Oxford, England), doi:10.1093/rheumatology/kew224
Sobanski, V., Giovannelli, J., Lynch, B.M., Schreiber, B.E., Nihtyanova, S.I., Harvey, J., ...Coghlan, J.G. (2016). Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. Arthritis & Rheumatology, 68 (2), 484-493. doi:10.1002/art.39432
Allanore, Y., Denton, C.P., Krieg, T., Cornelisse, P., Rosenberg, D., Schwierin, B., Matucci-Cerinic, M. (2016). Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort.. Annals of the rheumatic diseases, 75 (9), 1736-1740. doi:10.1136/annrheumdis-2016-209481
Parker, L.K., Ponte, C., Howell, K.J., Ong, V.H., Denton, C.P., Schreiber, B.E. (2016). Clinical features and management of erythromelalgia: long term follow-up of 46 cases.. Clinical and experimental rheumatology,
Antoniou, K.M., Margaritopoulos, G.A., Goh, N.S., Karagiannis, K., Desai, S.R., Nicholson, A.G., ...Hansell, D.M. (2016). Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension. ARTHRITIS & RHEUMATOLOGY, 68 (4), 1004-1012. doi:10.1002/art.39528
Margaritopoulos, G.A., Antoniou, K.M., Denton, C.P., Wells, A.U. (2016). Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease: Reply to Saketkoo et al.. Arthritis & rheumatology (Hoboken, N.J.), doi:10.1002/art.39930
Bosoni, P., Bellazzi, R., Tucker, A., Nihtyanova, S.I., Denton, C.P. (2016). Combining Unsupervised and Supervised Learning for Discovering Disease Subclasses.
Bruni, C., Ngcozana, T., Braschi, F., Guiducci, S., Bellando-Randone, S., Tofani, L., ...Matucci-Cerinic, M. (2016). CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND CHANGES IN DIGITAL ULCER STATUS IN SYSTEMIC SCLEROSIS PATIENTS.
Ikeda, T., Fragiadaki, M., Shi-Wen, X., Ponticos, M., Khan, K., Denton, C., ...Morimoto, C. (2016). Data on CUX1 isoforms in idiopathic pulmonary fibrosis lung and systemic sclerosis skin tissue sections.. Data in brief, 8 1377-1380. doi:10.1016/j.dib.2016.08.014
Mihai, C., Landewé, R., Van Der Heijde, D., Walker, U.A., Constantin, P.I., Gherghe, A.M., ...Avouac, J. (2016). Digital ulcers predict a worse disease course in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 75 (4), 681-686. doi:10.1136/annrheumdis-2014-205897
Khanna, D., Denton, C.P., Merkel, P.A., Krieg, T., Le Brun, F.-.O., Marr, A., ...Furst, D.E. (2016). Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis DUAL-1 and DUAL-2 Randomized Clinical Trials. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 315 (18), 1975-1988. doi:10.1001/jama.2016.5258
Raja, J., Denton, C.P. (2016). Emerging evidence-based therapies for systemic sclerosis. Indian Journal of Rheumatology, 11 (3), 153-163. doi:10.4103/0973-3698.187423
Evans, I.C., Barnes, J.L., Garner, I.M., Pearce, D.R., Maher, T.M., Xu, S., ...Laurent, G.J. (2016). Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis. CLINICAL SCIENCE, 130 (8), 575-586. doi:10.1042/CS20150697
Jewett, L.R., Kwakkenbos, L., Carrier, M.E., Malcarne, V.L., Bartlett, S.J., Furst, D.E., ...Harcourt, D. (2016). Examination of the association of sex and race/ethnicity with appearance concerns: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Clinical and Experimental Rheumatology, 34 92-99.
Kotecha, T., Schreiber, B.E., Handler, C.E., Denton, C.P., Coghlan, J.G. (2016). Follow-up haemodynamic assessment as a predictor of survival in scleroderma-associated pulmonary arterial hypertension.
Shreiner, A.B., Murray, C., Denton, C., Khanna, D. (2016). Gastrointestinal manifestations of systemic sclerosis. Journal of Scleroderma and Related Disorders, 1 (3), 247-256. doi:10.5301/jsrd.5000214
Denton, C.P., Matucci-Cerinic, M. (2016). Historical perspective of scleroderma. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 3-7). .
Moinzadeh, P., Frommolt, P., Franitza, M., Toliat, M.R., Becker, K., Nuernberg, P., ...Hunzelmann, N. (2016). Identification of an expression-based set of genes to predict the subset of patients with systemic scleroderma (SSc).
Wirz, E.G., Jaeger, V.K., Allanore, Y., Riemekasten, G., Hachulla, E., Distler, O., ...Vettori, S. (2016). Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database. Annals of the Rheumatic Diseases, 75 (7), 1285-1292. doi:10.1136/annrheumdis-2015-207271
Jaeger, V.K., Wirz, E.G., Allanore, Y., Rossbach, P., Riemekasten, G., Hachulla, E., ...Gurman, A.B. (2016). Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. PLoS ONE, 11 (10), doi:10.1371/journal.pone.0163894
Varga, J., Wigley, F.M., Denton, C.P. (2016). Introduction to section VIII: Management and outcome assessment. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 565-566). .
Ong, V.H., Denton, C.P. (2016). Investigative approaches to drug therapy. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 583-594). .
Avouac, J., Walker, U.A., Hachulla, E., Riemekasten, G., Cuomo, G., Carreira, P.E., ...Czirjak, L. (2016). Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study. Annals of the Rheumatic Diseases, 75 (1), 103-109. doi:10.1136/annrheumdis-2014-205295
Parker, L., Howell, K., Ong, V.H., Denton, C.P. (2016). Low Rate of Progression in Cases of Isolated Raynaud's Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests.
Cutolo, M., Herrick, A.L., Distler, O., Becker, M.O., Beltran, E., Carpentier, P., ...Chadha-Boreham, H. (2016). Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. Arthritis and Rheumatology, 68 (10), 2527-2539. doi:10.1002/art.39718
Bruni, C., Ngcozana, T., Braschi, F., Barskova, T., Guiducci, S., Bellando-Randone, S., ...Matucci-Cerinic, M. (2016). NAILFOLD VIDEOCAPILLAROSCOPY MAY NOT REFLECT CHANGE OF DIGITAL ULCERS STATUS IN A SHORT TERM EVALUATION OF SYSTEMIC SCLEROSIS PATIENTS.
Chighizola, C.B., Pregnolato, F., Meroni, P.L., Denton, C.P., Ong, V.H. (2016). N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 34 (5), S122-S128.
Chighizola, C.B., Pregnolato, F., Meroni, P.L., Denton, C.P., Ong, V.H. (2016). N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis.. Clinical and experimental rheumatology,
Moinzadeh, P., Denton, C.P. (2016). Overlap syndromes. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 65-74). .
Denton, C.P. (2016). Overview of gastrointestinal tract involvement. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 423-426). .
Denton, C.P. (2016). Overview of lung involvement: Diagnosis, differential diagnosis and monitoring. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 359-362). .
Khanna, D., Proudman, S., Frech, T.M., Nihtyanova, S., Domsic, R.T., Berrocal, V.J., ...Denton, C.P. (2016). Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma-Analysis from 4 International Cohorts.
Furst, D.E., Pope, J.E., Seibold, J.R., Bombardieri, S., Denton, C.P., Distler, O., ...Lafyatis, R. (2016). Progress and priorities in systemic sclerosis: The next 10 years - report from the world scleroderma foundation. Journal of Scleroderma and Related Disorders, 1 (1), 7-9. doi:10.5301/jsrd.5000195
Denton, C.P., Hudson, M. (2016). Renal crisis and other renal manifestations of scleroderma. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 317-330). .
Sobanski, V., Giovannelli, J., Denton, C.P., Coghlan, J.G. (2016). Reply.. Arthritis & rheumatology (Hoboken, N.J.), 68 (7), 1789-1790.
Bruni, C., Lages, A., Patel, H., Nihtyanova, S.I., Green, B., AbuHilal, M., ...Derrett-Smith, E. (2016). Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour.. Rheumatology, doi:10.1093/rheumatology/kew382
Humbert, M., Coghlan, J.G., Ghofrani, H.A., Grimminger, F., He, J.G., Riemekasten, G., ...de Oliveira Pena, J. (2016). Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.. Annals of the rheumatic diseases, doi:10.1136/annrheumdis-2015-209087
Khanna, D., Denton, C.P., Jahreis, A., van Laar, J.M., Frech, T.M., Anderson, M.E., ...Lakshminarayanan, S. (2016). Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. LANCET, 387 (10038), 2630-2640. doi:10.1016/S0140-6736(16)00232-4
Khanna, D., Denton, C.P., Jahreis, A., van Laar, J.M., Burke, L., Spotswood, H., ...Muller-Ladner, U. (2016). SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN EARLY SYSTEMIC SCLEROSIS: RESULTS FROM THE OPEN-LABEL PERIOD OF THE FASSCINATE TRIAL.
Denton, C.P. (2016). Scleroderma Lung Study II-clarity or obfuscation?. LANCET RESPIRATORY MEDICINE, 4 (9), 678-679. doi:10.1016/S2213-2600(16)30191-6
Stern, E.P., Denton, C.P. (2016). Scleroderma renal crisis. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 679-682). .
Varga, J., Denton, C.P., Wigley, F.M., Allanore, Y., Kuwana, M. (2016). Scleroderma: From pathogenesis to comprehensive management. .
Chakravarty, K., Ong, V.H., Denton, C.P. (2016). Secondary vasculitis in autoimmune connective tissue diseases. Current Opinion in Rheumatology, 28 (1), 60-65. doi:10.1097/BOR.0000000000000241
Denton, C.P., Hachulla, E., Riemekasten, G., Schwarting, A., Frenoux, J.-.M., Frey, A., ...Herrick, A. (2016). SELEXIPAG IN RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS: A RANDOMISED, PLACEBO-CONTROLLED, PHASE II STUDY.
Parkes, J.E., Rothwell, S., Day, P.J., McHugh, N.J., Betteridge, Z.E., Cooper, R.G., ...Lundberg, I.E. (2016). Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. Arthritis Research and Therapy, 18 (1), doi:10.1186/s13075-016-1061-7
Khanna, D., Berrocal, V.J., Giannini, E.H., Seibold, J.R., Merkel, P.A., Mayes, M.D., ...Assassi, S. (2016). The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 68 (2), 299-311. doi:10.1002/art.39501
Khanna, D., Berrocal, V.J., Giannini, E.H., Seibold, J.R., Merkel, P.A., Mayes, M.D., ...Assassi, S. (2016). The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. ARTHRITIS CARE & RESEARCH, 68 (2), 167-178. doi:10.1002/acr.22804
Ikeda, T., Fragiadaki, M., Shi-wen, X., Ponticos, M., Khan, K., Denton, C., ...Morimoto, C. (2016). Transforming growth factor-β-induced CUX1 isoforms are associated with fibrosis in systemic sclerosis lung fibroblasts. Biochemistry and Biophysics Reports, 7 246-252. doi:10.1016/j.bbrep.2016.06.022
Lynch, B.M., Stern, E.P., Ong, V., Harber, M., Burns, A., Denton, C.P. (2016). UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 34 (5), S106-S109.
Levis, A.W., Harel, D., Kwakkenbos, L., Carrier, M.E., Mouthon, L., Poiraudeau, S., ...Sauve, M. (2016). Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care and Research, 68 (11), 1704-1713. doi:10.1002/acr.22893
Riehm, K.E., Kwakkenbos, L., Carrier, M.E., Bartlett, S.J., Malcarne, V.L., Mouthon, L., ...Baron, M. (2016). Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. Arthritis Care and Research, 68 (8), 1195-1200. doi:10.1002/acr.22807

2015

Shiwen, X., Stratton, R., Nikitorowicz-Buniak, J., Ahmed-Abdi, B., Ponticos, M., Denton, C., ...Layne, M.D. (2015). A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis.. PLoS One, 10 (5), doi:10.1371/journal.pone.0126015
Gak, N., Derrett-Smith, E., Nihtyanova, S.I., Ong, V., Swale, V.S., Orteu, C.H., Denton, C.P. (2015). A STUDY OF MORPHEA IN SYSTEMIC SCLEROSIS: DEFINING LINKS BETWEEN LOCALIZED AND SYSTEMIC SCLEROSIS.
Denton, C.P. (2015). Advances in pathogenesis and treatment of systemic sclerosis. Clinical Medicine, 15 (6), s58-s63. doi:10.7861/clinmedicine.15-6-s58
Raja, J., Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2015). AN OBSERVATIONAL STUDY OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN THE TREATMENT OF GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS.
Raja, J., Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2015). AN OBSERVATIONAL STUDY OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN THE TREATMENT OF GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS.
Bruni, C., Lages, A., Patel, H., Harvey, J., Ong, V., Cerinic, M.M., ...Denton, C.P. (2015). ASSOCIATION OF ANTI-PM/SCL ANTIBODY WITH RISK OF MALIGNANCY IN SCLERODERMA.
Bruni, C., Lages, A., Patel, H., Harvey, J., Ong, V., Matucci-Cerinic, M., ...Denton, C.P. (2015). ASSOCIATION OF ANTI-PM/SCL ANTIBODY WITH RISK OF MALIGNANCY IN SCLERODERMA.
Toniolo, M., Dobrota, R., Moinzadeh, P., Ogawa, R., Furst, D.E., Denton, C.P., ...Distler, O. (2015). BIOMARKERS SENSITIVE TO CHANGE IN PATIENTS WITH SYSTEMIC SCLEROSIS - A SYSTEMATIC REVIEW.
Good, R., Trinder, S.L., Denton, C.P., Abraham, D., Holmes, A.M. (2015). Blood Outgrowth Endothelial Cells Isolated from Systemic Sclerosis Patients Exhibit a Pro-Inflammatory Phenotype. ARTHRITIS & RHEUMATOLOGY, 67
Trinder, S.L., Gilbane, A., Good, R., Derrett-Smith, E.C., Denton, C.P., Abraham, D., Holmes, A.M. (2015). Bromodomain Inhibitor JQ1 Modulates Smooth Muscle Cell Switching and Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension in Mice. ARTHRITIS & RHEUMATOLOGY, 67
Allanore, Y., Denton, C.P., Krieg, T., Cornelisse, P., Rosenberg, D., Schwierin, B., Matucci-Cerinic, M. (2015). CLINICAL CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH DIGITAL ULCER DISEASE WHO DEVELOPED GANGRENE: DATA FROM THE DUO REGISTRY.
Dickneite, G., Herwald, H., Korte, W., Allanore, Y., Denton, C.P., Cerinic, M.M. (2015). Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions. THROMBOSIS AND HAEMOSTASIS, 113 (4), 686-697. doi:10.1160/TH14-07-0625
Hughes, M., Ong, V.H., Anderson, M.E., Hall, F., Moinzadeh, P., Griffiths, B., ...Herrick, A.L. (2015). Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. RHEUMATOLOGY, 54 (11), 2015-2024. doi:10.1093/rheumatology/kev201
Raja, J., Denton, C.P. (2015). Cytokines in the immunopathology of systemic sclerosis. SEMINARS IN IMMUNOPATHOLOGY, 37 (5), 543-557. doi:10.1007/s00281-015-0511-7
Guerra, S.G., Fonseca, C., Nihtyanova, S.I., Stern, E., Abraham, D.J., Burns, A., ...Denton, C.P. (2015). DEFINING GENETIC RISK FOR SCLERODERMA RENAL CRISIS: A GENOME-WIDE ANALYSIS OF ANTI-RNA POLYMERASE ANTIBODY-POSITIVE SYSTEMIC SCLEROSIS.
Domsic, R.T., Nihtyanova, S.I., Wisniewski, S.R., Fine, M.J., Lucas, M., Kwoh, C.K., ...Jr, M.T.A. (2015). Derivation and External Validation of a Prediction Rule for Five-Year Mortality in Patients With Early Diffuse Cutaneous Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, 68 (4), 993-1003. doi:10.1002/art.39490
Ngcozana, T., Ong, V.H., Denton, C.P. (2015). DIGITAL VASCULOPATHY IN SCLERODERMA: FEASIBILITY AUDIT OF A NURSE-LED RAPID ACCESS DIGITAL ULCER CLINIC TO IMPROVE PATIENT CARE.
Denton, C.P., Coghlan, J.G., Ghofrani, H.-.A., Grimminger, F., He, J., Riemekasten, G., ...Pena, J.D.O. (2015). Efficacy and Safety of Riociguat in Patients with Pulmonary Arterial Hypertension (PAH) Associated with Connective Tissue Disease (CTD). ARTHRITIS & RHEUMATOLOGY, 67
Matucci-Cerinic, M., Krieg, T., Guillevin, L., Schwierin, B., Rosenberg, D., Cornelisse, P., Denton, C.P. (2015). Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Annals of the Rheumatic Diseases, 75 1770-1776. doi:10.1136/annrheumdis-2015-208121
Good, R.B., Gilbane, A.J., Trinder, S.L., Denton, C.P., Coghlan, G., Abraham, D.J., Holmes, A.M. (2015). Endothelial to Mesenchymal Transition Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension. AMERICAN JOURNAL OF PATHOLOGY, 185 (7), 1850-1858. doi:10.1016/j.ajpath.2015.03.019
Derrett-Smith, E., Sobanski, V., Trinder, S., Gilbane, A., Iglarz, M., Abraham, D., ...Denton, C.P. (2015). ENDOTHELIN RECEPTOR BLOCKADE PREVENTS DEVELOPMENT OF PULMONARY HYPERTENSION IN A MOUSE MODEL OF SCLERODERMA.
Chen, Y., Leask, A., Abraham, D.J., Kennedy, L., Shi-wen, X., Denton, C.P., ...Eastwood, M. (2015). Erratum to Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism [Fibrogenesis and Tissue Repair, 4 (2011), 9] 10.1186/1755-1536-4-9. Fibrogenesis and Tissue Repair, 8 (1), doi:10.1186/s13069-015-0021-1
Ponticos, M., Papaioannou, I., Xu, S., Holmes, A.M., Khan, K., Denton, C.P., ...Abraham, D.J. (2015). Failed degradation of JunB contributes to overproduction of type I collagen and development of dermal fibrosis in patients with systemic sclerosis.. Arthritis Rheumatol, 67 (1), 243-253. doi:10.1002/art.38897
Fonseca, M.C., Guerra, S., Stern, E., Nihtyanova, S.I., Abraham, D., Burns, A., ...Denton, C.P. (2015). Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies. ARTHRITIS & RHEUMATOLOGY, 67
Valentini, G., Iudici, M., Jaeger, V.K., Denton, C.P., Distler, O., Kowal-Bielecka, O.M., ...Jordan, S. (2015). Identification of a New Set of Activity Criteria for Systemic Sclerosis. Preliminary Report. ARTHRITIS & RHEUMATOLOGY, 67
Huscher, D., Adler, S., Siegert, E., Allanore, Y., Czirjak, L., Del Galdo, F., ...Frerix, M. (2015). IMMUNOSUPPRESSIVE "ROUTINE" TREATMENT OF OF SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE - RESULTS OF THE FP7 DESSCIPHER PROJECT OF THE EUSTAR GROUP.
Huscher, D., Adler, S., Siegert, E., Abignano, G., Allanore, Y., Avouac, J., ...Denton, C.P. (2015). Immunosuppressive "Routine" Treatment of SSc Patients with Limited Cutaneous Involvement and Interstitial Lung Disease. ARTHRITIS & RHEUMATOLOGY, 67
Gilbane, A.J., Derrett-Smith, E., Trinder, S.L., Good, R.B., Pearce, A., Denton, C.P., Holmes, A.M. (2015). Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor-beta-Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 191 (6), 665-677. doi:10.1164/rccm.201408-1464OC
Vettori, S., Allanore, Y., Czirjak, L., Del Galdo, F., Denton, C.P., Distler, O., ...Krummel-Lorenz, B. (2015). Incidence and Predictors of Severe Heart Disease in Systemic Sclerosis.
López-Isac, E., Campillo-Davo, D., Bossini-Castillo, L., Guerra, S.G., Assassi, S., Simeón, C.P., ...Beretta, L. (2015). Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.. Annals of the rheumatic diseases, 75 (8), 1521-1526.
Zafar, S., Abdi, B.A., Xing, F., Etomi, O., Wong, C., Abraham, D., ...Stratton, R.J. (2015). INTERLEUKIN-31 IS ELEVATED IN DERMAL INTERSTITIAL FLUID IN SYSTEMIC SCLEROSIS AND MAY BE A KEY MEDIATOR OF ITCH IN BOTH DIFFUSE AND LIMITED CUTANEOUS DISEASE.
Clark, K.E.N., Etomi, O., Denton, C.P., Ong, V.H., Murray, C.D. (2015). Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clinical and Experimental Rheumatology, 33 168-170.
Clark, K.E.N., Etomi, O., Denton, C.P., Ong, V.H., Murray, C.D. (2015). Intravenous immunoglobulin therapy for severe gastrointestinal involvement in systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 33 (4), S168-S170.
Denton, C.P., Khanna, D., Krieg, T., Le Brun, F.-.O., Merkel, P.A., Papadakis, K., ...Furst, D.E. (2015). MACITENTAN IN PATIENTS WITH DIGITAL ULCERS ASSOCIATED WITH SYSTEMIC SCLEROSIS: RESULTS FROM THE DUAL-1 AND DUAL-2 RANDOMISED CONTROLLED TRIALS.
Derrett-Smith, E.C., Sobanski, V., Gilbane, A., Trinder, S., Bauer, Y., Renault, B., ...Denton, C.P. (2015). Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling. ARTHRITIS & RHEUMATOLOGY, 67
Stern, E.P., Steen, V.D., Denton, C.P. (2015). Management of Renal Involvement in Scleroderma. Current Treatment Options in Rheumatology, 1 (1), 106-118. doi:10.1007/s40674-014-0004-1
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2015). Modelling of Longitudinal Changes in Lung Function in Patients with Systemic Sclerosis and Their Association with Development of Pulmonary Hypertension. ARTHRITIS & RHEUMATOLOGY, 67
Vij, R., Denton, C.P., Noth, I. (2015). Molecular Phenotyping A Guide to Improving Detection of Interstitial Lung Disease in Patients with Rheumatoid Arthritis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 191 (12), 1349-1350. doi:10.1164/rccm.201504-0751ED
Stern, E., Hong, C., Ong, V.H., Burns, A., Unwin, R., Denton, C.P. (2015). Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma. ARTHRITIS & RHEUMATOLOGY, 67
Clark, K.E., Lopez, H., Abdi, B.A., Guerra, S.G., Shiwen, X., Khan, K., ...Denton, C.P. (2015). Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis.. Arthritis Res Ther, 17 (1), doi:10.1186/s13075-015-0575-8
Quillinan, N., Clark, K.E.N., McIntosh, D., Vernes, J., Denton, C.P. (2015). Multiplex Serum Protein Analysis in Systemic Sclerosis Defines Potential Anti-Fibrotic Mechanisms and Markers of Response to Hyperimmune Caprine Serum. ARTHRITIS & RHEUMATOLOGY, 67
Saketkoo, L.A., Huscher, D., Denton, C.P., Riemekasten, G., Steen, V.D., Distler, O. (2015). Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database. ARTHRITIS & RHEUMATOLOGY, 67
Nagaraja, V., Denton, C.P., Khanna, D. (2015). Old medications and new targeted therapies in systemic sclerosis.. RHEUMATOLOGY, 54 (11), 1944-1953. doi:10.1093/rheumatology/keu285
Feeney, M., Syed, F., Khan, K., Xu, S., Sully, K., Trinder, S., ...Denton, C.P. (2015). Oncostatin M As a Potential Molecular Target in Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, 67
Nikitorowicz-Buniak, J., Denton, C.P., Abraham, D., Stratton, R. (2015). Partially Evoked Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFβ Signaling within Lesional Scleroderma Skin. PLoS One, 10 (7), doi:10.1371/journal.pone.0134092
Derrett-Smith, E.C., Gak, N., Nihtyanova, S.I., Ong, V.H., Swale, V., Orteu, C., Denton, C.P. (2015). Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, 67
Khanna, D., Allanore, Y., Denton, C.P., Matucci-Cerinic, M., Pope, J.E., Hinzmann, B., ...Distler, O. (2015). Patient Perception of Disease Burden in Diffuse Cutaneous Systemic Sclerosis. ARTHRITIS & RHEUMATOLOGY, 67
Sobanski, V., Giovannelli, J., Riemekasten, G., Airo, P., Vettori, S., Cozzi, F., ...Launay, D. (2015). PHENOTYPES DETERMINED BY CLUSTER ANALYSIS AND THEIR SURVIVAL IN THE PROSPECTIVE EUSTAR COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS.
Maurer, B., Graf, N., Michel, B.A., Müller-Ladner, U., Czirják, L., Denton, C.P., ...Khanna, D. (2015). Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.. ANNALS OF THE RHEUMATIC DISEASES, 74 (6), 1124-1131. doi:10.1136/annrheumdis-2014-205226
Denton, C.P., Ong, V.H. (2015). Pulmonary management of systemic sclerosis. In Rheumatology: Sixth Edition. (pp. 1200-1212). .
Denton, C.P., Khanna, D., van Laar, J.M., Jahreis, A., Cheng, S., Spotswood, H., ...Furst, D.E. (2015). SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: WEEK 24 DATA FROM A PHASE II/II TRIAL.
Khanna, D., Denton, C.P., Jahreis, A., van Laar, J.M., Cheng, S., Spotswood, H., ...Siegel, J. (2015). SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN ADULTS WITH SYSTEMIC SCLEROSIS: WEEK 48 DATA FROM THE FASSCINATE TRIAL.
Vettori, S., Cuomo, G., Jaeger, V.K., Frerix, M., Siegert, E., Lorand, V., ...Czirjak, L. (2015). SEVERE HEART DISEASE IN SYSTEMIC SCLEROSIS: PREVALENCE, RISK FACTORS AND CURRENT TREATMENT. A EUSTAR-DESSCIPHER STUDY.
Raja, J., Nihtyanova, S.I., Murray, C.D., Denton, C.P., Ong, V.H. (2015). Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. RHEUMATOLOGY, 55 (1), 115-119. doi:10.1093/rheumatology/kev318
Nihtyanova, S.I., Figorilli, F., Denton, C.P., Agarwal, B., Ong, V.H. (2015). Systemic Sclerosis Patients on Intensive Care Unit - Reasons for Admission and Determinants of Outcome. ARTHRITIS & RHEUMATOLOGY, 67
Agarwal, B., Nihtyanova, S., Figorilli, F., Denton, C., Ong, V. (2015). Systemic sclerosis patients on intensive care unit; reasons for admission and determinants of outcome.
Allanore, Y., Simms, R., Distler, O., Trojanowska, M., Pope, J., Denton, C.P., Varga, J. (2015). Systemic sclerosis.. Nature reviews. Disease primers, 1 15002-. doi:10.1038/nrdp.2015.2
Denton, C.P. (2015). Systemic sclerosis: From pathogenesis to targeted therapy. Clinical and Experimental Rheumatology, 33 3-7.
Denton, C.P. (2015). Systemic sclerosis: from pathogenesis to targeted therapy. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 33 (4), S3-S7.
Bruni, C., Raja, J., Denton, C.P., Matucci-Cerinic, M. (2015). The clinical relevance of sexual dysfunction in systemic sclerosis. AUTOIMMUNITY REVIEWS, 14 (12), 1111-1115. doi:10.1016/j.autrev.2015.07.016
Stern, E.P., Denton, C.P. (2015). The Pathogenesis of Systemic Sclerosis. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 41 (3), 367-+. doi:10.1016/j.rdc.2015.04.002
Khanna, D., Furst, D.E., Allanore, Y., Bae, S., Bodukam, V., Clements, P.J., ...Distler, O. (2015). Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards.. RHEUMATOLOGY, 54 (1), 144-151. doi:10.1093/rheumatology/keu288
Lopez-Isac, E., Bossini-Castillo, L., Guerra, S.G., Assassi, S., Simeon, C.P., Carreira, P.E., ...Santaniello, A. (2015). TYK2 and Systemic Sclerosis Susceptibility: a New Associated Locus in the IL-12 Pathway. ARTHRITIS & RHEUMATOLOGY, 67
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., ...Fligelstone, K. (2015). UPDATE OF EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS.
Chung, L., Valenzuela, A., Fiorentino, D., Stevens, K., Li, S., Harris, J., ...Lakshminarayanan, S. (2015). Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis.. ARTHRITIS CARE & RESEARCH, 67 (3), 425-430. doi:10.1002/acr.22434
Hachulla, E., Clerson, P., Airo, P., Cuomo, G., Allanore, Y., Caramaschi, P., ...Sarrace, M. (2015). VALUE OF SYSTOLIC PULMONARY ARTERIAL PRESSURE AS A PROGNOSTIC FACTOR OF DEATH IN SYSTEMIC SCLEROSIS EUSTAR POPULATION. RHEUMATOLOGY, 54 (7), 1262-1269. doi:10.1093/rheumatology/keu450
Denton, C.P. (2015). WHAT ARE WE AIMING TO TREAT IN SYSTEMIC SCLEROSIS TRIALS? DOES ONE SIZE FIT ALL?.

2014

López-Isac, E., Bossini-Castillo, L., Simeon, C.P., Egurbide, M.V., Alegre-Sancho, J.J., Callejas, J.L., ...Santaniello, A. (2014). A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research and Therapy, 16 (1), doi:10.1186/ar4432
Gilbane, A.J., Derrett-Smith, E.C., Pearce, A., Denton, C.P., Holmes, A.M. (2014). Aberrant Bmp Signalling In The Development Of Pulmonary Complications In Scleroderma. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 189
Gilbane, A., Derrett-Smith, E.C., Pearce, A., Denton, C.P., Holmes, A.M. (2014). ABERRANT BMP SIGNALLING MAY CONTRIBUTE TO PULMONARY COMPLICATIONS IN A TGF DEPENDENT MURINE MODEL OF SCLERODERMA.. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 32 (2), S32.
Nikitorowicz-Buniak, J., Xu, S., Denton, C.P., Stratton, R., Abraham, D. (2014). ABNORMALLY DIFFERENTIATING KERATINOCYTES IN THE EPIDERMIS OF SYSTEMIC SCLEROSIS PATIENTS SHOW ENHANCED SECRETION OF CCN2 AND S100A9.
Guerra, S.G., Abdi, B.A., Ong, V.H., Abraham, D.J., Denton, C.P., Fonseca, C. (2014). ABSENCE OF ASSOCIATION FOR DDAH1 POLYMORPHISM, RS17384213, WITH SCLERODERMA RENAL CRISIS HIGHLIGHTS DIVERSITY IN RENAL COMPLICATIONS OF CONNECTIVE TISSUE DISEASE.
Bruni, C., Lages, A., Patel, H., Harvey, J., Ong, V.H., Matucci-Cerinic, M., ...Denton, C.P. (2014). An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma.. ARTHRITIS & RHEUMATOLOGY, 66 S750.
Moinzadeh, P., Fonseca, C., Hellmich, M., Shah, A.A., Chighizola, C., Denton, C.P., Ong, V.H. (2014). Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.. Arthritis Res Ther, 16 (1), R53-?. doi:10.1186/ar4486
Visovatti, S.H., Distler, O., Coghlan, J.G., Denton, C.P., Grünig, E., Bonderman, D., ...Seibold, J.R. (2014). Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study.. ARTHRITIS RESEARCH & THERAPY, 16 (6), doi:10.1186/s13075-014-0493-1
Good, R., Trinder, S., Abdi, S.A., Yu, R., Denton, C.P., Abraham, D., Holmes, A. (2014). CHARACTERISATION OF LATE-OUTGROWTH ENDOTHELIAL PROGENITOR CELLS FROM SYSTEMIC SCLEROSIS PATIENTS. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 32 (2), S32-S33.
Becvar, R., Matucci-Cerinic, M., Denton, C.P., Schwierin, B., Du Roure, C., Rosenberg, D., ...Guillevin, L. (2014). CLINICAL FEATURES AND CHARACTERISTICS OF PATIENTS WITH DIGITAL ULCERS (DU) IN SYSTEMIC SCLEROSIS (SSC) IN THE CZECH REPUBLIC: DATA FROM THE DUO REGISTRY.
Saketkoo, L.A., Mittoo, S., Huscher, D., Khanna, D., Dellaripa, P.F., Distler, O., ...Denton, C.P. (2014). Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials (vol 69, pg 428, 2014). THORAX, 69 (9),
Saketkoo, L.A., Mittoo, S., Huscher, D., Khanna, D., Dellaripa, P.F., Distler, O., ...Denton, C.P. (2014). Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials.. THORAX, 69 (5), 428-436. doi:10.1136/thoraxjnl-2013-204202
Hansi, N., Thoua, N., Carulli, M., Chakravarty, K., Lal, S., Smyth, A., ...Mclaughlin, J. (2014). Consensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clinical and experimental rheumatology, 32 (6),
Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., ...Machado, R.F. (2014). Correction: Updated clinical classification of pulmonary hypertension (Journal of the American College of Cardiology (2013) 62, (D34-D41)). Journal of the American College of Cardiology, 63 (7), 1p-. doi:10.1016/j.jacc.2013.12.004
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2014). Current management strategies for systemic sclerosis. Clinical and Experimental Rheumatology, 32 (SUPPL.81),
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2014). Current management strategies for systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 32 (2), S156-S164.
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2014). Current management strategies for systemic sclerosis.. Clinical and experimental rheumatology, 32 (2 Suppl 81), 156-164.
Domsic, R.T., Nihtyanova, S.I., Wisniewski, S.R., Fine, M.J., Lucas, M., Kwoh, C.K., ...Medsger, T.A. (2014). Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis.. ARTHRITIS & RHEUMATOLOGY, 66 (6), 1616-1624. doi:10.1002/art.38381
Domsic, R.T., Nihtyanova, S.I., Lucas, M., Wisniewski, S.R., Fine, M.J., Kwoh, C.K., ...Medsger, T.A. (2014). Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients..
Khanna, D., Berrocal, V., Giannini, E., Mayes, M., Merkel, P.A., Siegel, J., ...Allanore, Y. (2014). Development of a Composite Index for Clinical Trials in Early Diffuse Cutaneous Systemic sclerosis-the Combined Response Index in Systemic Sclerosis.. ARTHRITIS & RHEUMATOLOGY, 66 S1311-S1312.
Coghlan, J.G., Denton, C.P., Grünig, E., Bonderman, D., Distler, O., Khanna, D., ...Doelberg, M. (2014). Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.. ANNALS OF THE RHEUMATIC DISEASES, 73 (7), 1340-1349. doi:10.1136/annrheumdis-2013-203301
Denton, C.P. (2014). HOW TO TREAT RAPIDLY PROGRESSIVE SSC. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 32 (2), S13.
Garner, I.M., Evans, I.C., Barnes, J.L., Maher, T.M., Renzoni, E.A., Denton, C.P., ...McAnulty, R.J. (2014). Hypomethylation Of The Tnxb Gene Contributes To Increased Expression And Deposition Of Tenascin-X In Idiopathic Pulmonary Fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 189
Lopez-Isac, E., Bossini-Castillo, L., Guerra, S.G., Denton, C., Fonseca, C., Assassi, S., ...Ortego-Centeno, N. (2014). Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus. ARTHRITIS & RHEUMATOLOGY, 66 (12), 3521-3523. doi:10.1002/art.38870
Alade, R., Xu, S., Khan, K., Tam, A., Denton, C.P., Ong, V.H. (2014). IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma..
Alade, R.O., Xu, S., Denton, C.P., Ong, V.H. (2014). IL6 TRANS-SIGNALLING MEDIATES M2 MACROPHAGE POLARIZATION AND FIBROTIC RESPONSE IN SSc.
Mayes, M.D., Bossini-Castillo, L., Gorlova, O., Martin, J.E., Zhou, X., Chen, W.V., ...Arnett, F.C. (2014). Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. AMERICAN JOURNAL OF HUMAN GENETICS, 94 (1), 47-61. doi:10.1016/j.ajhg.2013.12.002
Gilbane, A.J., Derrett-Smith, E.C., Pearce, A., Denton, C.P., Holmes, A.M. (2014). Increased Degradation of BMPR2 in a TGF beta Dependent Transgenic Mouse Model of Scleroderma with Susceptibility to Pulmonary Arterial Hypertension.. ARTHRITIS & RHEUMATOLOGY, 66 S332.
Wells, A.U., Denton, C.P. (2014). Interstitial lung disease in connective tissue disease--mechanisms and management.. NATURE REVIEWS RHEUMATOLOGY, 10 (12), 728-739. doi:10.1038/nrrheum.2014.149
Wells, A.U., Margaritopoulos, G.A., Antoniou, K.M., Denton, C. (2014). Interstitial lung disease in systemic sclerosis. Seminars in Respiratory and Critical Care Medicine, 35 (2), 213-221. doi:10.1055/s-0034-1371541
Stratton, R., Xu, S., Nikitorowicz-Buniak, J., Abdi-Ahmed, B., Ponticos, M., Denton, C.P., ...Smith, B. (2014). INVESTIGATING THE ROLE OF MRTF-A IN SYSTEMIC SCLEROSIS.
Avouac, J., Walker, U.A., Czirjak, L., Denton, C.P., Ladner, U.M., Allanore, Y. (2014). JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY.
Avouac, J., Walker, U., Hachulla, E., Riemekasten, G., Cuomo, G., Carreira, P.E., ...Czirjak, L. (2014). Joint and Tendon Involvement Predict Severe Disease Progression in Systemic Sclerosis: A Prospective Study.
Nihtyanova, S.I., Fonseca, C., Ong, V.H., Denton, C.P. (2014). LONG-TERM SURVIVAL IN SYSTEMIC SCLEROSIS PATIENTS: DEVELOPMENT OF A PREDICTIVE MODEL.
Leask, A., Shi-Wen, X., Khan, K., Chen, Y., Holmes, A., Eastwood, M., ...Abraham, D.J. (2014). Loss of protein kinase Cε results in impaired cutaneous wound closure and myofibroblast function.. JOURNAL OF CELL SCIENCE, 127 (15), 3396. doi:10.1242/jcs.158261
Ngcozana, T., Ong, V., Denton, C.P. (2014). Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists.. BMJ Case Reports, doi:10.1136/bcr-2013-203174
Johnson, S.R., Naden, R.P., Fransen, J., van den Hoogen, F., Pope, J.E., Baron, M., ...Distler, O. (2014). Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria.. JOURNAL OF CLINICAL EPIDEMIOLOGY, 67 (6), 706-714. doi:10.1016/j.jclinepi.2013.12.009
Clark, K.E.N., Lopez, H., Xue, S., Abdi, B., Nikotorowicz-Buniak, J., Khan, K., ...Stratton, R.J. (2014). MULTIPLEX CYTOKINE ANALYSIS OF DERMAL INTERSTITIAL BLISTER FLUID IN SYSTEMIC SCLEROSIS DEFINES POTENTIAL PATHOGENIC PATHWAYS AND DIFFERENTIATES CLINICAL SUBSETS.
Nihtyanova, S.I., Schreiber, B.E., Ong, V.H., Rosenberg, D., Moinzadeh, P., Coghlan, J.G., ...Denton, C.P. (2014). Prediction of pulmonary complications and long-term survival in systemic sclerosis.. ARTHRITIS & RHEUMATOLOGY, 66 (6), 1625-1635. doi:10.1002/art.38390
Minier, T., Guiducci, S., Bellando-Randone, S., Bruni, C., Lepri, G., Czirják, L., ...Allanore, Y. (2014). Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: Evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Annals of the Rheumatic Diseases, 73 (12), 2087-2093. doi:10.1136/annrheumdis-2013-203716
Butt, S.K., Alam, A., Raeburn, A., Liwanag, J., Ong, V.H., Denton, C.P., ...Emmanuel, A. (2014). PRELIMINARY SIGNIFICANT FINDINGS FROM A RANDOMISED CONTROL TRIAL OF POSTERIOR TIBIAL NERVE STIMULATION IN SYSTEMIC SCLEROSIS ASSOCIATED FAECAL INCONTINENCE.
Derrett-Smith, E.C., Sobanski, V., Trinder, S., Gilbane, A.J., Iglarz, M., Abraham, D.J., ...Denton, C.P. (2014). Prevention of SU5416-Induced Pulmonary Hypertension in a TGF beta Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan.. ARTHRITIS & RHEUMATOLOGY, 66 S751-S752.
Gillespie, J., Derrett-Smith, E.C., McDermott, M., Emery, P., Denton, C.P., Del Galdo, F. (2014). Priming of WNT Signalling during Fibrosis Is Mediated By TGF-beta Induced Axin-2 Downregulation.. ARTHRITIS & RHEUMATOLOGY, 66 S431.
Denton, C.P. (2014). RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS.
Lynch, B.M., Sobanski, V., Handler, C.E., Schreiber, B.E., Coghlan, J.G., Burns, A., Denton, C.P. (2014). Reduced eGFR in systemic sclerosis associated pulmonary arterial hypertension is a marker of severity. IRISH JOURNAL OF MEDICAL SCIENCE, 183 S102-S103.
Kundu, D., Abraham, D., Black, C.M., Denton, C.P., Bruckdorfer, K.R. (2014). Reduced levels of S-nitrosothiols in plasma of patients with systemic sclerosis and Raynaud's phenomenon.. Vascul Pharmacol, 63 (3), 178-181. doi:10.1016/j.vph.2014.09.003
Lages, A., Beynon, H., Denton, C.P., Ong, V. (2014). REVISITING ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND SARCOIDOSIS: PREVALENCE AND CLINICAL FEATURES.
Khanna, D., Denton, C.P., van Laar, J.M., Jahreis, A., Cheng, S., Spotswood, H., ...Furst, D.E. (2014). Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial.. ARTHRITIS & RHEUMATOLOGY, 66 S386.
Khanna, D., Denton, C.P., Jagerschmidt, A., Jasson, M., Distler, O., Allanore, Y. (2014). SAR100842, an Antagonist of Lysophaphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study.. ARTHRITIS & RHEUMATOLOGY, 66 S387.
Lopez, H., Clark, K., Shiwen, X., Denton, C.P., Martin, G., Abraham, D., Stratton, R. (2014). SCLERODERMA BLISTER FLUID PROMOTES PDGF-DEPENDENT LUNG FIBROBLAST MIGRATION ON ALIGNED COLLAGEN SUBSTRATES: ANTAGONISM BY IMATINIB AND HEPARIN IN COMBINATION.
Lynch, B.M., Sobanski, V., Handler, C.E., Schreiber, B.E., Coghlan, J.G., Ong, V., ...Denton, C.P. (2014). Scleroderma renal crisis and pulmonary arterial hypertension are rare in the same patient. IRISH JOURNAL OF MEDICAL SCIENCE, 183 S102.
Orteu, C.H., Denton, C.P. (2014). Scleromyxoedema. In Skin Manifestations in Rheumatic Disease. (pp. 265-271). .
O'Kane, D., Jackson, M.V., Kissenpfennig, A., Spence, S., Damkat-Thomas, L., Tolland, J.P., ...McAuley, D.F. (2014). SMAD inhibition attenuates epithelial to mesenchymal transition by primary keratinocytes in vitro.. EXPERIMENTAL DERMATOLOGY, 23 (7), 497-503. doi:10.1111/exd.12452
Derrett-Smith, E.C., Denton, C.P. (2014). Systemic sclerosis: Clinical features and management. Medicine (United Kingdom), 42 (3), 167-173. doi:10.1016/j.mpmed.2013.12.004
Müller-Ladner, U., Tyndall, A., Czirjak, L., Denton, C., Matucci-Cerinic, M. (2014). Ten years EULAR Scleroderma Research and Trials (EUSTAR): What has been achieved?. Annals of the Rheumatic Diseases, 73 (2), 324-327. doi:10.1136/annrheumdis-2013-203997
Lynch, B.M., Penn, H., Harvey, J., Burns, A., Denton, C.P. (2014). The prognosis of Scleroderma Renal Crisis in RNA-polymerase III antibody (ARA) positive compared to ARA negative patients. IRISH JOURNAL OF MEDICAL SCIENCE, 183 S102.
Lynch, B.M., Penn, H., Harvey, J., Burns, A., Denton, C.P. (2014). THE PROGNOSIS OF SCLERODERMA RENAL CRISIS IN RNA-POLYMERASE III ANTIBODY-POSITIVE COMPARED TO RNA-POLYMERASE III ANTIBODY-NEGATIVE PATIENTS.
Abdi, B.A., Etomi, O.T., Xu, S., Abraham, D., Denton, C.P., Stratton, R.J. (2014). THE ROLE OF STEM CELL FACTOR AND c-Kit IN PATIENTS WITH SYSTEMIC SCLEROSIS.
Liakouli, V., Scarcia, M., Abignano, G., Derrett-Smith, E.C., Gillespie, J., Cipriani, P., ...Mavria, G. (2014). Transforming Growth Factor Beta Induces anti Angio and Vasculo-Genesis Phenotype in Dermal Fibroblasts through Secretion of Pigment Epithelium Derived Factor.. ARTHRITIS & RHEUMATOLOGY, 66 S337.
Quillinan, N.P., McIntosh, D., Vernes, J., Haq, S., Denton, C.P. (2014). Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.. ANNALS OF THE RHEUMATIC DISEASES, 73 (1), 56-61. doi:10.1136/annrheumdis-2013-203674
Adler, S., Huscher, D., Allanore, Y., Czirjak, L., Del Galdo, F., Denton, C.P., ...Mueller-Ladner, U. (2014). USE OF IMMUNOSUPPRESSANTS IN SSC PATIENTS WITH INTERSTITIAL LUNG DISEASE - RESULTS OF THE DESSCIPHER PROJECT OF THE EUSTAR GROUP. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 32 (2), S85-S86.
Clark, K.E.N., Lopez, H., Xu, S., Abdi, B.A., Martin, G., Khan, K., ...Stratton, R.J. (2014). Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis.. ARTHRITIS & RHEUMATOLOGY, 66 S333-S334.

2013

Van Den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., ...Carreira, P.E. (2013). 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. ANNALS OF THE RHEUMATIC DISEASES, 72 (11), 1747-1755. doi:10.1136/annrheumdis-2013-204424
Van Den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., ...Carreira, P.E. (2013). 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative. Arthritis and Rheumatism, 65 (11), 2737-2747. doi:10.1002/art.38098
van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., ...Carreira, P.E. (2013). 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.. ARTHRITIS AND RHEUMATISM, 65 (11), 2737-2747. doi:10.1002/art.38098
Martin, J.E., Assassi, S., Diaz-Gallo, L.M., Broen, J.C., Simeon, C.P., Castellvi, I., ...González-Gay, M.A. (2013). A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 22 (19), 4021-4029. doi:10.1093/hmg/ddt248
Gilbane, A.J., Derrett-Smith, E.C., Trinder, S., Pearce, A., Denton, C.P., Holmes, A.M. (2013). Altered BMP Signalling In a TGF beta Dependent Murine Model Of Scleroderma May Contribute To Development Of Pulmonary Arterial Hypertension.
Denton, C.P., Coghlan, J.G., Gruenig, E., Bonderman, D., Distler, O., Khanna, D., ...Doelberg, M. (2013). AN EVIDENCE-BASED TOOL FOR DETECTION OF PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: THE DETECT STUDY.
Tang, X., Peng, R., Phillips, J.E., Deguzman, J., Ren, Y., Apparsundaram, S., ...DeMartino, J.A. (2013). Assessment of Brd4 Inhibition in Idiopathic Pulmonary Fibrosis Lung Fibroblasts and in Vivo Models of Lung Fibrosis. AMERICAN JOURNAL OF PATHOLOGY, 183 (2), 470-479. doi:10.1016/j.ajpath.2013.04.020
van Laar, J.M., Nihtyanova, S.I., Naraghi, K., Denton, C.P., Tyndall, A. (2013). Autologous HSCT for systemic sclerosis.. LANCET, 381 (9883), 2079-2080. doi:10.1016/S0140-6736(13)61239-8
Khanna, D., Distler, O., Coghlan, J.G., Denton, C.P., Gruenig, E., Bonderman, D., ...Torres-Martin, J.-.V. (2013). BASELINE CHARACTERISTICS OF SYSTEMIC SCLEROSIS PATIENTS WITH BORDERLINE MEAN PULMONARY ARTERY PRESSURE: POST-HOC ANALYSIS FROM THE DETECT STUDY.
Valerio, C.J., Schreiber, B.E., Handler, C.E., Denton, C.P., Coghlan, J.G. (2013). Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.. ARTHRITIS AND RHEUMATISM, 65 (4), 1074-1084. doi:10.1002/art.37838
Sobanski, V., Lynch, B., Schreiber, B.E., Handler, C., Denton, C.P., Coghlan, J.G. (2013). Can Changes In NT-Probnp Predict Early Response To Therapy and Prognosis In Systemic Sclerosis Associated Pre-Capillary Pulmonary Hypertension?.
Sobanski, V., Lynch, B.M., Schreiber, B.E., Handler, C.E., Denton, C.P., Coghlan, J.G. (2013). CAN CHANGES IN NT-PROBNP PREDICT EARLY RESPONSE TO THERAPY AND PROGNOSIS IN SYSTEMIC SCLEROSIS ASSOCIATED PRE-CAPILLARY PULMONARY HYPERTENSION?.
Denton, C.P. (2013). CASE 2 DISCUSSION: CALCINOSIS CUTIS. ANNALS OF THE RHEUMATIC DISEASES, 71 25-26. doi:10.1136/annrheumdis-2012-eular.1576
Dobarro, D., Schreiber, B.E., Handler, C., Beynon, H., Denton, C.P., Coghlan, J.G. (2013). Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data.. AMERICAN JOURNAL OF CARDIOLOGY, 111 (2), 278-285. doi:10.1016/j.amjcard.2012.09.031
Matucci-Cerinic, M., Krieg, T., Guillevin, L., Schwierin, B., Scott, M., Rosenberg, D., Denton, C.P. (2013). CLINICAL FEATURES OF SYSTEMIC SCLEROSIS IN PATIENTS WITH AND WITHOUT RECURRENT DIGITAL ULCERS: FINDINGS FROM THE DUO REGISTRY.
Hong, C.F., Khan, K., Alade, R., Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2013). CLINICAL SIGNIFICANCE OF IL-6 AND CCL2 UPREGULATION IN SERUM AND RENAL BIOPSIES FROM CASES OF SCLERODERMA RENAL CRISIS.
Bossini-Castillo, L., Martin, J.E., Broen, J., Simeon, C.P., Beretta, L., Gorlova, O.Y., ...Carreira, P. (2013). Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 72 (4), 602-607. doi:10.1136/annrheumdis-2012-201888
Derrett-Smith, E.C., Dooley, A., Gilbane, A.J., Trinder, S.L., Khan, K., Baliga, R., ...Denton, C.P. (2013). Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.. Arthritis Rheum, 65 (11), 2928-2939. doi:10.1002/art.38078
Good, R.W.G., Trinder, S.L.T., Abdi, B.A.A., Yu, R.Y., Denton, C.P.D., Abraham, D.J.A., Holmes, A.M.H. (2013). ENDOTHELIAL PROGENITOR CELLS FORM BIOLOGICAL EXCLUSION BARRIERS SIMILAR TO THAT OF MATURE ENDOTHELIAL CELLS- A THERAPEUTIC POTENTIAL IN SYSTEMIC SCLEROSIS?.
Parker, L., Ponte, C., Denton, C.P., Schreiber, B.E. (2013). ERYTHROMELALGIA CLINICAL CHARACTERISTICS AND RESPONSE TO THERAPY IN 46 PATIENTS FROM A SINGLE CENTRE.
Ramanayake, W., Jones, H., Orriss, I., Arnett, T., Pitsillides, A., Denton, C.P., ...Poulet, B. (2013). Fibrillin-1 Expression and Function Is Needed For Normal Joint Function and Mutations Leads To Osteoarthritis.
Guillevin, L., Hunsche, E., Denton, C.P., Krieg, T., Schwierin, B., Rosenberg, D., ...Trautinger, F. (2013). Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 31 (2), S71-S80.
Guillevin, L., Hunsche, E., Denton, C.P., Krieg, T., Schwierin, B., Rosenberg, D., Matucci-Cerinic, M. (2013). Functional impairment of systemic scleroderma patients with digital ulcerations: Results from the DUO registry. Clinical and Experimental Rheumatology, 31 (SUPPL.76),
Guillevin, L., Hunsche, E., Denton, C.P., Krieg, T., Schwierin, B., Rosenberg, D., ...DUO Registry, G.r.o.u.p. (2013). Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry.. Clinical and experimental rheumatology, 31 (2 Suppl 76), 71-80.
Garner, I.M., Evans, I.C., Maher, T.M., Renzoni, E.A., Denton, C.P., Scotton, C.J., ...McAnulty, R.J. (2013). Genome-wide analysis identifies multiple genes with altered methylation and expression in IPF and SSc lung fibroblasts.
Miller, F.W., Cooper, R.G., Vencovsky, J., Rider, L.G., Danko, K., Wedderburn, L.R., ...Ytterberg, S.R. (2013). Genome-Wide Association Study of Dermatomyositis Reveals Genetic Overlap With Other Autoimmune Disorders. ARTHRITIS AND RHEUMATISM, 65 (12), 3239-3247. doi:10.1002/art.38137
Amin, K., Sivakumar, B., Clarke, A., Puri, A., Denton, C., Butler, P.E. (2013). Hand disease in scleroderma: a clinical correlate for chronic hand transplant rejection. SpringerPlus, 2 (1), doi:10.1186/2193-1801-2-577
Garner, I.M., Evans, I.C., Barnes, J.L., Maher, T.M., Renzoni, E.A., Denton, C.P., ...McAnulty, R.J. (2013). Hypomethylation of the TNXB gene contributes to increased expression and deposition of tenascin X in idiopathic pulmonary fibrosis.
Alade, R., Khan, K., Shiwen, X., Denton, C.P., Ong, V. (2013). IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma..
Mayes, M.D., Bossini-Castillo, L., Gorlova, O., Martin, J.E., Zhou, X., Chen, W., ...Gregersen, P.K. (2013). Immunochip Analysis Identifies New Susceptibility Loci For Systemic Sclerosis: Implications For Pathogenesis.
Denton, C.P., Guillevin, L., Hunsche, E., Rosenberg, D., Schwierin, B., Scott, M., ...Herrick, A. (2013). IMPACT OF DIGITAL ULCERS IN SCLERODERMA ON WORK AND DAILY ACTIVITIES: A SUBGROUP ANALYSIS OF UK PATIENTS ENROLLED IN THE DUO REGISTRY.
Diaz-Gallo, L.-.M., Simeon, C.P., Broen, J.C., Ortego-Centeno, N., Beretta, L., Vonk, M.C., ...González-Gay, M.A. (2013). Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility.. ANNALS OF THE RHEUMATIC DISEASES, 72 (7), 1233-1238. doi:10.1136/annrheumdis-2012-202357
Nihtyanova, S., Schreiber, B., Ong, V., Denton, C.P. (2013). INCIDENCE AND PREDICTORS OF PULMONARY COMPLICATIONS IN SYSTEMIC SCLEROSIS.
Stock, C., Sato, H., Fonseca, C., Wells, A.U., Denton, C.P., Abraham, D.J., ...Renzoni, E.A. (2013). IRF5 POLYMORPHISMS IN SYSTEMIC SCLEROSIS.
Avouac, J., Czirjak, L., Walker, U.A., Denton, C.P., Mueller-Ladner, U., Allanore, Y., Network, E.U.S.T.A.R. (2013). JOINT AND TENDON INVOLVEMENT PREDICT SEVERE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: A EUSTAR PROSPECTIVE STUDY. ANNALS OF THE RHEUMATIC DISEASES, 72 498.
Maurer, B., Distler, A., Dees, C., Khan, K., Denton, C.P., Abraham, D., ...Hw Distler, J. (2013). Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.. ANNALS OF THE RHEUMATIC DISEASES, 72 (12), 2039-2046. doi:10.1136/annrheumdis-2013-203729
Matucci-Cerinic, M., Guillevin, L., Denton, C.P., Schwierin, B., Rosenberg, D., Krieg, T. (2013). MANAGEMENT OF DIGITAL ULCER DISEASE VARIES ACROSS EUROPE: FINDINGS FROM THE DUO REGISTRY.
Lindahl, G.E., Stock, C.J., Shi-Wen, X., Leoni, P., Sestini, P., Howat, S.L., ...Grutters, J.C. (2013). Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.. RESPIRATORY RESEARCH, 14 doi:10.1186/1465-9921-14-80
Stock, C.J., Sato, H., Fonseca, C., Banya, W.A.S., Molyneaux, P.L., Adamali, H., ...Hansell, D.M. (2013). Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.. THORAX, 68 (5), 436-441. doi:10.1136/thoraxjnl-2012-201786
Clark, K.E.N., Lopez, H., Nikotorowicz-Buniak, J., Shiwen, X., Khan, K., Martin, G., ...Stratton, R.J. (2013). Multiplex Cytokine Analysis Of Dermal Interstitial Blister Fluid In Systemic Sclerosis Defines Potential Pathogenic Pathways and Differentiates Clinical Subsets.
Carmona, F.D., Cénit, M.C., Diaz-Gallo, L.-.M., Broen, J.C.A., Simeón, C.P., Carreira, P.E., ...González-Gay, M.A. (2013). New insight on the Xq28 association with systemic sclerosis.. ANNALS OF THE RHEUMATIC DISEASES, 72 (12), 2032-2038. doi:10.1136/annrheumdis-2012-202742
Loder, C.D., Denton, C.P., Haddock, J., Wagner, T., Dobaro, D., Handler, C., ...Coghlan, J.G. (2013). OCT As A Rule Out Test For Thromboembolism In Pulmonary Arterial Hypertension: Insights From A OCT Study Of The Pulmonary Vascular Tree.
Nihtyanova, S., Ong, V., Denton, C.P. (2013). ORGAN-BASED COMPLICATIONS AND SURVIVAL IN MALE AND FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS.
Derrett-Smith, E., Neal, M., Abraham, D.J., Salama, A., Little, M.A., Denton, C.P. (2013). Perturbed Response To Experimental Renal Injury In a TGF beta Dependent Mouse Model Of Scleroderma..
Nihtyanova, S.I., Schreiber, B.E., Ong, V.H., Coghlan, J.G., Wells, A.U., Denton, C.P. (2013). Prediction Of Pulmonary Complications In Systemic Sclerosis Model Development and Validation.
Lynch, B.M., Sobanski, V., Handler, C.E., Schreiber, B.E., Denton, C.P., Coghlan, J.G. (2013). PULMONARY ARTERIAL HYPERTENSION COMPLICATING PRIMARY SJOGREN SYNDROME: A RARE ASSOCIATION.
Sobanski, V., Lynch, B., Schreiber, B.E., Nihtyanova, S.I., Harvey, J., Handler, C., ...Coghlan, J.G. (2013). Pulmonary Hypertension In Patients With Anti-U1-RNP Antibodies.
derrett-smith, E., Nihtyanova, S., harvey, J., Salama, A.D., denton, C. (2013). Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology,
Denton, C.P. (2013). ROLE OF FIBROBLASTS IN SCLERODERMA. ANNALS OF THE RHEUMATIC DISEASES, 71 12. doi:10.1136/annrheumdis-2012-eular.1522
Gilbane, A.J., Denton, C.P., Holmes, A.M. (2013). Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells.. ARTHRITIS RESEARCH & THERAPY, 15 (3), doi:10.1186/ar4230
Lynch, B., Sobanski, V., Handler, C., Schreiber, B.E., Coghlan, J.G., Ong, V.H., ...Denton, C.P. (2013). Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient.
De Lauretis, A., Sestini, P., Pantelidis, P., Hoyles, R., Hansell, D.M., Goh, N.S.L., ...Denton, C.P. (2013). Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.. JOURNAL OF RHEUMATOLOGY, 40 (4), 435-446. doi:10.3899/jrheum.120725
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2013). Systemic Sclerosis Disease Subset Is a Better Predictor Of Long Term Outcome Than Autoantibody Profile..
Denton, C.P., Ong, V.H. (2013). Targeted therapies for systemic sclerosis.. NATURE REVIEWS RHEUMATOLOGY, 9 (8), 451-464. doi:10.1038/nrrheum.2013.46
Penn, H., Quillinan, N., Khan, K., Chakravarty, K., Ong, V.H., Burns, A., Denton, C.P. (2013). Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility.. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 106 (9), 839-848. doi:10.1093/qjmed/hct111
Lynch, B., Penn, H., Harvey, J., Burns, A., Denton, C.P. (2013). The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients.
Trinder, S.L.L., Shi-wen, X., Abdi, B.A., Denton, C.P., Budd, D.C., Abraham, D.J., Holmes, A.M. (2013). THE ROLE OF ENDOTHELIN RECEPTORS (ETRA/B) IN FIBROCYTE DIFFERENTIATION.
Carmona, F.D., Martin, J.E., Beretta, L., Simeón, C.P., Carreira, P.E., Callejas, J.L., ...Camps, M.T. (2013). The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS ONE, 8 (1), doi:10.1371/journal.pone.0054419
Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., ...Machado, R.F. (2013). Updated clinical classification of pulmonary hypertension.
Simonneau, G., Robbins, I.M., Beghetti, M., Channick, R.N., Delcroix, M., Denton, C.P., ...Jing, Z.-.C. (2013). Updated clinical classification of pulmonary hypertension.. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 62 (25), D34-D41. doi:10.1016/j.jacc.2013.10.029
Chung, L., Vergara, A.M.V., Fiorentino, D., Stevens, K., Li, S., Harris, J., ...Lakshminarayanan, S. (2013). Validation Of a Novel Radiographic Scoring System For Calcinosis Affecting The Hands Of Patients With Systemic Sclerosis..
Hachulla, E., Denton, C., Coghlan, G. (2013). Value of early diagnosis of pulmonary arterial hypertension associated with systemic sclerosis. In Novel Insights into Systemic Sclerosis Management. (pp. 105-116). .

2012

Bossini-Castillo, L., Martin, J.E., Broen, J., Gorlova, O., Simeón, C.P., Beretta, L., ...Carreira, P. (2012). A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 21 (4), 926-933. doi:10.1093/hmg/ddr522
Stock, C., Sato, H., Fonseca, C., Lindahl, G.E., Maher, T.M., Wells, A.U., ...Renzoni, E.A. (2012). A MUC5B PROMOTER POLYMORPHISM AND PULMONARY FIBROSIS IN SSc.
Bossini-Castillo, L., Simeon, C.P., Beretta, L., Broen, J.C., Vonk, M.C., Ríos-Fernández, R., ...Castillo, M.J. (2012). A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis.. ARTHRITIS RESEARCH & THERAPY, 14 (2), doi:10.1186/ar3809
Quillinan, N.P., McIntosh, D., Haq, S., Denton, C.P. (2012). A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy.
Trinder, S.L., Gilbane, A., Ponticos, M., Donovan, J., Denton, C.P., Abraham, D.J., Holmes, A.M. (2012). A Putative Role for the TGF beta Accessory Receptors Betaglycan and Endoglin in pulmonary Complications of Scleroderma..
Broen, J.C.A., Bossini-Castillo, L., van Bon, L., Vonk, M.C., Knaapen, H., Beretta, L., ...Worthington, J. (2012). A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators.. ARTHRITIS AND RHEUMATISM, 64 (1), 264-271. doi:10.1002/art.33325
Fonseca, C., Ahmed, B., Ong, V., Denton, C.P., Abraham, D. (2012). ANALYSIS OF A POLYMORPHISM (RS763361) IN THE CD226 GENE IN UK PATIENTS WITH SSc.
Moinzadeh, P., Fonseca, C., Abraham, D.J., Ong, V.H., Denton, C.P. (2012). ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE IL-7R AND IL-7 GENE IN SSc PATIENTS.
Donovan, J., Denton, C.P., Norman, J., Abraham, D.A. (2012). ANALYSIS OF SPECIFIC PDGFR alpha AND PDGFR beta SIGNAL TRANSDUCTION PATHWAYS IN SSc FIBROBLASTS AND EXAMINATION OF CUTANEOUS WOUND HEALING AND FIBROSIS IN A PDGFR alpha KNOCKOUT MOUSE.
Betteridge, Z.E., Woodhead, F., Bunn, C., Denton, C.P., Abraham, D., Desai, S., ...McHugh, N. (2012). ANTI-EIF2 IS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS.
Moinzadeh, P., Fonseca, C., Hellmich, M., Shah, A., Chighizola, C., Denton, C.P., Ong, V. (2012). ASSOCIATION OF SYSTEMIC SCLEROSIS WITH DIFFERENT AUTOANTIBODY SUBGROUPS AND MALIGNANCIES: A RETROSPECTIVE REGISTRY-BASED UK COHORT STUDY.
Schreiber, B.E., Dobarro, D., Warrell, C.E., Handler, C., Denton, C.P., Coghlan, G. (2012). BIG IS BEAUTIFUL: BODY SIZE AND SURVIVAL IN CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY ARTERIAL HYPERTENSION.
Moinzadeh, P., Denton, C.P., Abraham, D., Ong, V., Hunzelmann, N., Eckes, B., Krieg, T. (2012). Biomarkers for skin involvement and fibrotic activity in scleroderma.. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 26 (3), 267-276. doi:10.1111/j.1468-3083.2011.04206.x
Ishorari, J., Bunn, C., Beynon, H., Denton, C.P., Stratton, R. (2012). CLINICAL AND LABORATORY FEATURES OF PATIENTS PRESENTING TO A RHEUMATOLOGY CLINIC WITH POSITIVE ANTI-C1Q ANTIBODY SEROLOGY.
Khan, K., Xu, S., Nihtyanova, S., Derrett-Smith, E., Abraham, D., Denton, C.P., Ong, V.H. (2012). Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.. ANNALS OF THE RHEUMATIC DISEASES, 71 (7), 1235-1242. doi:10.1136/annrheumdis-2011-200955
Carreira, P., Carmona, L., Joven, B.E., Denton, C.P., Allanore, Y., Walker, U.A., ...Muller-Ladner, U. (2012). CLINICAL ASSOCIATIONS OF PULMONARY HYPERTENSION IN EARLY SSc: A REPORT FROM THE EULAR SCLERODERMA TRIALS AND RESEARCH GROUP (EUSTAR) DATABASE.
Chung, L., Denton, C.P., Distler, O., Furst, D.E., Khanna, D., Merkel, P.A. (2012). Clinical trial design in scleroderma: where are we and where do we go next?. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 30 (2), S97-S102.
Chung, L., Denton, C.P., Distler, O., Furst, D.E., Khanna, D., Merkel, P.A. (2012). Clinical trial design in scleroderma: Where are we and where do we go next?. Clinical and Experimental Rheumatology, 30 (SUPPL.71),
Chung, L., Denton, C.P., Distler, O., Furst, D.E., Khanna, D., Merkel, P.A., Scleroderma Clinical Trials, C.o.n.s.o.r.t.i.u.m. (2012). Clinical trial design in scleroderma: where are we and where do we go next?. Clinical and experimental rheumatology, 30 (2 Suppl 71), S97-102.
Bossini-Castillo, L., Martin, J.E., Simeon, C.P., Beretta, L., Gorlova, O.Y., Vonk, M.C., ...Hoffmann-Vold, A.-.M. (2012). Confirmation of TNIP1 As a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study..
Denton, C.P., Krieg, T., Guillevin, L., Schwierin, B., Rosenberg, D., Silkey, M., ...DUO Registry, i.n.v.e.s.t.i.g.a.t.o.r.s. (2012). Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry.. ANNALS OF THE RHEUMATIC DISEASES, 71 (5), 718-721. doi:10.1136/annrheumdis-2011-200631
Saketkoo, L.A., Huscher, D., Khanna, D., Dellaripa, P.F., Flaherty, K., Oddis, C.V., ...Distler, O. (2012). Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains..
Rosenberg, D.M., Schwierin, B.S., Palmer, M., Denton, C.P., Guillevin, L., Krieg, T., Matucci-Cerinic, M. (2012). Digital Ulcers Outcome Registry (DUO) in Patients with Systemic Sclerosis (SSc): Methodology To Characterize Patients in Terms of Recurrence of Digital Ulcers (DU).
Guillevin, L., Denton, C.P., Hunsche, E., Rosenberg, D., Schwierin, B., Silkey, M., ...Matucci-Cerinic, M. (2012). DIGITAL ULCERS SEVERELY IMPACT WORK AND DAILY ACTIVITIES- RESULTS FROM THE DUO REGISTRY.
Buniak, J.N., Denton, C.P., Abraham, D.J., Stratton, R.J. (2012). Enhanced Release of S100A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis..
Tam, A., Sonnylal, S., Leask, A., Denton, C.P., de Crombrugghe, B., Norman, J., Abraham, D.J. (2012). EPITHELIAL-TO-MESENCHYMAL TRANSITION AND LUNG FIBROSIS.
Derrett-Smith, E., Hoyles, R., Moinzadeh, P., Chighizola, C., Khan, K., Ong, V., ...Denton, C.P. (2012). EXPRESSION PROFILING OF SKIN AND LUNG TISSUE AND EXPLANTED FIBROBLASTS IN THE T beta RII Delta K-FIB TRANSGENIC MOUSE MODEL OF SCLERODERMA.
Domsic, R.T., Nihtyanova, S., Wisniewski, S.R., Fine, M.J., Kwoh, C.K., Denton, C.P., Jr, M.T.A. (2012). External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients..
Xu, S., Thompson, K., Khan, K., Liu, S., Denton, C.P., Leask, A., Abraham, D.J. (2012). FAK/SRC INHIBITION ALLEVIATES THE PERSISTENT FIBROTIC PHENOTYPE OF LESIONAL SCLERODERMA FIBROBLASTS.
Thoua, N.M., Abdel-Halim, M., Forbes, A., Denton, C.P., Emmanuel, A.V. (2012). Fecal incontinence in systemic sclerosis is secondary to neuropathy.. AMERICAN JOURNAL OF GASTROENTEROLOGY, 107 (4), 589-595. doi:10.1038/ajg.2011.399
Shi-wen, X., Thompson, K., Khan, K., Liu, S., Murphy-Marshman, H., Baron, M., ...Abraham, D.J. (2012). Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts.. RHEUMATOLOGY, 51 (12), 2146-2154. doi:10.1093/rheumatology/kes234
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2012). Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis..
Khan, K., Thoua, N., Dooley, A., Derrett-Smith, E., Ong, V., Abraham, D.J., Denton, C.P. (2012). GUT FIBROSIS IS ASSOCIATED WITH REDUCED COLONIC CONTRACTILITY IN A TGF-beta MOUSE MODEL.
Thoua, N.M., Derrett-Smith, E.C., Khan, K., Dooley, A., Shi-Wen, X., Denton, C.P. (2012). Gut fibrosis with altered colonic contractility in a mouse model of scleroderma.. RHEUMATOLOGY, 51 (11), 1989-1998. doi:10.1093/rheumatology/kes191
Snowden, J.A., Saccardi, R., Allez, M., Ardizzone, S., Arnold, R., Cervera, R., ...Mancardi, G. (2012). Haematopoietic SCT in severe autoimmune diseases: Updated guidelines of the European group for blood and marrow transplantation. Bone Marrow Transplantation, 47 (6), 770-790. doi:10.1038/bmt.2011.185
Sullivan, K.M., Wigley, F.M., Denton, C.P., van Laar, J.M., Furst, D.E. (2012). Haemopoietic stem-cell transplantation for systemic sclerosis. LANCET, 379 (9812), 219. doi:10.1016/S0140-6736(12)60100-7
Denton, C.P., Black, D.C.M. (2012). Historical perspective. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 3-6). .
Martin, J.E., Broen, J.C., David Carmona, F., Teruel, M., Simeon, C.P., Vonk, M.C., ...Fonollosa, V. (2012). Identification of CSK as a systemic sclerosis genetic risk factor through genome wide association study follow-up. Human Molecular Genetics, 21 (12), 2825-2835. doi:10.1093/hmg/dds099
Moinzadeh, P., Fonseca, C., Khan, K., Abraham, D., Ong, V., Denton, C.P. (2012). IL7 AXIS IN SSC: ANALYSIS OF LIGAND AND RECEPTOR SNP POLYMORPHISMS AND SERUM IL7 LEVELS.
Moinzadeh, P., Howell, K., Ong, V., Nihtyanova, S., Denton, C.P. (2012). IMPACT OF ANA SUBTYPE ON PROGRESSION FROM ISOLATED RP TO SSC: IMPLICATIONS FOR CLASSIFICATION AND EARLY DIAGNOSIS.
Moinzadeh, P., Nihtyanova, S.I., Howell, K., Ong, V.H., Denton, C.P. (2012). Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clinical Reviews in Allergy and Immunology, 43 (3), 249-255. doi:10.1007/s12016-012-8331-1
Moinzadeh, P., Nihtyanova, S.I., Howell, K., Ong, V.H., Denton, C.P. (2012). Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 43 (3), 249-255. doi:10.1007/s12016-012-8331-1
Khan, K., Shiwen, X., Abraham, D., Denton, C.P., Ong, V. (2012). IMPACT OF IL-6 TRANS-SIGNALLING IN DRIVING FIBROSIS VIA JAK2/STAT3 SIGNALLING PATHWAYS IN EARLY DCSSC.
Ngcozana, T., Denton, C.P., Parker, L., Black, C.M., Ong, V. (2012). IMPACT OF SEXUAL DYSFUNCTION AND PSYCHOLOGICAL EFFECTS IN WOMEN WITH SYSTEMIC SCLEROSIS.
Webber, M., Dobarro, D., Handler, C., Denton, C.P., Schreiber, B.E., Coghlan, J.G. (2012). Inflammatory Muscle Disease Associated Pulmonary Hypertension - Clinical Features and Survival At a National Referral Centre..
Cénit, M.C., Simeón, C.P., Vonk, M.C., Callejas-Rubio, J.L., Espinosa, G., Carreira, P., ...Román-Ivorra, J.A. (2012). Influence of the IL6 gene in susceptibility to systemic sclerosis. Journal of Rheumatology, 39 (12), 2294-2302. doi:10.3899/jrheum.120506
Ong, V.H., Denton, C.P. (2012). Investigative approaches to drug therapy. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 603-613). .
Warrell, C.E., Dobarro, D., Handler, C., Denton, C.P., Schreiber, B.E., Coghlan, J.G. (2012). IS THERE AN ASSOCIATION BETWEEN WARFARIN AND SURVIVAL IN SSC-PAH PATIENTS TREATED WITH FIRST-LINE BOSENTAN MONOTHERAPY?.
Fransen, J., Johnson, S.R., van den Hoogen, F., Baron, M., Allanore, Y., Carreira, P.E., ...Furst, D.E. (2012). Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise.. ARTHRITIS CARE & RESEARCH, 64 (3), 351-357. doi:10.1002/acr.20679
Foeldvari, I., Tyndall, A., Zulian, F., Müller-Ladner, U., Czirjak, L., Denton, C., ...Matucci-Cerinic, M. (2012). Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: Data from the Eustar database. Rheumatology (United Kingdom), 51 (10), 1832-1837. doi:10.1093/rheumatology/kes144
Bossini-Castillo, L., Simeon, C.P., Beretta, L., Broen, J., Vonk, M.C., Luis Callejas, J., ...Gonzalez-Gay, M.A. (2012). KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. ARTHRITIS RESEARCH & THERAPY, 14 (6), doi:10.1186/ar4124
Nihtyanova, S.I., Ong, V.H., Denton, C.P. (2012). Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis..
Khan, K., Shiwen, X., Abraham, D.J., Denton, C.P., Ong, V. (2012). OVEREXPRESSION OF IL-6 IN EARLY dcSSc MAY DRIVE FIBROTIC RESPONSE VIA JAK2/STAT3 SIGNALLING PATHWAYS.
Denton, C.P., Lafyatis, R. (2012). Overview of animal models. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 291-307). .
Denton, C.P. (2012). Overview: Epidemiology, genetics and classification. .
Denton, C.P. (2012). Overview: Pulmonary manifestations and management. .
Matucci-Cerinic, M., Guillevin, L., Denton, C.P., Schwierin, B., Rosenberg, D., Silkey, M., Krieg, T. (2012). PATIENTS WITH ONGOING DIGITAL ULCERS HAVE HIGHER DISEASE BURDEN COMPARED TO PATIENTS WITH A HISTORY BUT NO CURRENT DIGITAL ULCERS: FINDINGS FROM THE DUO REGISTRY.
Merkel, P.A., Silliman, N.P., Clements, P.J., Denton, C.P., Furst, D.E., Mayes, M.D., ...Seibold, J.R. (2012). Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.. ARTHRITIS AND RHEUMATISM, 64 (10), 3420-3429. doi:10.1002/art.34427
Warrell, C., Dobarro, D., Handler, C., Denton, C.P., Schreiber, B.E., Coghlan, J.G. (2012). PREDICTORS OF BOSENTAN MONOTHERAPY DISCONTINUATION IN SSc-PAH PATIENTS.
Varga, J., Denton, C.P., Wigley, F.M. (2012). Preface. .
Alcacer-Pitarch, B., Buch, M.H., Gray, J., Denton, C.P., Herrick, A., Navarro-Coy, N., ...Siddle, H.J. (2012). Pressure and pain In Systemic sclerosis/Scleroderma - an evaluation of a simple intervention (PISCES): randomised controlled trial protocol. BMC MUSCULOSKELETAL DISORDERS, 13 doi:10.1186/1471-2474-13-11
Derrett-Smith, E., Hoyles, R., Khan, K., Abraham, D.J., Denton, C.P. (2012). Resident Lung Fibroblast Gene Expression Signatures Predict Susceptibility or Resistance to Experimental Lung Fibrosis..
Carreira, P.E., Carmona, L., Joven, B.E., Denton, C.P., Allanore, Y., Walker, U.A., ......E.u.s.t.a.r. (2012). Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database..
Watson, J.M., Buniak, J.N., Shiwen, X., Abraham, D.J., Denton, C.P., Stratton, R.J. (2012). Role of Endosomal and Cell Membrane Toll-Like Receptors in Keratinocyte Activation by Systemic Sclerosis Autoantibodies..
Chighizola, C., Meroni, P.L., Schreiber, B.E., Coghlan, J.G., Denton, C.P., Ong, V.H. (2012). Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 30 (2), S81-S85.
Chighizola, C., Meroni, P.L., Schreiber, B.E., Coghlan, J.G., Denton, C.P., Ong, V.H. (2012). Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients. Clinical and Experimental Rheumatology, 30 (SUPPL.71),
Chighizola, C., Meroni, P.L., Schreiber, B.E., Coghlan, J.G., Denton, C.P., Ong, V.H. (2012). Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients.. Clin Exp Rheumatol, 30 (2 Suppl 71), S81-S85.
Denton, C.P. (2012). SCLERODERMA IN MEN.
Denton, C.P., Steen, V. (2012). Scleroderma renal crisis. In Scleroderma: From Pathogenesis to Comprehensive Management. (pp. 361-371). .
Keir, G.J., Maher, T.M., Hansell, D.M., Denton, C.P., Ong, V.H., Singh, S., ...Renzoni, E.A. (2012). Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.. EUROPEAN RESPIRATORY JOURNAL, 40 (3), 641-648. doi:10.1183/09031936.00163911
Moinzadeh, P., Khan, K., Ong, V.H., Denton, C.P. (2012). Sustained improvement of diffuse systemic sclerosis following human cytomegalovirus infection offers insight into pathogenesis and therapy.. RHEUMATOLOGY, 51 (12), 2296-2298. doi:10.1093/rheumatology/kes137
Schreiber, B.E., Keir, G., Dobarro, D., Handler, C., Nihtyanova, S., Suntharaligam, J., ...Wells, A.U. (2012). Systemic Sclerosis Associated Pulmonary Hypertension - Is Pulmonary Veno-Occlusive Disease As Common As They Say?.
Martin, J.E., Carmona, F.D., Broen, J.C.A., Simeón, C.P., Vonk, M.C., Carreira, P., ...Tolosa, C. (2012). The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis. Genes and Immunity, 13 (2), 191-196. doi:10.1038/gene.2011.72
Ngcozana, T., Parker, L., Denton, C.P., Ong, V. (2012). The Impact of Sexual Difficulties in Women with Scleroderma and Interpersonal Relationships.
Chighizola, C., Penn, H., Meroni, P.L., Denton, C.P., Ong, V. (2012). THE ROLE OF N-TPROBNP IN SCLERODERMA RENAL CRISIS.
Meier, F.M.P., Frommer, K.W., Dinser, R., Walker, U.A., Czirjak, L., Denton, C.P., ...Valentini, G. (2012). Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.. ANNALS OF THE RHEUMATIC DISEASES, 71 (8), 1355-1360. doi:10.1136/annrheumdis-2011-200742
Kia, S., Khan, K., Yu, R., Shiwen, X., Nikitorowics-Buniak, J., Watson, J., ...Stratton, R.J. (2012). USE OF FIBROBLAST POPULATED COLLAGEN LATTICES TO ASSAY FIBROCYTE ACTIVITY IN SSc.

2011

Bossini-Castillo, L., Broen, J.C.A., Simeon, C.P., Beretta, L., Vonk, M.C., Ortego-Centeno, N., ...Navarrete, N. (2011). A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 70 (4), 638-641. doi:10.1136/ard.2010.141838
Ngcozana, T., Denton, C.P., Black, C.M., Parker, L., Brough, G., Ong, V. (2011). A STUDY OF SEXUAL DYSFUNCTION AMONGST MEN WITH SYSTEMIC SCLEROSIS IN THE UK: PREVALENCE AND PSYCHOLOGICAL IMPACT.
Hoyles, R.K., Derrett-Smith, E.C., Khan, K., Shiwen, X., Howat, S.L., Wells, A.U., ...Denton, C.P. (2011). An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor.. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 183 (2), 249-261. doi:10.1164/rccm.201002-0279OC
Kowal-Bielecka, O., Avouac, J., Pittrow, D., Huscher, D., Behrens, F., Denton, C.P., ...Nash, P. (2011). Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).. JOURNAL OF RHEUMATOLOGY, 38 (11), 2419-2427. doi:10.3899/jrheum.110344
Gliddon, A.E., Dore, C.J., Dunphy, J., Betteridge, Z., McHugh, N.J., Maddison, P.J. (2011). Antinuclear Antibodies and Clinical Associations in a British Cohort with Limited Cutaneous Systemic Sclerosis. JOURNAL OF RHEUMATOLOGY, 38 (4), 702-705. doi:10.3899/jrheum.100754
Carmona, F.D., Simeon, C.P., Beretta, L., Carreira, P., Vonk, M.C., Ríos-Fernández, R., ...Rodríguez-Rodríguez, L. (2011). Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Annals of the Rheumatic Diseases, 70 (11), 2050-2052. doi:10.1136/ard.2010.148874
Matucci-Cerinic, M., Denton, C.P., Furst, D.E., Mayes, M.D., Hsu, V.M., Carpentier, P., ...Merkel, P.A. (2011). Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.. ANNALS OF THE RHEUMATIC DISEASES, 70 (1), 32-38. doi:10.1136/ard.2010.130658
Pakozdi, A., Nihtyanova, S., Moinzadeh, P., Ong, V.H., Black, C.M., Denton, C.P. (2011). Clinical and serological hallmarks of systemic sclerosis overlap syndromes.. JOURNAL OF RHEUMATOLOGY, 38 (11), 2406-2409. doi:10.3899/jrheum.101248
Bossini-Castillo, L., Simeon, C.P., Beretta, L., Vonk, M.C., Luis Callejas-Rubio, J., Espinosa, G., ...Rodriguez-Carballeira, M. (2011). Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. RHEUMATOLOGY, 50 (11), 1976-1981. doi:10.1093/rheumatology/ker259
McCann, M.R., Monemdjou, R., Ghassemi-Kakroodi, P., Fahmi, H., Perez, G., Liu, S., ...Denton, C.P. (2011). Correction: MPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Research and Therapy, 13 (2), doi:10.1186/ar3285
Chighizola, C., Ong, V.H., Denton, C.P. (2011). Cyclophosphamide as disease-modifying therapy for scleroderma: Pros and cons. International Journal of Clinical Rheumatology, 6 (2), 219-230. doi:10.2217/ijr.10.112
de Luise, C., Louie, M.J., Hwang, L.-.J., Denton, C.P., Hoeper, M.M. (2011). Demographic and Clinical Characteristics of the Thelin Outcomes for Patient Surveillance (TOPS) Registry.
Saketkoo, L.A., Huscher, D., Khanna, D., Dellaripa, P.F., Flaherty, K., Matteson, E.L., ...Denton, C.P. (2011). Developing a Disease Activity and Therapeutic Response Index in Connective Tissue Disease Related Interstitial Lung Disease: Initial Results of a Delphi Exercise.
Schreiber, B.E., Valerio, C., Keir, G., Handler, C., Wells, A.U., Denton, C.P., Coghlan, J.G. (2011). Diffusion of Carbon Monoxide Predicts Survival in Systemic Sclerosis Patients with Pulmonary Hypertension and Interstitial Lung Disease.
Holmes, A.M., Ponticos, M., Shi-Wen, X., Denton, C.P., Abraham, D.J. (2011). Elevated CCN2 expression in scleroderma: a putative role for the TGFβ accessory receptors TGFβRIII and endoglin.. Journal of cell communication and signaling, 5 173-177.
Khan, K., Shi-wen, X., Abraham, D.J., Denton, C.P., Ong, V. (2011). Enhanced IL-6 Trans-Signalling in Early dcSSc May Drive Fibrotic Response Via JAK2/STAT3 Signalling Pathways.
Beyer, C., Distler, J.H.W., Allanore, Y., Aringer, M., Avouac, J., Czirják, L., ...Fligelstone, K. (2011). EUSTAR biobanking: Recommendations for the collection, storage and distribution of biospecimens in scleroderma research. Annals of the Rheumatic Diseases, 70 (7), 1178-1182. doi:10.1136/ard.2010.142489
Derrett-Smith, E., Hoyles, R., Moinzadeh, P., Chighizola, C.B., Khan, K., Ong, V., ...Denton, C.P. (2011). Expression Profiling of Skin and Lung Tissue and Explanted Fibroblasts in a Transgenic Mouse Model of Scleroderma.
Alizadeh, B.Z., Broen, L., Rueda, B., Hesselstrand, R., Wuttge, D., Simeon, C., ...Herrick, A. (2011). Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European study (EUSTAR) (Journal of Rheumatology (2010) 37 (1673-1679)). Journal of Rheumatology, 38 (4), 788-. doi:10.3899/jrheum.091259C2
Thoua, N., Khan, K., Dooley, A., Derrett-Smith, E., Denton, C.P. (2011). Gut Fibrosis with Associated Diminished Colonic Contractility in a Transgenic Mouse Model of Scleroderma. Arthritis and Rheumatism, 63 (10), S585.
Puri, A., Sivakumar, B., Amin, K., Burr, N., Haloob, N., Clarke, A., ...Butler, P.E. (2011). Hand Disease in Systemic Sclerosis: A Clinical Correlate for Chronic Hand Transplant Rejection.
Chighizola, C.B., Moinzadeh, P., Khan, K., Wood, T.A., Meroni, P.L., Abraham, D.J., ...Denton, C.P. (2011). Identification of a Gene Expression Signature in Limited Cutaneous Systemic Sclerosis That Includes Several Vascular Genetic Factors.
Gorlova, O., Martin, J.-.E., Rueda, B., Koeleman, B.P.C., Ying, J., Teruel, M., ...Simeon, C.P. (2011). Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy.. PLoS Genet, 7 (7), doi:10.1371/journal.pgen.1002178
Schreiber, B.E., Valerio, C.J., Keir, G.J., Handler, C., Wells, A.U., Denton, C.P., Coghlan, J.G. (2011). Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests.. ARTHRITIS AND RHEUMATISM, 63 (11), 3531-3539. doi:10.1002/art.30535
Goh, N.S.L., Desai, S.R., Anagnostopoulos, C., Hansell, D.M., Hoyles, R.K., Sato, H., ...Wells, A.U. (2011). Increased epithelial permeability in pulmonary fibrosis in relation to disease progression.. EUROPEAN RESPIRATORY JOURNAL, 38 (1), 184-190. doi:10.1183/09031936.00010910
Derrett-Smith, E., Dooley, A., Baliga, R., Hobbs, A., Abraham, D.J., Denton, C.P. (2011). Intermittent Systemic VEGF Inhibition Induces Pulmonary Arterial Hypertension In a Transgenic Mouse Model of Scleroderma. Arthritis and Rheumatism, 63 (10), S1022-S1023.
Thoua, N.M., Schizas, A., Forbes, A., Denton, C.P., Emmanuel, A.V. (2011). Internal anal sphincter atrophy in patients with systemic sclerosis.. Rheumatology (Oxford), 50 1596-1602. doi:10.1093/rheumatology/ker153
Parapuram, S.K., Xu, S.-.W., Elliott, C., Welch, I.D., Jones, H., Baron, M., ...Leask, A. (2011). Loss of PTEN Expression by Dermal Fibroblasts Causes Skin Fibrosis. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131 (10), 1996-2003. doi:10.1038/jid.2011.156
Herrick, A.L., van den Hoogen, F., Gabrielli, A., Tamimi, N., Reid, C., O'Connell, D., ...Denton, C.P. (2011). Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.. ARTHRITIS AND RHEUMATISM, 63 (3), 775-782. doi:10.1002/art.30195
McCann, M.R., Monemdjou, R., Ghassemi-Kakroodi, P., Fahmi, H., Perez, G., Liu, S., ...Denton, C.P. (2011). mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. ARTHRITIS RESEARCH & THERAPY, 13 (1), doi:10.1186/ar3226
McCann, M.R., Monemdjou, R., Ghassemi-Kakroodi, P., Fahmi, H., Perez, G., Liu, S., ...Denton, C.P. (2011). mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis (vol 13, pg 402, 2011). ARTHRITIS RESEARCH & THERAPY, 13 (2), doi:10.1186/ar3285
Avouac, J., Fransen, J., Walker, U.A., Riccieri, V., Smith, V., Muller, C., ...Cutolo, M. (2011). Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. ANNALS OF THE RHEUMATIC DISEASES, 70 (3), 476-481. doi:10.1136/ard.2010.136929
Tan, A., Denton, C.P., Mikhailidis, D.P., Seifalian, A.M. (2011). Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 29 (2), S66-S74.
Tan, A., Denton, C.P., Mikhailidis, D.P., Seifalian, A.M. (2011). Recent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): A review. Clinical and Experimental Rheumatology, 29 (2 SUPPL. 65),
Galluccio, F., Walker, U.A., Nihtyanova, S., Moinzadeh, P., Hunzelmann, N., Krieg, T., ...Kayser, C. (2011). Registries in systemic sclerosis: a worldwide experience. RHEUMATOLOGY, 50 (1), 60-68. doi:10.1093/rheumatology/keq355
Denton, C.P., Hachulla, E. (2011). Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening.. European Respiratory Review, 20 (122), 270-276. doi:10.1183/09059180.00006111
Valerio, C.J., Schreiber, B.E., Handler, C., Denton, C.P., Coghlan, J.G. (2011). Survival in patients with pulmonary arterial hypertension associated with connective tissue disease over the past decade.
Valerio, C.J., Schreiber, B.E., Handler, C., Denton, C.P., Coghlan, J.G. (2011). Survival in patients with pulmonary arterial hypertension associated with connective tissue disease over the past decade.
Denton, C.P., Avouac, J., Behrens, F., Furst, D.E., Foeldvari, I., Humbert, M., ...Nash, P. (2011). Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.. ARTHRITIS RESEARCH & THERAPY, 13 (3), doi:10.1186/ar3346
Amin, K., Clarke, A., Sivakumar, B., Puri, A., Fox, Z., Brough, V., ...Butler, P. (2011). The psychological impact of facial changes in scleroderma (vol 16, pg 304, 2011). PSYCHOLOGY HEALTH & MEDICINE, 16 (4), 492. doi:10.1080/13548506.2011.598718
Amin, K., Clarke, A., Sivakumar, B., Puri, A., Fox, Z., Brough, V., ...Butler, P. (2011). The psychological impact of facial changes in scleroderma.. PSYCHOLOGY HEALTH & MEDICINE, 16 (3), 304-312. doi:10.1080/13548506.2010.540250
Chen, Y., Leask, A., Abraham, D.J., Kennedy, L., Shi-Wen, X., Denton, C.P., ...Eastwood, M. (2011). Thrombospondin 1 is a key mediator of transforming growth factor β-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism.. Fibrogenesis and Tissue Repair, 4 (1), doi:10.1186/1755-1536-4-9
Denton, C.P., Hoyles, R.K., Derrett-Smith, E., Abraham, D.J. (2011). Tissue-Specific Knockout/Knockdown of Type 2 TGF-beta Receptor and Protection against Bleomycin Injury/Fibrosis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 184 (8), 983-984. doi:10.1164/ajrccm.184.8.983a

2010

Ong, V., Nihtyanova, S., Black, C.M., Denton, C.P. (2010). A clinically defined subset of DcSSc with thrombocytosis is associated with high serum IL-6 level.
Eastwood, M., Shi-wen, X., Denton, C.P., Renzoni, E., Abraham, D.J. (2010). Altered gene expression in fibroblasts cultured in 3-D collagen lattices subjected to biomechanical load.
Zolnowska, M., Ponticos, M., Pantelidis, P., Denton, C.P., Abraham, D., Fonseca, C. (2010). ANALYSIS OF POLYMORPHISMS IN THE HOMEOBOX TRANSCRIPTION FACTOR NKX2-5 GENE IN PATIENTS WITH SYSTEMIC SCLEROSIS. CLIN EXP RHEUMATOL, 28 (2), S139.
Coghlan, J.G., Pope, J., Denton, C.P. (2010). Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. CURRENT OPINION IN PULMONARY MEDICINE, 16 S27-S34. doi:10.1097/01.mcp.0000370208.45756.e8
Thoua, N.M., Bunce, C., Brough, G., Forbes, A., Emmanuel, A.V., Denton, C.P. (2010). Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology, 49 (9), 1770-1775. doi:10.1093/rheumatology/keq147
Thoua, N.M., Bunce, C., Brough, G., Forbes, A., Emmanuel, A.V., Denton, C.P. (2010). Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre.. RHEUMATOLOGY, 49 (9), 1770-1775. doi:10.1093/rheumatology/keq147
Nihtyanova, S.I., Denton, C.P. (2010). Autoantibodies as predictive tools in systemic sclerosis.. NATURE REVIEWS RHEUMATOLOGY, 6 (2), 112-116. doi:10.1038/nrrheum.2009.238
Thoua, N.M., Denton, C.P., Emmanuel, A.V., Forbes, A. (2010). Bioelectrical impedance is a useful adjunctive tool in assessing nutritional status in systemic sclerosis patients with gastrointestinal symptoms.
Valerio, C., Handler, C., Denton, C.P., Coghlan, J.G. (2010). BOSENTAN & SITAXENTAN IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE.
Schreiber, B.E., Valerio, C., Handler, C., Kier, G., Wells, A., Denton, C.P., Coghlan, G.J. (2010). Can we predict presence of pulmonary hypertension in scleroderma using lung function data?.
Tyndall, A.J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P.E., ...Distler, O. (2010). Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 69 (10), 1809-1815. doi:10.1136/ard.2009.114264
Avouac, J., Walker, U., Tyndall, A., Kahan, A., Matucci-Cerinic, M., Allanore, Y., ...Giacomelli, R. (2010). Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. Journal of Rheumatology, 37 (7), 1488-1501. doi:10.3899/jrheum.091165
Foeldvari, I., Nihtyanova, S.I., Wierk, A., Denton, C.P. (2010). Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort.. JOURNAL OF RHEUMATOLOGY, 37 (11), 2422-2426. doi:10.3899/jrheum.100001
Valerio, C.J., Handler, C.E., Kabunga, P., Smith, C.J., Denton, C.P., Coghlan, J.G. (2010). Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.. RHEUMATOLOGY, 49 (11), 2147-2153. doi:10.1093/rheumatology/keq241
Herrick, A.L., Lunt, M., Silman, A.J., Denton, C.P. (2010). Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis.. RHEUMATOLOGY, 49 (8), 1607-1608. doi:10.1093/rheumatology/keq115
Blumbach, K., Zweers, M.C., Brunner, G., Peters, A.S., Schmitz, M., Schulz, J.-.N., ...Eckes, B. (2010). Defective granulation tissue formation in mice with specific ablation of integrin-linked kinase in fibroblasts - role of RhoA/ROCK signaling and TGF beta 1 levels.
Blumbach, K., Zweers, M.C., Brunner, G., Peters, A.S., Schmitz, M., Schulz, J.-.N., ...Faessler, R. (2010). Defective granulation tissue formation in mice with specific ablation of integrin-linked kinase in fibroblasts - role of TGF beta 1 levels and RhoA activity. JOURNAL OF CELL SCIENCE, 123 (22), 3872-3883. doi:10.1242/jcs.063024
Denton, C.P., Guillevin, L., Krieg, T., Schwierin, B., Rosenberg, D., Silkey, M., Matucci-Cerinic, M. (2010). DEMOGRAPHICS AND PREVIOUS COMPLICATIONS/INTERVENTIONS IN PATIENTS WITH DIGITAL ULCERS AND DIFFERENT SUBSETS OF SCLERODERMA: PRELIMINARY FINDINGS FROM THE DUO REGISTRY.
Matucci-Cerinic, M., Guillevin, L., Denton, C.P., Schwierin, B., Rosenberg, D., Silkey, M., Krieg, T. (2010). DEMOGRAPHICS AND PREVIOUS COMPLICATIONS/INTERVENTIONS IN PATIENTS WITH DIGITAL ULCERS AND DIFFERENT SUBSETS OF SCLERODERMA: PRELIMINARY FINDINGS FROM THE DUO REGISTRY.
Hachulla, E., Denton, C.P. (2010). Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.. European Respiratory Review, 19 (118), 314-320. doi:10.1183/09059180.00007810
Kowal-Bielecka, O., Avouac, J., Pittrow, D., Huscher, D., Behrens, F., Denton, C.P., ...Nash, P. (2010). Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group.. JOURNAL OF RHEUMATOLOGY, 37 (1), 105-115. doi:10.3899/jrheum.090661
Dooley, A., Xu, S.-.W., Aden, N., Tranah, T., Desai, N., Denton, C.P., ...Bruckdorfer, K.R. (2010). Effects of the green tea antioxidant epigallocatechin-3-gallate on collagen production and fibroblast activity in systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S64.
Pearson, J.D., Shi-Wen, X., Howat, S.L., Denton, C.P., Abraham, D.J. (2010). Endothelin-1 and systemic sclerosis. In Advances in Vascular Medicine. (pp. 105-111). .
Aden, N., Nuttall, A., Shiwen, X., de Winter, P., Leask, A., Black, C.M., ...Stratton, R.J. (2010). Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis.. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 130 (9), 2191-2200. doi:10.1038/jid.2010.120
Shi-wen, X., Tam, A., Sonnylal, S., Stratton, R., Leask, A., Denton, C.P., ...Abraham, D.J. (2010). Epithelial to mesenchymal switching in the pathogenesis of systemic sclerosis.
Khanna, D., Denton, C.P. (2010). Evidence-based management of rapidly progressing systemic sclerosis.. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 24 (3), 387-400. doi:10.1016/j.berh.2009.12.002
Liu, S., Xu, S.-.W., Blumbach, K., Eastwood, M., Denton, C.P., Eckes, B., ...Leask, A. (2010). Expression of integrin beta 1 by fibroblasts is required for tissue repair in vivo. JOURNAL OF CELL SCIENCE, 123 (21), 3674-3682. doi:10.1242/jcs.070672
Derrett-Smith, E.C., Baliga, R., Dooley, A., Khan, K., Shi-Wen, X., Abraham, D., Denton, C.P. (2010). FIBROBLAST-SPECIFIC ACTIVATION OF TGF beta IN VIVO RECAPITULATES A HYPOXIC PULMONARY HYPERTENSION PHENOTYPE IN MICE.
Khan, K., Hoyles, R.K., Xu, S., Derrett-Smith, E., Abraham, D., Denton, C.P. (2010). FIBROCYTE RECRUITMENT AND MYOFIBROBLAST DIFFERENTIATION AFTER ACUTE LUNG INJURY IS BLOCKED BY SELECTIVE INHIBITION OF TGF beta SIGNALING IN RESIDENT INTERSTITIAL FIBROBLASTS.
Khan, K., Hoyles, R.K., Shiwen, X., Derrett-Smith, E., Abraham, D.J., Denton, C.P. (2010). Fibrocyte recruitment and myofibroblast diffrentiation after acute lung injury is blocked by selective inhibition of tgfbeta signalling in resident interstitial fibroblasts. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S68.
Alizadeh, B.Z., Broen, J., Rueda, B., Hesselstrand, R., Wuttge, D., Simeon, C., ...Herrick, A. (2010). Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European study (EUSTAR). Journal of Rheumatology, 37 (8), 1673-1679. doi:10.3899/jrheum.091259
Alizadeh, B.Z., Broen, J., Rueda, B., Hesselstrand, R., Wuttge, D., Simeon, C., ...Herrick, A. (2010). Functional variants of Fc gamma receptor (FCGR2A) and FCGR3A are not associated with susceptibility to systemic sclerosis in a large European study (EUSTAR) (Journal of Rheumatology (2010)). Journal of Rheumatology, 37 (9), 1979-. doi:10.3899/jrheum.091259C1
Pantelidis, P., Fonseca, C., DeWan, A., Wu, A., Woodhead, F., Futema, M., ...Denton, C.P. (2010). Genome-wide association study (GWAS) in a UK systemic sclerosis cohort.
Pantelidis, P., Fonseca, C., DeWan, A., Wu, C., Woodhead, F., Futema, M., ...Sackler, R. (2010). Genome-wide association study in UK systemic sclerosis cohort. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S73.
Lindahl, G.E., Shi-Wen, X., Aggrey-Fynn, G., Norman, J.T., Denton, C.P., Abraham, D.J., ...Renzoni, E.A. (2010). Global gene expression profiling of scleroderma lung fibroblasts identifies a heterogeneous expression pattern of activated genes and consistent repression of interferon related pathways. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S69.
Nihtyanova, S.I., Tang, E.C., Coghlan, J.G., Wells, A.U., Black, C.M., Denton, C.P. (2010). Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 103 (2), 109-115. doi:10.1093/qjmed/hcp174
Carreira, P.E., Carmona, L., Joven, B.E., Denton, C.P., Allanore, Y., Walker, U., Matucci-Cerinic, M. (2010). INFLUENCE OF AGE ON CLINICAL EXPRESSION OF EARLY SYSTEMIC SCLEROSIS PATIENTS: A REPORT FROM THE EULAR SCLERODERMA TRIALS AND RESEARCH GROUP (EUSTAR) DATABASE.
Ong, V.H., Denton, C.P. (2010). Innovative therapies for systemic sclerosis.. CURRENT OPINION IN RHEUMATOLOGY, 22 (3), 264-272. doi:10.1097/BOR.0b013e328337c3d6
Blumbach, K., Zweers, M.C., Brunner, G., Peters, A.S., Schulz, J.-.N., Denton, C.P., ...Eckes, B. (2010). INTEGRIN-LINKED KINASE CONTROLS MYOFIBROBLAST DIFFERENTIATION VIA RHOA/ROCK ACTIVITY AND TGF-beta LEVELS. WOUND REPAIR AND REGENERATION, 18 (6), A80.
Huscher, D., Pittrow, D., Distler, O., Denton, C.P., Foeldvari, I., Humbert, M., ...Behrens, F. (2010). Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (2), S47-S52.
Huscher, D., Pittrow, D., Distler, O., Denton, C.P., Foeldvari, I., Humbert, M., ...Behrens, F. (2010). Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Clinical and Experimental Rheumatology, 28 (2 SUPPL. 58),
Huscher, D., Pittrow, D., Distler, O., Denton, C.P., Foeldvari, I., Humbert, M., ...Behrens, F. (2010). Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.. Clinical and experimental rheumatology, 28 (2 Suppl 58), S47-S52.
Rossi, A., Sozio, F., Sestini, P., Renzoni, E.A., Khan, K., Denton, C.P., ...Weber, E. (2010). Lymphatic and blood vessels in scleroderma skin, a morphometric analysis. HUMAN PATHOLOGY, 41 (3), 366-374. doi:10.1016/j.humpath.2009.08.009
Howit, S., Buisson, A., Denton, C.P., Abraham, D.J., Pearson, J.D. (2010). MICROVASCULAR IMPLICATIONS IN SCLERODERMA: TO MODEL THE EFFECTS OF ISCHAEMIA REPERFUSION IN SCLERODERMA ON EXPRESSION OF FIBROGENIC AGENTS BY ENDOTHELIAL CELLS. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (2), S104.
Dooley, A., Shi-Wen, X., Aden, N., Tranah, T., Desai, N., Denton, C.P., ...Bruckdorfer, R. (2010). Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.. RHEUMATOLOGY, 49 (11), 2024-2036. doi:10.1093/rheumatology/keq208
Weber, E., Rossi, A., Sozio, F., Sestini, P., Renzoni, E.A., Khan, K., ...Abraham, D.J. (2010). MORPHOMETRIC EVALUATION OF LYMPHATIC AND BLOOD VESSELS IN SCLERODERMA SKIN. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (2), S97.
Jones, H., Derrett-Smith, E., Shiwen, X., Khan, K., Denton, C.P., Abraham, D., ...So, P. (2010). NON-INVASIVE IMAGING FOR THE ASSESSMENT OF DERMAL FIBROSIS.
Valerio, C.J., Handler, C., Reddecliffe, S., Gallimore, A., Mullard, K., Das, C., ...Coghlan, J.G. (2010). N-terminal pro B-type natriuretic peptide and outcomes in scleroderma associated pulmonary arterial hypertension.
Herrick, A.L., Lunt, M., Whidby, N., Ennis, H., Silman, A., McHugh, N., Denton, C.P. (2010). Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.. JOURNAL OF RHEUMATOLOGY, 37 (1), 116-124. doi:10.3899/jrheum.090668
van Laar, J.M., Farge, D., Tyndall, A., Mayes, M., Sullivan, K., Denton, C.P. (2010). PANEL SESSION REPORT: SYSTEMIC SCLEROSIS.
Denton, C.P. (2010). PATHOGENESIS AND TREATMENT OF SCLERODERMA RENAL CRISIS.
Derrett-Smith, E.C., Dooley, A., Baliga, R., Hobbs, A., MacAllister, R., Abraham, D., Denton, C.P. (2010). Perturbed VEGF signalling within the pulmonary vasculature of a TGF beta dependent mouse model of systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S63.
Valerio, C.J., Handler, C., Schreiber, B., Denton, C.P., Coghlan, J.G. (2010). Progression of pulmonary artery pressures: what does 20-24 mean?.
Valerio, C.J., Handler, C., Kabunga, P., Denton, C.P., Coghlan, J.G. (2010). Pulmonary vascular compliance and the effect of endothelin receptor antagonism.
Seibold, J.R., Denton, C.P., Furst, D.E., Guillevin, L., Rubin, L.J., Wells, A., ...Chadha-Boreham, H. (2010). Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.. ARTHRITIS AND RHEUMATISM, 62 (7), 2101-2108. doi:10.1002/art.27466
Chighizola, C., Nithyanova, S., Meroni, P.L., Coghlan, G., Denton, C.P., Ong, V. (2010). Role of n-terminal pro-bnp in detecting heart involvement in systemic sclerosis patients. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S61.
Nandagudi, A., Xu, S., Leask, A., Denton, C.P., Abraham, D., Stratton, R. (2010). ROLE OF THE RAS/MEK/ERK SIGNAL TRANSDUCTION PATHWAY IN FIBROBLAST ACTIVATION IN SYSTEMIC SCLEROSIS.
Xu, S., Eastwood, M., Stratton, R., Denton, C.P., Abraham, D., Leask, A. (2010). ROSIGLITAZONE ALLEVIATES THE PERSISTENT FIBROTIC PHENOTYPE OF LESIONAL SKIN SCLERODERMA FIBROBLASTS. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (2), S97.
Shi-wen, X., Eastwood, M., Stratton, R.J., Denton, C.P., Leask, A., Abraham, D.J. (2010). Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.. RHEUMATOLOGY, 49 (2), 259-263. doi:10.1093/rheumatology/kep371
Khan, K., Hoyles, R., Derrett-Smith, F., Shiwen, X., Abraham, D., Denton, C.P. (2010). SELECTIVE INHIBITION OF TGFBETA SIGNALLING IN RESIDENT PULMONARY FIBROBLASTS BLOCKS FIBROCYTE RECRUITMENT AND MYOFIBROBLAST DIFFERENTIATION AFTER ACUTE LUNG INJURY. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (2), S103.
Valerio, C.J., Handler, C., Denton, C.P., Coghlan, J.G. (2010). SURVIVAL IN PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE TREATED WITH ILOPROST OR TREPOSTINIL.
Sivakumar, B., Haloob, N., Puri, A., Latif, A., Ghani, S., Brough, V., ...Butler, P.E. (2010). Systemic sclerosis as a model of chronic rejection in facial composite tissue transplantation.. JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 63 (10), 1669-1676. doi:10.1016/j.bjps.2009.08.020
Derrett-Smith, E.C., Denton, C.P. (2010). Systemic sclerosis: clinical features and management. Medicine, 38 (2), 109-115. doi:10.1016/j.mpmed.2009.10.014
Khanna, D., Seibold, J.R., Wells, A., Distler, O., Allanore, Y., Denton, C., Furst, D.E. (2010). Systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials, outcome measures, and future study design. Current Rheumatology Reviews, 6 (2), 138-144. doi:10.2174/157339710791330768
Derrett-Smith, E.C., Dooley, A., Khan, K., Shi-wen, X., Abraham, D., Denton, C.P. (2010). Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma.. ARTHRITIS RESEARCH & THERAPY, 12 (2), doi:10.1186/ar2986
Shi-Wen, X., Eastwood, M., Denton, C.P., Leask, A., Abraham, D.J. (2010). The PPAR gamma agonist rosiglitazone reverses the persistent fibrotic phenotype of scleroderma fibroblasts.
Eastwood, M., Chen, Y., Shi-wen, X., Denton, C.P., Black, C.M., Abraham, D.J. (2010). Thrombospondin 1-a key mediator of matrix contraction depend on MEK/ERK in SSc pathogenesis.
Renzoni, E.A., Shi-Wen, X., Nicholson, A.G., Maher, T.M., Dusmet, M., Suleman-Verjee, L., ...Wells, A.U. (2010). Upregulation of angiotensin signalling pathways underlies the increased contractility observed in pulmonary fibrosis lung fibroblasts. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 28 (5), S74.
Avouac, J., Kowal-Bielecka, O., Pittrow, D., Huscher, D., Behrens, F., Denton, C.P., ...Nash, P. (2010). Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group.. ANNALS OF THE RHEUMATIC DISEASES, 69 (7), 1360-1363. doi:10.1136/ard.2009.120303

2009

Buick, T.A., Howell, K.J., Gush, R., Denton, C.P., Smith, R.E. (2009). A comparison of infrared thermography (IRT) and full-field laser perfusion imaging (FLPI) for assessment of hand cold challenge and dermal inflammation. Thermology International, 19 (2), 43-46.
Nihtyanova, S.I., Parker, J.C., Black, C.M., Bunn, C.C., Denton, C.P. (2009). A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis.. RHEUMATOLOGY, 48 (10), 1218-1221. doi:10.1093/rheumatology/kep215
Denton, C.P., Engelhart, M., Tvede, N., Wilson, H., Khan, K., Shiwen, X., ...van den Hoogen, F.H. (2009). An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.. ANNALS OF THE RHEUMATIC DISEASES, 68 (9), 1433-1439. doi:10.1136/ard.2008.096123
Derrett-Smith, E.C., Denton, C.P., Sonnylal, S. (2009). Animal models of scleroderma: lessons from transgenic and knockout mice.. CURRENT OPINION IN RHEUMATOLOGY, 21 (6), 630-635. doi:10.1097/BOR.0b013e32833130c1
Penn, H., Tennant-Eyles, A.J., Howat, S.L., Stratton, R.J., Coglan, J.G., Pearson, J.D., Denton, C.P. (2009). Anti-endothelial cell antibody levels are low in scleroderma internal organ vasculopathies..
Nihtyanova, S., Wierk, A., Denton, C.P. (2009). Characteristics of juvenile onset systemic sclerosis patients in an adult single centre cohort Does this patient population present a survival bias?.
Pakozdi, A., Nihtyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P. (2009). CLINICAL AND SEROLOGICAL HALLMARKS OF SYSTEMIC SCLEROSIS OVERLAP SYNDROMES.
Lindahl, G., Leoni, P., Ponticos, M., Xu, S.-.W., Renzoni, E., Holmes, A., ...Abraham, D.J. (2009). CONSTITUTIVE NUCLEAR ACCUMULATION OF CBF IN SYSTEMIC SCLEROSIS PULMONARY FIBROBLASTS: A PUTATIVE TRANSCRIPTIONAL MECHANISM UNDERLYING THE FIBROTIC PHENOTYPE.
Tang, E.C., Nihtyanova, S.I., Denton, C.P. (2009). CONTEMPORARY OUTCOME IN SYSTEMIC SCLEROSIS: IMPROVED SURVIVAL WITH EARLIER RECOGNITION OF ORGAN-BASED COMPLICATIONS.
Ong, V.H., Carulli, M.T., Xu, S., Khan, K., Lindahl, G., Abraham, D.J., Denton, C.P. (2009). Cross-talk between MCP-3 and TGF beta promotes fibroblast collagen biosynthesis. EXPERIMENTAL CELL RESEARCH, 315 (2), 151-161. doi:10.1016/j.yexcr.2008.11.001
Porticos, M., Holmes, A., Xu, S.-.W., Hoyles, R., Bou-Gharios, G., Black, C.M., ...Lindahl, G.E. (2009). CTGF Contributes to collagen type I expression in the bleomycin model of lung fibrosis and in human pulmonary fibroblasts by MAPK dependent transcriptional activation. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27 (3), S84.
Matucci-Cerinic, M., Guillevin, L., Denton, C.P., Schwierin, B., Rosenberg, D., Silkey, M., Krieg, T. (2009). Demographics and previous complications/interventions in patients with digital ulcers and different subsets of scleroderma: preliminary findings front the DUO registry.
Zweers, M.C., Schmitz, M., Peters, A., Denton, C.P., Faessler, R., Gullberg, D., ...Eckes, B. (2009). Dermal reconstitution following injury requires integrin-linked kinase. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27 (3), S76.
Steen, V., Denton, C.P., Pope, J.E., Matucci-Cerinic, M. (2009). Digital ulcers: overt vascular disease in systemic sclerosis.
Quillinan, N.P., Denton, C.P. (2009). Disease-modifying treatment in systemic sclerosis: current status.. CURRENT OPINION IN RHEUMATOLOGY, 21 (6), 636-641. doi:10.1097/BOR.0b013e3283310d57
Khan, K., Hoyles, R., Xu, S., Abraham, D., Denton, C.P. (2009). DISRUPTION OF TGFBETA SIGNALLING IN DERMAL FIBROBLASTS DELAYS SKIN WOUND HEALING AND REDUCES FIBROCYTE RECRUITMENT.
Nihtyanova, S.I., Parker, J.C., Black, C.M., Bunn, C.C., Denton, C.P. (2009). DOES ANTI-RNA-POLYMERASE ANTIBODY LEVEL PREDICT ORGAN INVOLVEMENT OR DISEASE OUTCOME IN PATIENTS WITH SYSTEMIC SCLEROSIS?.
Pakozdi, A., Wilson, H., Black, C.M., Denton, C.P. (2009). Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27 (3), S5-S8.
Pakozdi, A., Wilson, H., Black, C.M., Denton, C.P. (2009). Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. Clinical and experimental rheumatology, 27 (3 Suppl 54), 5-8.
Pakozdi, A., Wilson, H., Black, C.M., Denton, C.P. (2009). Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?. Clinical and Experimental Rheumatology, 27 (3 SUPPL. 54),
Kowal-Bielecka, O., Landewe, R., Avouac, J., Chwiesko, S., Miniati, I., Czirjak, L., ...Fligelstone, K. (2009). EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). ANNALS OF THE RHEUMATIC DISEASES, 68 (5), 620-628. doi:10.1136/ard.2008.096677
Avouac, J., Kowal-Bielecka, O., Landewe, R., Chwiesko, S., Miniati, I., Czirjak, L., ...Fligelstone, K. (2009). European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systematic literature research. Annals of the Rheumatic Diseases, 68 (5), 629-634. doi:10.1136/ard.2008.095299
Thoua, N.M., Forbes, A., Denton, C.P., Emmanuel, A.V. (2009). Faecal Incontinence in Systemic Sclerosis Is Related to Neuropathy.
Walker, U.A., Tyndall, A., Czirják, L., Denton, C.P., Farge-Bancel, D., Kowal-Bielecka, O., ...EUSTAR, c.o.-.a.u.t.h.o.r.s. (2009). Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database.. ANNALS OF THE RHEUMATIC DISEASES, 68 (6), 856-862. doi:10.1136/ard.2008.091348
Denton, C.P., Khan, K., Hoyles, R.K., Shiwen, X., Leoni, P., Chen, Y., ...Abraham, D.J. (2009). Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing.. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129 (1), 194-204. doi:10.1038/jid.2008.171
Liu, S., Kapoor, M., Xu, S.-.W., Kennedy, L., Denton, C.P., Abraham, D.J., Leask, A. (2009). Investigation of the role of Racl in a bleomycin-induced scleroderma model using fibroblast-specific Racl knockout mice. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27 (3), S72.
Denton, C.P., Derrett-Smith, E.C. (2009). Juvenile-onset systemic sclerosis: children are not small adults.. RHEUMATOLOGY, 48 (2), 96-97. doi:10.1093/rheumatology/ken418
Ito, K., Sawamura, D., Goto, M., Nakamura, H., Nishie, W., Sakai, K., ...Uitto, J. (2009). Keratinocyte-/Fibroblast-Targeted Rescue of Col7a1-Disrupted Mice and Generation of an Exact Dystrophic Epidermolysis Bullosa Model Using a Human COL7A1 Mutation. AMERICAN JOURNAL OF PATHOLOGY, 175 (6), 2508-2517. doi:10.2353/ajpath.2009.090347
Herrick, A.L., Roberts, C., Tracey, A., Silman, A., Anderson, M., Goodfield, M., ...Denton, C.P. (2009). Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis.. ARTHRITIS AND RHEUMATISM, 60 (3), 878-882. doi:10.1002/art.24333
Liu, S., Kapoor, M., Denton, C.P., Abraham, D.J., Leask, A. (2009). Loss of beta 1 Integrin in Mouse Fibroblasts Results in Resistance to Skin Scleroderma in a Mouse Model. ARTHRITIS AND RHEUMATISM, 60 (9), 2817-2821. doi:10.1002/art.24801
Liu, S., Kapoor, M., Denton, C.P., Abraham, D.J., Leask, A. (2009). LOSS OF INTEGRIN 1 RESULTS IN RESISTANCE TO BLEOMYCIN-INDUCED SCLERODERMA. WOUND REPAIR AND REGENERATION, 17 (4), A72.
Kapoor, M., McCann, M., Liu, S., Huh, K., Denton, C.P., Abraham, D.J., Leask, A. (2009). Loss of Peroxisome Proliferator-Activated Receptor gamma in Mouse Fibroblasts Results in Increased Susceptibility to Bleomycin-Induced Skin Fibrosis. ARTHRITIS AND RHEUMATISM, 60 (9), 2822-2829. doi:10.1002/art.24761
Khanna, D., Distler, O., Avouac, J., Behrens, F., Clements, P.J., Denton, C., ...Kowal-Bielecka, O. (2009). Measures of response in clinical trials of systemic sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and outcome measures in pulmonary arterial hypertension related to systemic sclerosis (EPOSS).
Dooley, A., Xu, S., Aden, N., Tranah, T., Desai, N., Denton, C.P., ...Bruckdorfer, R. (2009). MODULATION OF TYPE I COLLAGEN SYNTHESIS AND FIBROBLAST FUNCTION IN SYSTEMIC SCLEROSIS BY THE GREEN TEA ANTIOXIDANT (-)-EPIGALLOCATECHIN-3-GALLATE.
Beirne, P., Pantelidis, P., Charles, P., Wells, A.U., Abraham, D.J., Denton, C.P., ...Kelleher, P. (2009). Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis. EUROPEAN RESPIRATORY JOURNAL, 34 (6), 1376-1382. doi:10.1183/09031936.00028209
Herrick, A.L., Lunt, M., Whidby, N., Ennis, H., Silman, A., McHugh, N., Denton, C.P. (2009). OBSERVATIONAL STUDY OF TREATMENT OUTCOME IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
Shiwen, X., Rajkumar, V., Denton, C.P., Leask, A., Abraham, D.J. (2009). Pericytes display increased CCN2 expression upon culturing.. JOURNAL OF CELL COMMUNICATION AND SIGNALING, 3 (1), 61-64. doi:10.1007/s12079-009-0053-7
Ponticos, M., Holmes, A.M., Shi-wen, X., Leoni, P., Khan, K., Rajkumar, V.S., ...Denton, C.P. (2009). Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.. 60 2142-2155. doi:10.1002/art.24620
Kapoor, M., Shi-Wen, X., Denton, C.P., Abraham, D.J., Leask, A. (2009). PPAR-GAMMA AGONIST ROSIGLITAZONE ALLEVIATES THE FIBROTIC PHENOTYPE OF SKIN SCLERODERMA FIBROBLASTS. WOUND REPAIR AND REGENERATION, 17 (4), A70.
Derrett-Smith, E.C., Khan, K., Xu, S., De Winter, P., Abraham, D., Denton, C.P. (2009). Pulmonary and systemic vasculopathy in a TGF-beta dependent mouse model of systemic sclerosis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27 (3), S82.
Shi-wen, X., Liu, S., Eastwood, M., Sonnylal, S., Denton, C.P., Abraham, D.J., Leask, A. (2009). Rac Inhibition Reverses the Phenotype of Fibrotic Fibroblasts. PLoS ONE, 4 (10), doi:10.1371/journal.pone.0007438
Xu, S.-.W., Liu, S., Eastwood, M., Sonnylal, S., Denton, C.P., Abraham, D.J., Leask, A. (2009). Rac inhibition reverses the phenotype of fibrotic fibroblasts.. PLOS ONE, 4 (10), doi:10.1371/journal.pone.0007438
Denton, C.P., Lapadula, G., Mouthon, L., Müller-Ladner, U. (2009). Renal complications and scleroderma renal crisis.. RHEUMATOLOGY, 48 32-35. doi:10.1093/rheumatology/ken483
Shi-wen, X., Parapuram, S.K., Pala, D., Chen, Y., Carter, D.E., Eastwood, M., ...Leask, A. (2009). Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts.. ARTHRITIS AND RHEUMATISM, 60 (1), 234-241. doi:10.1002/art.24223
Sivakumar, B., Haloob, N., Puri, A., Latif, A., Ghani, S., Brough, V., ...Butler, P.E. (2009). Systemic sclerosis as a model of chronic rejection in facial composite tissue transplantation. J.Plast.Reconstr.Aesthet.Surg.,
Cai, C.-.L., Martin, J.C., Sun, Y., Cui, L., Wang, L., Ouyang, K., ...Zhang, X. (2009). Tbx18 and the fate of epicardial progenitors Cai et al. reply. NATURE, 458 (7240), E9-E10. doi:10.1038/nature07917
Xu, S.-.W., Pala, D., Chen, Y., Eastwood, M., Denton, C.P., Abraham, D.J., Leask, A. (2009). TGF beta-INDUCED alpha-SMOOTH MUSCLE ACTIN EXPRESSION AND EXTRACELLULAR MATRIX CONTRACTION IN FIBROBLASTS REQUIRES TAK1. WOUND REPAIR AND REGENERATION, 17 (4), A79.
Matucci-Cerinic, M., Allanore, Y., Czirják, L., Tyndall, A., Müller-Ladner, U., Denton, C., ...Tyrrel-Kennedy, A. (2009). The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Annals of the Rheumatic Diseases, 68 (9), 1377-1380. doi:10.1136/ard.2008.106302
Chen, Y., Leask, A., Abraham, D.J., Kennedy, L., Xu, S.-.W., Denton, C.P., ...Eastwood, M. (2009). Thrombospondin 1 is a key mediator of TGF beta-mediated cell contractility in systemic sclerosis via a MEK/ERK-dependent mechanism. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 27 (3), S83.
Howell, K.J., Lavorato, A., Visentin, M.T., Smith, R.E., Schaefer, G., Jones, C.D., ...Woo, P. (2009). Validation of a protocol for the assessment of skin temperature and blood flow in childhood localised scleroderma. Skin Research and Technology, 15 (3), 346-356.
Howell, K.J., Lavorato, A., Visentin, M.T., Smith, R.E., Schaefer, G., Jones, C.D., ...Woo, P. (2009). Validation of a protocol for the assessment of skin temperature and blood flow in childhood localised scleroderma.. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 15 (3), 346-356. doi:10.1111/j.1600-0846.2009.00371.x
Derrett-Smith, E.C., Dooley, A., Khan, K., Xu, S.-.W., De Winter, P., Abraham, D., Denton, C.P. (2009). VASCULOPATHY IN A TGF-beta DEPENDENT MOUSE MODEL OF SYSTEMIC SCLEROSIS.

2008

Cai, C.-.L., Martin, J.C., Sun, Y., Cui, L., Wang, L., Ouyang, K., ...Zhang, X. (2008). A myocardial lineage derives from Tbx18 epicardial cells. NATURE, 454 (7200), 104-U4. doi:10.1038/nature06969
Fonseca, C., Pantelidis, P., Denton, C.P., Black, C.M., Abraham, D. (2008). Analysis of polymorphisms in the endothelin axis in patients with Raynaud's phenomenon.
Fonseca, C., Pantelidis, P., Ponticos, M., Abraham, D., Black, C.M., Denton, C.P. (2008). Analysis of polymorphisms in the endothelin axis in patients with Raynaud's phenomenon and erythromelalgia.
Carulli, M.T., Handler, C., Coghlan, J.G., Black, C.M., Denton, C.P. (2008). Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?. ANNALS OF THE RHEUMATIC DISEASES, 67 (1), 105-109. doi:10.1136/ard.2006.067967
Foeldvari, I., Nihtyanova, S., Wierk, A., Denton, C.P. (2008). Characteristics of juvenile onset systemic sclerosis patients in an adult single centre cohort.
Nihtyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P. (2008). Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis.. ANNALS OF THE RHEUMATIC DISEASES, 67 (1), 120-123. doi:10.1136/ard.2007.072686
Khan, K., Hoyles, R.K., Shiwen, X., Howat, S., Abraham, D.J., Denton, C.P. (2008). Conditional post-natal deletion of T beta RII defines a pivotal role for resident fibroblasts in the fibrotic response to lung injury.
Hoyles, R.K., Khan, K., Shiwen, X., Wells, A.U., Abraham, D.J., Denton, C.P. (2008). CONDITIONAL POSTNATAL DELETION OF TBRII DEFINES A PIVOTAL ROLE FOR RESIDENT FIBROBLASTS IN THE FIBROTIC RESPONSE TO LUNG INJURY.
Zweers, M.C., Schmitz, M., Denton, C.P., Faessler, R., Krieg, T., Eckes, B. (2008). Crucial role for fibroblast integrin-linked kinase in murine wound healing.
Nihtyanova, S.I., Denton, C.P. (2008). Current approaches to the management of early active diffuse scleroderma skin disease.. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 34 (1), 161-+. doi:10.1016/j.rdc.2007.11.005
Distler, O., Behrens, F., Pittrow, D., Huscher, D., Denton, C.P., Foeldvari, I., ...Opitz, C.F. (2008). Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 59 (6), 867-875. doi:10.1002/art.23718
Distler, O., Behrens, F., Pittrow, D., Huscher, D., Denton, C.P., Foeldvari, I., ...Opitz, C.F. (2008). Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis (vol 59, pg 867, 2008). ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 59 (8), 1202.
Khanna, D., Lovell, D.J., Giannini, E., Clements, P.J., Merkel, P.A., Seibold, J.R., ...Steen, V.D. (2008). Development of a provisional core set of response measures for clinical trials of systemic sclerosis.. ANNALS OF THE RHEUMATIC DISEASES, 67 (5), 703-709. doi:10.1136/ard.2007.078923
Penn, H., Denton, C.P. (2008). Diagnosis, management and prevention of scleroderma renal disease.. CURRENT OPINION IN RHEUMATOLOGY, 20 (6), 692-696. doi:10.1097/BOR.0b013e3283108df7
Khan, K., Hoyles, R.K., Xu, S., Abraham, D.J., Denton, C.P. (2008). Disruption of TGFbeta signalling in dermal fibroblasts delays skin wound healing and reduces fibrocyte recruitment.
Shiwen, X., Rajkumar, V., Khan, K., Dashwood, M., Black, C., Denton, C.P., ...Abraham, D. (2008). Endothelin-1 activates mesenchymal progenitor cells in scleroderma.
Hoyles, R.K., Khan, K., Shiwen, X., Howat, S.L., Lindahl, G.E., Leoni, P., ...Abraham, D.J. (2008). Fibroblast-specific perturbation of transforming growth factor beta signaling provides insight into potential pathogenic mechanisms of scleroderma-associated lung fibrosis - Exaggerated response to alveolar epithelial injury in a novel mouse model. ARTHRITIS AND RHEUMATISM, 58 (4), 1175-1188. doi:10.1002/art.23379
Kapoor, M., Liu, S., Shi-Wen, X., Huh, K., McCann, M., Denton, C.P., ...Leask, A. (2008). GSK-3 beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism (Retracted article. See vol. 118, pg. 3812, 2008). JOURNAL OF CLINICAL INVESTIGATION, 118 (11), 3812. doi:10.1172/JCI35381
Kapoor, M., Liu, S., Shi-wen, X., Huh, K., McCann, M., Denton, C.P., ...Leask, A. (2008). GSK-3β in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism (Journal of Clinical Investigation (2008) 118, (3279-3290) DOI: 10.1172/JCI35381). Journal of Clinical Investigation, 118 (11), 3812-. doi:10.1172/JCI35381R1
Chen, Y., Leask, A., Abraham, D.J., Pala, D., Shiwen, X., Khan, K., ...Goetinck, P. (2008). Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.. ARTHRITIS AND RHEUMATISM, 58 (2), 577-585. doi:10.1002/art.23146
Hoyles, R.K., Khan, K., Xu, S., Howat, S., Wells, A.U., Abraham, D.J., ...Denton, C.P. (2008). Inducible disruption of TGF signalling in resident lung fibroblasts prevents experimental fibrosis.
Pakozdi, A., Howell, K., Wilson, H., Fox, S., Gonzalez, L., Black, C.M., Denton, C.P. (2008). Inhaled iloprost for the treatment of Raynaud's phenomenon.
Pakozdi, A., Howell, K., Wilson, H., Fox, S., Gonzalez, L., Black, C.M., Denton, C.P. (2008). Inhaled iloprost for the treatment of Raynaud's phenomenon. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 26 (4), 709.
Goh, N.S.L., Desai, S.R., Veeraraghavan, S., Hansell, D.M., Copley, S.J., Maher, T.M., ...Devaraj, A. (2008). Interstitial lung disease in systemic sclerosis: a simple staging system.. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 177 (11), 1248-1254. doi:10.1164/rccm.200706-877OC
Hoyles, R.K., Sato, H., Desai, S., Goh, N.S., Du Bois, R.M., Black, C.M., ...Wells, A.U. (2008). KL-6, A serum marker of alveolar epithelial damage, predicts scleroderma associated lung fibrosis severity and outcome.
Penn, H., Coghlan, J.G., Black, C.M., Denton, C.P. (2008). Levels of total TGF beta-1 reflect clinical phenotype in systemic sclerosis.
Pakozdi, A., Wilson, H., Fox, S., Black, C.M., Denton, C.P. (2008). Long term therapy with lansoprazole does not slow progression of oesophageal involvement in systemic sclerosis?.
Denton, C.P., Pope, J.E., Peter, H.-.H., Gabrielli, A., Boonstra, A., van den Hoogen, F.H.J., ...Dölberg, M. (2008). Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.. ANNALS OF THE RHEUMATIC DISEASES, 67 (9), 1222-1228. doi:10.1136/ard.2007.079921
Peter, H.-.H., Gabrielli, A., Guillevin, L., Pope, J., Denton, C.P. (2008). Long-term effects of bosentan treatment on survival in patients with pulmonary arterial hypertension related to connective tissue disease: TRUST 3-year data.
Leask, A., Shi-Wen, X., Khan, K., Chen, Y., Holmes, A., Eastwood, M., ...Abraham, D.J. (2008). Loss of protein kinase Cepsilon results in impaired cutaneous wound closure and myofibroblast function. 121 3459-3467. doi:10.1242/jcs.029215
Dooley, A., Shiwen, X., Tranah, T., Desai, N., Denton, C.P., Black, C.M., ...Bruckdorfer, R. (2008). Modulation of fibroblast function and differentiation in systemic sclerosis by the green tea antioxidant (-)-epigallocatechin-3-gallate.
Jones, H., Derrett-Smith, E., Denton, C.P., Abraham, D., Bou-Gharios, G., So, P. (2008). Non-invasive imaging for the assessment of dermal fibrosis. J Cell Sci, 121 (20), 3459-3467.
Hengstman, G.J.D., De Bleecker, J.L., Feist, E., Vissing, J., Denton, C.P., Manoussakis, M.N., ...van den Hoogen, F.H.J. (2008). Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.. EUROPEAN NEUROLOGY, 59 (3-4), 159-163. doi:10.1159/000114036
Juarez, M., Marshall, R., Denton, C., Evely, R. (2008). Paraneoplastic scleroderma secondary to hairy cell leukaemia successfully treated with cladribine. Rheumatology, 47 (11), 1734-1735. doi:10.1093/rheumatology/ken367
Aden, N., Shiwen, X., Aden, D., Black, C., Nuttall, A., Denton, C.P., ...Stratton, R. (2008). Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer.. RHEUMATOLOGY, 47 (12), 1754-1760. doi:10.1093/rheumatology/ken370
Derrett-Smith, E.C., Khan, K., Shiwen, X., De Winter, P., Abraham, D., Denton, C.P. (2008). Pulmonary Vasculopathy in a TGF-beta dependent mouse model of scleroderma.
Denton, C.P. (2008). Renal manifestations of systemic sclerosis--clinical features and outcome assessment.. Rheumatology (Oxford, England), 47 Suppl 5
Denton, C.P. (2008). Renal manifestations of systemic sclerosis--clinical features and outcome assessment.. RHEUMATOLOGY, 47 V54-V56. doi:10.1093/rheumatology/ken307
Aden, N., Xu, S., Nuttall, A., Denton, C.P., Black, C.M., Abraham, D.J., Stratton, R.J. (2008). Role of epidermis in scleroderma.
Liu, S., Kapoor, M., Shi-wen, X., Kennedy, L., Denton, C.P., Glogauer, M., ...Leask, A. (2008). Role of Rac1 in a bleomycin-induced scleroderma model using fibroblast-specific Rac1-knockout mice. ARTHRITIS AND RHEUMATISM, 58 (7), 2189-2195. doi:10.1002/art.23595
Nihtyanova, S.I., Parker, J.C., Black, C.M., Bunn, C.C., Denton, C.P. (2008). Serial anti-RNA-polymerase antibody levels in patients with systemic sclerosis.
Carulli, M.T., Spagnolo, P., Fonseca, C., Welsh, K.I., Dubois, R.M., Black, C.M., Denton, C.P. (2008). Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis. J.Rheumatol., 35 (5), 839-844.
Carulli, M.T., Spagnolo, P., Fonseca, C., Welsh, K.I., duBois, R.M., Black, C.M., Denton, C.P. (2008). Single-nucleotide polymorphisms in CCL2 gene are not associated with susceptibility to systemic sclerosis. JOURNAL OF RHEUMATOLOGY, 35 (5), 839-844.
Madani, G., Katz, R.D., Haddock, J.A., Denton, C.P., Bell, J.R. (2008). The role of radiology in the management of systemic sclerosis.. CLINICAL RADIOLOGY, 63 (9), 959-967. doi:10.1016/j.crad.2008.05.007
Merkel, P.A., Silliman, N.P., Denton, C.P., Furst, D.E., Khanna, D., Emery, P., ...Akesson, A. (2008). Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 59 (5), 699-705. doi:10.1002/art.23564
Baker, D., Denton, C. (2008). Vascular Complications of Systemic Sclerosis: A Molecular Perspective. In Abraham, D., Handler, C., Dashwood, M., Coghlan, G. (Eds.), Vascular Complications in Human Disease: Mechanisms and Consequences. (pp. 119-127). London: Springer-Verlag.

2007

Fonseca, C., Lindahl, G., Ponticos, M., Sestini, P., Renzoni, E.A., Spagnolo, P., ...McHugh, N. (2007). A polymorphism in the CTGF promoter region associated with systemic sclerosis. New England Journal of Medicine, 357 (12), 1210-1220.
Eckes, B., Zweers, M.C., Peters, A., Denton, C.P., Faessler, R., Krieg, T. (2007). Ablation of integrin-linked kinase in fibroblasts: Altered mechanical properties resulting in disturbed wound healing.
Denton, C., Black, C. (2007). Blocage de l'endothéline dans la sclérodermie systémique : rationnel et bénéfice clinique. Revue de Medecine Interne, 28 (SUPPL. 3), doi:10.1016/S0248-8663(07)80019-1
Goh, N.S.L., Veeraraghavan, S., Desai, S.R., Cramer, D., Hansell, D.M., Denton, C.P., ...Wells, A.U. (2007). Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis and Rheumatism, 56 (6), 2005-2012. doi:10.1002/art.22696
Walker, U.A., Tyndall, A., Czirják, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., ...Riemekasten, G. (2007). Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group database. Annals of the Rheumatic Diseases, 66 (6), 754-763. doi:10.1136/ard.2006.062901
Rubin, L.J., Black, C.M., Denton, C.P., Seibold, J.R. (2007). Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease.
Khan, K., Leoni, P., Hoyles, R.K., Shiwen, X., Abraham, D.J., Denton, C.P. (2007). Constitutive activation of p42/44 MAP Kinase signalling in mice with fibroblast-specific deletion of TRII.
Xu, S.-.W., Renzoni, E.A., Kennedy, L., Howat, S., Chen, Y., Pearson, J.D., ...Black, C.M. (2007). Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. MATRIX BIOLOGY, 26 (8), 625-632. doi:10.1016/j.matbio.2007.06.003
Shi-wen, X., Kennedy, L., Renzoni, E.A., Bou-Gharios, G., du Bois, R.M., Black, C.M., ...Leask, A. (2007). Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts.. ARTHRITIS AND RHEUMATISM, 56 (12), 4189-4194. doi:10.1002/art.23134
Shiwen, X., Liu, S., Kennedy, L., Black, C.M., Denton, C.P., Least, A., Abraham, D.J. (2007). Focal adhesion kinase is necessary for pro-fibrotic gene expression in normal and scleroderma fibroblasts.
Pope, J.E., Black, C., Matucci-Cerinic, M., Denton, C.P., Furst, D.E., Korn, J.H., ...Seibold, J.R. (2007). Functional correlates of reduction of digital ulcers by Bosentan therapy in patients with systemic sclerosis (SSC).
Fonseca, C., Denton, C.P. (2007). Genetic association studies in systemic sclerosis: more evidence of a complex disease. J.Rheumatol., 34 (5), 903-905.
Fonseca, C., Denton, C.P. (2007). Genetic association studies in systemic sclerosis: More evidence of a complex disease. JOURNAL OF RHEUMATOLOGY, 34 (5), 903-905.
Weibel, L., Howell, K.J., Visentin, M.T., Rudiger, A., Denton, C.P., Zulian, F., ...Harper, J.I. (2007). Laser Doppler flowmetry for assessing localized scleroderma (morphoea) in children.
Weibel, L., Howell, K.J., Visentin, M.T., Rudiger, A., Denton, C.P., Zulian, F., ...Harper, J.I. (2007). Laser Doppler Flowmetry for assessing localized scleroderma in children. Arthritis Rheum, 56 (10), 3489-3495.
Nihtyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P. (2007). Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - A retrospective analysis. Rheumatology, 46 (3), 442-445. doi:10.1093/rheumatology/kel244
Tennent, G.A., Dziadzio, M., Triantafillidou, E., Davies, P., Gallimore, J.R., Denton, C.P., Pepys, M.B. (2007). Normal circulating serum amyloid P component concentration in systemic sclerosis. Arthritis Rheum, 56 (6), 2013-2017. doi:10.1002/art.22694
Sonnylal, S., Denton, C.P., Zheng, B., Keene, D.R., He, R., Adams, H.P., ...Behringer, R.R. (2007). Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. ARTHRITIS AND RHEUMATISM, 56 (1), 334-344. doi:10.1002/art.22328
Gliddon, A.E., Dore, C.J., Black, C.M., McHugh, N., Moots, R., Denton, C.P., ...Chakravarty, K. (2007). Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. ARTHRITIS AND RHEUMATISM, 56 (11), 3837-3846. doi:10.1002/art.22965
Denton, C.P., Merkel, P.A., Furst, D.E., Khanna, D., Emery, P., Hsu, V.M., ...Akesson, A. (2007). Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.. Arthritis and Rheumatism, 56 (1), 323-333. doi:10.1002/art.22289
Shand, L., Lunt, M., Nihtyanova, S., Hoseini, M., Silman, A., Black, C.M., Denton, C.P. (2007). Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis and Rheumatism, 56 (7), 2422-2431. doi:10.1002/art.22721
Penn, H., Howie, A.J., Kingdon, E.J., Bunn, C.C., Stratton, R.J., Black, C.M., ...Denton, C.P. (2007). Scleroderma renal crisis: patient characteristics and long-term outcomes.. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 100 (8), 485-494. doi:10.1093/qjmed/hcm052
Penn, H., Howie, A.J., Kingdon, E.J., Bunn, C.C., Stratton, R.J., Black, C.M., ...Denton, C.P. (2007). Scleroderma renal crisis-patient characteristics and outcomes in 110 cases from a single centre.
Pepys, M.B., Terment, G.A., Denton, C.P. (2007). Serum amyloid P and fibrosis in systemic sclerosis: comment on the article by Terment et al - Reply. Arthritis Rheum, 56 (12), 4229-4230. doi:10.1002/art.23150
Buch, M.H., Denton, C.P., Furst, D.E., Guillevin, L., Rubin, L.J., Wells, A.U., ...Chadha-Boreham, H. (2007). Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. ANNALS OF THE RHEUMATIC DISEASES, 66 (2), 169-173. doi:10.1136/ard.2006.054866
Rubin, L.J., Black, C.M., Denton, C.P., Seibold, J.R. (2007). Systemic sclerosis and related connective tissue diseases: present and future. ARTHRITIS RESEARCH & THERAPY, 9 doi:10.1186/ar2185
Woodhead, F.A., Sato, H., Desai, S.R., Hoyles, R.K., Wells, A.U., Welsh, K.I., ...Dubois, R.M. (2007). Systemic sclerosis-related diffuse pulmonary fibrosis quantified by high resolution computed tomography: Autoantibody and HLA associations.
Zulian, F., Woo, P., Athreya, B.H., Laxer, R.M., Medsger, T.A., Lehman, T.J.A., ...Russo, R. (2007). The pediatric rheumatology European Society American College of Rheumatology European league against rheumatism provisional classification criteria for juvenile systemic sclerosis. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 57 (2), 203-212. doi:10.1002/art.22551
Zulian, F., Woo, P., Athreya, B.H., Laxer, R.M., Medsger, T.A., Lehman, T.J., ...Russo, R. (2007). The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum, 57 (2), 203-212.
Denton, C.P. (2007). Therapeutic targets in systemic sclerosis.. ARTHRITIS RESEARCH & THERAPY, 9 doi:10.1186/ar2190
Denton, C.P., Nihtyanova, S.I. (2007). Therapy of pulmonary arterial hypertension in systemic sclerosis: an update.. Current Rheumatology Reports, 9 (2), 158-164. doi:10.1007/s11926-007-0011-4
Lytton, S.D., Denton, C.P., Nutzenberger, A.M. (2007). Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: Clinical efficacy and potential mechanisms of action.
Serednicka, K., Smyth, A.E., Black, C.M., Denton, C.P. (2007). Using a self-reported functional score to assess disease progression in systemic sclerosis.. Rheumatology, 46 (7), 1107-1110. doi:10.1093/rheumatology/kel432

2006

Serednicka, K., Klareskog, L., Smyth, A.E., Black, C.M., Denton, C.P. (2006). A longitudinal comparison of the Scleroderma Functional Score with the HAQ disability index.
Hoyles, R.K., Ellis, R.W., Wellsbury, J., Lees, B., Newlands, P., Goh, N.S.L., ...McHugh, N.J. (2006). A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and Rheumatism, 54 (12), 3962-3970. doi:10.1002/art.22204
Ponticos, M., Holmes, A.M., Fonseca, C., Bou-Gharios, G., Denton, C.P., Black, C.M., Abraham, D.J. (2006). A novel TGF-beta response element located in the human collagen type I alpha 2 far upstream enhancer is SMAD-independent.
Hoyles, R.K., Khan, K., Shiwen, X., Lindahl, G.E., Garcia, P., Wells, A.U., ...Denton, C.P. (2006). Alveolar epithelial cell injury triggers lung fibrosis in a mouse model of scleroderma..
Akram, M.R., Handler, C.E., Williams, M., Carulli, M.T., Andron, M., Black, C.M., ...Coghlan, J.G. (2006). Angiographically proven coronary artery disease in scleroderma. RHEUMATOLOGY, 45 (11), 1395-1398. doi:10.1093/rheumatology/kel120
Hoyles, R.K., Black, C.M., du Bois, R.M., Denton, C.P., Wells, A.U. (2006). Autoantibody profile rather than extent of skin disease predicts severity of pulmonary fibrosis in systemic sclerosis.
Shiwen, X., Leask, A., Renzoni, E., Howat, S., Bou-Gharios, G., Pearson, J., ...Black, C.M. (2006). Bosentan attenuates the profibrotic gene expression profile of lung fibroblasts in scleroderma.
Black, C., Denton, C.P., Furst, D.E., Matucci-Cerinic, M., Mayes, M.D., Popes, J., ...Korn, J.H. (2006). Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis open label extension to a double-blind trial.
Denton, C.P., Humbert, M., Rubin, L., Black, C.M. (2006). Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.. Annals of the Rheumatic Diseases, 65 (10), 1336-1340. doi:10.1136/ard.2005.048967
Rigamonti, C., Shand, L.M., Feudjo, M., Bunn, C.C., Black, C.M., Denton, C.P., Burroughs, A.K. (2006). Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut, 55 (3), 388-394. doi:10.1136/gut.2005.075002
Chen, Y., Shi-wen, X., Eastwood, M., Black, C.M., Denton, C.P., Leask, A., Abraham, D.J. (2006). Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts.. Arthritis and Rheumatism, 54 (4), 1309-1316.
Fonseca, C., Renzoni, E., Sestini, P., Pantelidis, P., Lagan, A., Bunn, C., ...Denton, C.P. (2006). Endothelin axis polymorphisms in patients with scleroderma. Arthritis and Rheumatism, 54 (9), 3034-3042.
Dziadzio, M., Anastassiades, C.P., Hawkins, P.N., Potter, M., Gabrielli, A., Brough, G.M., ...Denton, C.P. (2006). From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature. CLINICAL RHEUMATOLOGY, 25 (1), 3-15. doi:10.1007/s10067-004-1076-3
Pope, J.E., Black, C., Matucci-Cerinic, M., Denton, C.P., Furst, D.E., Korn, J.H., ...Seibold, J.R. (2006). Functional correlates of reduction of digital ulcers by bosentan therapy in patients with systemic sclerosis (SSc)..
Fonseca, C., Lindahl, G.E., Ponticos, M., Garcia, P., Holmes, A., Xu, S.-.W., ...Denton, C.P. (2006). Functional polymorphism in the CTGF promoter is associated with systemic sclerosis and identifies a novel repressor site.
Gliddon, A.E., Dore, C.J., Maddison, P.J. (2006). Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 55 (3), 473-479. doi:10.1002/art.21999
Denton, C.P., Khan, K., Leoni, P., Shiwen, X., Abraham, D.J., Black, C.M. (2006). Key features of late-stage systemic sclerosis are replicated through conditional deletion of the type II TGF beta receptor in fibroblasts.
Kingdon, E.J., Mani, A.R., Frost, M.T., Denton, C.P., Powis, S.H., Black, C.M., Moore, K. (2006). Low plasma protein Nitrotyroxine levels distinguish primary Raynaud's phenomenon from scleroderma.. Annals of the Rheumatic Diseases, 65 952-954.
Hoyles, R.K., Shiwen, X., Lindahl, G.E., Khan, K., Abraham, D.J., Black, C.M., Denton, C.P. (2006). Lung fibroblast gene expression and fibroblast - Alveolar epithelial cell cross-talk in a transgenic mouse model of systemic sclerosis.
Leask, A., Kennedy, L., van Beek, J., Chen, Y., Shi-wen, X., Denton, C.P., ...Black, C.M. (2006). Matrix contraction by scleroderma fibroblasts requires TGF beta receptor ALK5, ras/MEK/ERK and syndecan 4.
Denton, C.P., Black, C.M., Abraham, D.J. (2006). Mechanisms and consequences of fibrosis in systemic sclerosis.. NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2 (3), 134-144. doi:10.1038/ncprheum0115
Distler, O., Behrens, F., Huscher, D., Foeldvari, I., Zink, A., Nash, P., ...Seibold, J. (2006). Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. RHEUMATOLOGY, 45 (12), 1455-1457. doi:10.1093/rheumatology/kel273
Hoyles, R.K., Khan, K., Shiwen, X., Lindahl, G.E., Garcia, P., Wells, A.U., ...Denton, C.P. (2006). Perturbed transforming growth factor beta signalling in fibroblasts increases the susceptibility of alveolar epithelial cells to injury in a novel mouse model of systemic sclerosis.
Rajkumar, V.S., Shiwen, X., Bostrom, M., Leoni, P., Muddle, J., Ivarsson, M., ...Black, C.M. (2006). Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. American Journal Of Pathology, 169 (6), 2254-2265. doi:10.2353/ajpath.2006.060196
Aden, N.H., Shiwen, X., Denton, C.P., Black, C.M., Abraham, D.J., Stratton, R.J. (2006). Proteomic studies of scleroderma lesional skin show delayed keratinocyte maturation.
Williams, M.H., Handler, C.E., Akram, R., Smith, C.J., Das, C., Smee, J., ...Coghlan, J.G. (2006). Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. European Heart Journal, 27 (12), 1485-1494.
Waters, C.E., Xu, S.W., Denton, C.P., Abraham, D.J., Pearson, J.D. (2006). Signaling pathways regulating intercellular adhesion molecule 1 expression by endothelin 1 - Comparison with interleukin-1 beta in normal and scleroderma dermal fibroblasts. ARTHRITIS AND RHEUMATISM, 54 (2), 649-660. doi:10.1002/art.21572
Williams, M.H., Das, C., Handler, C.E., Akram, M.R., Davar, J., Denton, C.P., ...Coghlan, J.G. (2006). Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart, 92 (7), 926-932.
Denton, C.P., Black, C.M. (2006). Systemic Sclerosis, Scleroderma. In The Autoimmune Diseases, Fourth Edition. (pp. 369-379). .
Denton, C.P. (2006). Systemic sclerosis: clinical features and management. Medicine, 34 (11), 480-488. doi:10.1053/j.mpmed.2006.08.007
Lindahl, G.E., Holmes, A.M., Ponticos, M., Fonseca, C., Garcia, P., Shi-wen, X., ...Black, C. (2006). Transcriptional mechanisms regulating CTGF gene expression in systemic sclerosis: CBF binding, Sp1 activation by ERK1/2 and repression by Sp3.

2005

Denton, C.P., Lindahl, G.E., Khan, K., Shiwen, X., Ong, V.H., Gaspar, N.J., ...Eastwood, M. (2005). Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II Transforming growth factor-{beta} receptor (T{beta}RII{delta}k).. Journal of Biological Chemistry, 280 (16), 16053-16065. doi:10.1074/jbc.M413134200
Fonseca, C., Lindahl, G.E., Garcia, P., Holmes, A.M., Xu, S.W., du Bois, R.M., ...Abraham, D. (2005). Analysis of a functional polymorphism in the CTGF/CCN2 promoter in Systemic Sclerosis..
Minasian, M., Stanford, M., Graham, E., Denton, C.P., Black, C. (2005). Bilateral ischaemic retinal vasculopathy in scleroderma. British Journal of Ophthalmology, 89 (8), 1064-1065. doi:10.1136/bjo.2004.061499
Carulli, M.T., Ong, V.H., Ponticos, M., Shiwen, X., Abraham, D.J., Black, C.M., Denton, C.P. (2005). Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.. ARTHRITIS AND RHEUMATISM, 52 (12), 3772-3782. doi:10.1002/art.21396
Dziadzio, M., Smith, R.E., Abraham, D.J., Black, C.M., Denton, C.P. (2005). Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.. RHEUMATOLOGY, 44 (12), 1518-1524. doi:10.1093/rheumatology/kei088
Denton, C.P., Khan, K., Leoni, P., Xu, S.W., Abraham, D.J., Black, C.M. (2005). Conditional fibroblast-specific deletion of type 2 transforming growth factor beta receptor replicates digital contractures of late-stage scleroderma..
Carulli, M.T., Ong, V.H., Abraham, D.J., Coghlan, G.J., Black, C.M., Denton, C.P. (2005). Evaluation of CCL2 as a potential biomarker of pulmonary vascular disease in limited cutaneous systemic sclerosis.
Williams, M.H., Das, C., Handler, C.E., Akram, M.R., Davar, J., Denton, C.P., ...Coghlan, J.G. (2005). Improved survival of systemic sclerosis-associated pulmonary arterial hypertension (SSC-PAH) in the endothelin antagonist era.
Garg, N., Shand, L.M., Pathak, R., Myint, F., Baker, D., Black, C., ...Hamilton, G. (2005). Lower and upper limb macrovascular disease is uncommon in scleroderma but is amenable to angioplasty. Rheumatology, 44 I130.
Ong, V.H., Brough, G., Denton, C.P. (2005). Management of systemic sclerosis. Clinical Medicine, Journal of the Royal College of Physicians of London, 5 (3), 214-219. doi:10.7861/clinmedicine.5-3-214
Williams, M.H., Das, C., Handler, C.E., Akram, M.R., Davar, J., Denton, C.P., ...Coghlan, J.G. (2005). Modern treatment algorithms improve survival in systemic sclerosis associated pulmonary hypertension.
Dziadzio, M., Usinger, W., Leask, A., Abraham, D., Black, C.M., Denton, C., Stratton, R. (2005). N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma.. Quarterly Journal of Medicine, 98 (7), 485-492.
Williams, M.H., Handler, C.E., Akram, M.R., Das, C., Smee, J., Denton, C.P., ...Black, C.M. (2005). Prognostic value of brain natriuretic peptide (BNP) in patients with pulmonary arterial hypertension (PAH).
Robertson, L., Pignone, A., Kowal-Bielecka, O., Fiori, G., Denton, C.P., Matucci-Cerinic, M. (2005). Pulmonary arterial hypertension in systemic sclerosis: Diagnostic pathway and therapeutic approach. Annals of the Rheumatic Diseases, 64 (6), 804-807. doi:10.1136/ard.2004.026427
Rajkumar, V.S., Howell, K., Csiszar, K., Denton, C.P., Black, C.M., Abraham, D.J. (2005). Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis.. ARTHRITIS RESEARCH & THERAPY, 7 (5), R1113-R1123. doi:10.1186/ar1790
Lagan, A.L., Pantelidis, P., Renzoni, E.A., Fonseca, C., Beirne, P., Taegtmeyer, A.B., ...du Bois, R.M. (2005). Single-nucleotide polymorphisms in the SPARC gene are not associated with susceptibility to scleroderma. Rheumatology, 44 (2), 197-201. doi:10.1093/rheumatology/keh460
Williams, M.H., Das, C., Handler, C.E., Akram, M.R., Denton, C.P., Smith, C.J., ...Coghlan, J.G. (2005). Survival of patients with systemic sclerosis-associated pulmonary arterial hypertension has improved in the endothelin antagonist era.
Denton, C.P., Black, C.M. (2005). Targeted therapy comes of age in scleroderma.. TRENDS IN IMMUNOLOGY, 26 (11), 596-602. doi:10.1016/j.it.2005.09.002
Williams, M.H., Handler, C.E., Akram, M.R., Nair, D., Denton, C.P., Smith, C.J., ...Coghlan, J.G. (2005). Value of brain natriuretic peptide in pulmonary arterial hypertension.
Williams, M.H., Handler, C.E., Akram, R., Das, C., Smee, J., Denton, C.P., ...Black, C.M. (2005). Value of n-terminal pro brain natriuretic peptide in risk stratisfication and clinical management of patients with scleroderma-associated pulmonary arterial hypertension.

2004

Farge, D., Passweg, J., van Laar, J.M., Marjanovic, Z., Besenthal, C., Finke, J., ...Black, C. (2004). Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.. Annals of the Rheumatic Diseases, 63 (8), 974-981.
Saccardi, R., Tyndall, A., Coghlan, G., Denton, C., Edan, G., Emdin, M., ...Furst, D. (2004). Consensus statement concerning cardiotoxicity occurring during haemotopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.
Desai, S.R., Veeraraghavan, S., Hansell, D.M., Nikolakopolou, A., Goh, N.S., Nicholson, A.G., ...du Bois, R.M. (2004). CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.. Radiology, 232 (2), 560-567.
Korn, J.H., Mayes, M., Cerinic, M.M., Rainisio, M., Pope, J., Hachulla, E., ...Seibold, J.R. (2004). Digital ulcers in systemic sclerosis - Prevention by treatment with bosentan, an oral endothelin receptor antagonist. ARTHRITIS AND RHEUMATISM, 50 (12), 3985-3993. doi:10.1002/art.20676
Korn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., ...Seibold, J.R. (2004). Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.. Arthritis and Rheumatism, 50 (12), 3985-3993.
Lindahl, G.E., Shiwen, X., Chambers, R.C., Denton, C.P., Abraham, D.J., Black, C.M., Laurent, G.J. (2004). DNA BINDING-ACTIVITY OF CCAAT-BINDING FACTOR (CBF) IS STRONGLY ENHANCED IN ACTIVATED LUNG FIBROBLASTS FROM PATENTS WITH SYSTEMIC SCLEROSIS. RHEUMATOLOGY, 43 98-99.
Xu, S.-.W., Howat, S.L., Renzoni, E.A., Holmes, A., Pearson, J.D., Dashwood, M.R., ...Black, C.M. (2004). Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK.. JOURNAL OF BIOLOGICAL CHEMISTRY, 279 (22), 23098-23103. doi:10.1074/jbc.M311430200
Xu, S.W., Howat, S.L., Renzoni, E.A., Holmes, A., Pearson, J.D., Dashwood, M.R., ...Black, C.M. (2004). Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK.. Journal of Biological Chemistry, 279 (22), 23098-23103. doi:10.1074/jbc.M311430200
Xu, S.W., Chen, Y.L., Denton, C.P., Eastwood, M., Renzoni, E.A., Bou-Gharios, G., ...Black, C.M. (2004). Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Molecular Biology of the Cell, 15 (6), 2707-2719. doi:10.1091/mbc.E03-12-0902
Renzoni, E.A., Abraham, D.J., Howat, S., Shi-Wen, X., Sestini, P., Bou-Gharios, G., ...Denton, C.P. (2004). Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts.. Respiratory Research, 5 (1), 24-.
Leask, A., Denton, C.P., Abraham, D.J. (2004). Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma.. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 122 (1), 1-6. doi:10.1046/j.0022-202X.2003.22133.x
Denton, C.P., Black, C.M. (2004). Pulmonary Arterial Hypertension in Connective Tissue Disease. .
Denton, C.P., Black, C.M. (2004). Scleroderma--clinical and pathological advances.. Best Practice and Research Clinical Rheumatology, 18 (3), 271-290.
Dziadzio, M., Smith, R.E., Abraham, D.J., Stratton, R.J., Gabrielli, A., Black, C.M., Denton, C.P. (2004). Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review.. Clinical and Experimental Rheumatology, 22 (3), 356-367.
Denton, C.P., Ong, V.H. (2004). Systemic Sclerosis. .
Mukerjee, D., Yap, L.B., Ong, V., Denton, C.P., Howells, K., Black, C.M., Coghlan, J.G. (2004). The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.. Annals of the Rheumatic Diseases, 63 (12), 1627-1631.
Sato, H., Lagan, A.L., Alexopoulou, C., Vassilakis, D.A., Ahmad, T., Pantelidis, P., ...Black, C. (2004). The TNF-863A Allele Strongly Associates with Anticentromere Antibody Positivity in Scleroderma. Arthritis and Rheumatism, 50 (2), 558-564. doi:10.1002/art.20065
Denton, C.P., Abraham, D.J. (2004). Transgenic analysis of scleroderma: understanding key pathogenic events in vivo.. AUTOIMMUNITY REVIEWS, 3 (4), 285-293. doi:10.1016/j.autrev.2003.10.003

2003

Smyth, A.E., MacGregor, A.J., Mukerjee, D., Brough, G.M., Black, C.M., Denton, C.P. (2003). A cross-sectional comparison of three self-reported functional indices in scleroderma. Rheumatology, 42 (6), 732-738.
Matucci- Cerinic, M., D'Angelo, S., Denton, C.P., Vlachoyiannopoulos, P., Silver, R. (2003). Assessment of lung involvement. Clinical and Experimental Rheumatology, 21 (3 SUPPL. 29),
Denton, C.P., Black, C.M. (2003). Bosentan for scleroderma associated pulmonary arterial hypertension - A subgroup analysis of two placebo controlled trials..
Gerry Coghlan, J., Denton, C.P. (2003). Cardiac Involvement in Scleroderma. .
Cheng, K.S., Tiwari, A., Boutin, A., Denton, C.P., Black, C.M., Morris, R., ...Seifalian, A.M. (2003). Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology, 42 (11), 1299-1305.
Holmes, A., Abraham, D.J., Chen, Y., Denton, C., Shi-wen, X., Black, C.M., Leask, A. (2003). Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. Journal of Biological Chemistry, 278 (43), 41728-41733.
(2003). Differentiation of primary and secondary raynaud's disease by carotid arterial stiffness. European Journal of Vascular and Endovascular Surgery, 25 (4), 336-341.
Swale, V.J., Perrett, C.M., Denton, C.P., Black, C.M., Rustin, M.H. (2003). Etanercept-induced systemic lupus erythematosus. Clinical and Experimental Dermatology, 28 (6), 604-607.
Denton, C.P., Zheng, B., Evans, L.A., Shi-wen, X., Ong, V.H., Fisher, I., ...de Crombrugghe, B. (2003). Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. Journal of Biological Chemistry, 278 (27), 25109-25119. doi:10.1074/jbc.M300636200
Ong, V.H., Evans, L.A., Shiwen, X., Fisher, I.B., Rajkumar, V., Abraham, D.J., ...Denton, C.P. (2003). Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis and Rheumatism, 48 (7), 1979-1991. doi:10.1002/art.11164
Mukerjee, D., St George, D., Coleiro, B., Knight, C., Denton, C.P., Davar, J., ...Coghlan, J.G. (2003). Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Annals of the Rheumatic Diseases, 62 (11), 1088-1093.
Denton, C.P., Black, C.M. (2003). Pulmonary hypertension in systemic sclerosis. Rheumatic Disease Clinics of North America, 29 (2), 335-49, vii.

2002

Denton, C.P., Haddock, J., Black, C.M. (2002). Assessment of systemic sclerosis. In Isenberg, D.A., Renton, P. (Eds.), Imaging in Rheumatology. Oxford University Press.
Zheng, B., Zhang, Z., Black, C.M., de Crombrugghe, B., Denton, C.P. (2002). Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. American Journal of Pathology, 160 (5), 1609-1617.
Balbir-Gurman, A., Denton, C.P., Nichols, B., Knight, C.J., Nahir, A.M., Martin, G., Black, C.M. (2002). Non-invasive measurement of biomechanical skin properties in systemic sclerosis. Annals of the Rheumatic Diseases, 61 (3), 237-241.
Denton, C.P. (2002). Systemic sclerosis. Medicine, 30 (10), 36-41. doi:10.1383/medc.30.10.36.28247
Black, C.M., Denton, C.P. (2002). Systemic sclerosis and related disorders. In Warrell, D.A., Cox, T.M., Firth, J.D., Benz, E.J. (Eds.), Oxford Textbook of Medicine. Oxford University Press.
Denton, C.P., Black, C.M. (2002). Vascular scleroderma. In Asheron, R., Triplett, D., Cervera, R. (Eds.), Vascular manifestations of systemic autoimmune diseases. CRC Press.

2001

Denton, C.P., Shiwen, X., Zheng, B., Rajkumar, V., Abraham, D.J., de Crombrugghe, R., Black, C.M. (2001). A fibrotic phenotype is induced by expression of a mutant human TGF beta receptor in transgenic mice. RHEUMATOLOGY, 40 78-79.
Denton, C.P., Bing, Z., Xu, S.W., Zhang, Z.P., Bou-Gharios, G., Eberspaecher, H., ...de Crombrugghe, B. (2001). Activation of a fibroblast-specific enhancer of the Pro alpha 2(I) collagen gene in tight-skin mice. Arthritis and Rheumatism, 44 (3), 712-722. doi:10.1002/1529-0131(200103)44:3<712::AID-ANR121>3.0.CO;2-1
Denton, C.P., Zheng, B., Shiwen, X., Zhang, Z., Bou-Gharios, G., Eberspaecher, H., ...De Crombrugghe, B. (2001). Activation of a fibroblast-specific enhancer of the proα2(I) collagen gene in tight-skin mice. Arthritis and Rheumatism, 44 (3), 712-722. doi:10.1002/1529-0131(200103)44:3<712::AID-ANR121>3.0.CO;2-1
Tormey, V.J., Bunn, C.C., Denton, C.P., Black, C.M. (2001). Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology, 40 (10), 1157-1162.
Antoniv, T.T., De Val, S., Wells, D., Denton, C.P., Rabe, C., de Crombrugghe, B., ...Bou-Gharios, G. (2001). Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene. Journal of Biological Chemistry, 276 (24), 21754-21764.
Denton, C.P., Black, C.M. (2001). Combination therapies for systemic sclerosis.. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 23 (1-2), 109-129. doi:10.1007/s002810100058
Shi-wen, X., Denton, C.P., Dashwood, M.R., Holmes, A.M., Bou-Gharios, G., Pearson, J.D., ...Abraham, D.J. (2001). Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. Journal of Investigative Dermatology, 116 (3), 417-425.
Xu, S.W., Denton, C.P., Dashwood, M.R., Holmes, A.M., Bou-Gharios, G., Pearson, J.D., ...Abraham, D.J. (2001). Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 116 (3), 417-425. doi:10.1046/j.1523-1747.2001.01256.x
Smyth, A.E., Denton, C.P., Brough, G.M., Mukerjee, D., Black, C.M. (2001). Prospective comparison of three self-reported disease indices in scleroderma. RHEUMATOLOGY, 40 115.
MacGregor, A.J., Canavan, R., Knight, C., Denton, C.P., Davar, J., Coghlan, J., Black, C.M. (2001). Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. RHEUMATOLOGY (OXFORD), 40 (4), 453-459.
Wollheim, F.A., Denton, C.P., Abraham, D.J. (2001). Sixth international workshop on scleroderma research, Oxford, UK, 30 July - 2 August 2000. Arthritis Research and Therapy, 3 (1), 34-40. doi:10.1186/ar137
Denton, C.P., Abraham, D.J. (2001). Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Current Opinion in Rheumatology, 13 (6), 505-511.
Coleiro, B., Marshall, S.E., Denton, C.P., Howell, K., Blann, A., Welsh, K.I., Black, C.M. (2001). Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology, 40 (9), 1038-1043.
Denton, C.P., Black, C.M. (2001). Vascular manifestations of progressive systemic sclerosis. In Vascular Manifestations of Systemic Autoimmune Diseases. (pp. 319-342). .

2000

Denton, C.P., Black, C.M. (2000). Combination therapy for systemic sclerosis. Springer Seminars in Rheumatology,
Denton, C.P., Howell, K., Stratton, R.J., Black, C.M. (2000). Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clinical and Experimental Rheumatology, 18 (4), 499-502.
Denton, C.P., Black, C.M. (2000). Scleroderma and related disorders: therapeutic aspects. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 14 (1), 17-35. doi:10.1053/berh.1999.0075
Denton, C.P., Black, C.M. (2000). Scleroderma and related disorders: therapeutic aspects. Best Practice and Research Clinical Rheumatology, 14 (1), 17-35.
Denton, C.P., Black, C.M. (2000). Systemic sclerosis in childhood. In Harper, J.I., Oranje, A.P., Prose, N.S. (Eds.), Textbook of Paediatric Dermatology. .

1999

Black, C.M., Silman, A.J., Herrick, A.I., Denton, C.P., Wilson, H., Newman, J., ...Shi-Wen, X. (1999). Interferon-σ does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism, 42 (2), 299-305. doi:10.1002/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R
Dziadzio, M., Denton, C.P., Smith, R., Howell, K., Blann, A., Bowers, E., Black, C.M. (1999). Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum., 42 (12), 2646-2655.
Denton, C.P., Black, C.M. (1999). Novel therapeutic strategies in scleroderma.. Current rheumatology reports, 1 (1), 22-27. doi:10.1007/s11926-999-0020-6
Denton, C.P., Bunce, T.D., Darado, M.B., Roberts, Z., Wilson, H., Howell, K., ...Black, C.M. (1999). Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon 5. Rheumatology, 38 (4), 309-315.
Denton, C.P., Black, C.M. (1999). Systemic sclerosis: An overview of pathogenesis and treatment. CPD Rheumatology, 1 (1), 33-39.

1998

Bunn, C.C., Denton, C.P., Shi-Wen, X., Knight, C., Black, C.M. (1998). ANTI-RNA polymerases and other autoantibody specificities in systemic sclerosis. British Journal of Rheumatology, 37 (1), 15-20. doi:10.1093/rheumatology/37.1.15
Xu, S.W., Denton, C.P., Dashwood, M.R., Abraham, D.J., Black, C.M. (1998). Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 31 S545-S547. doi:10.1097/00005344-199800001-00157
Shi-wen, X., Denton, C.P., Holmes, A., Dashwood, M.R., Abraham, D.J., Black, C.M. (1998). Endothelins: Effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. Journal of Cardiovascular Pharmacology, 31
Denton, C.P., Shi-Wen, X., Sutton, A., Abraham, D.J., Black, C.M., Pearson, J.D. (1998). Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 114 (2), 293-300.

1997

Denton, C.P., Cailes, J.B., Phillips, G.D., Wells, A.U., Black, C.M., Bois, R.M.D.U. (1997). Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. British Journal of Rheumatology, 36 (2), 239-243. doi:10.1093/rheumatology/36.2.239
Denton, C.P., Shi-wen, X., Black, C.M., Pearson, J.D. (1997). Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. Journal of Investigative Dermatology, 108 (3), 269-274. doi:10.1111/1523-1747.ep12286455
Shi-Wen, X.U., Denton, C.P., McWhirter, A., Bou-Gharios, G., Abraham, D.J., Du Bois, R.M., Black, C.M. (1997). Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis and Rheumatism, 40 (7), 1237-1244. doi:10.1002/1529-0131(199707)40:7<1237::AID-ART7>3.0.CO;2-Y

1996

Denton, C.P., Black, C.M. (1996). Management of Hand Involvement in Systemic Sclerosis. Hand Therapy, 1 (4), 13-15. doi:10.1177/175899839600100406
Denton, C.P., Shiwen, X., Welsh, K.I., Pearson, J.D., Black, C.M. (1996). Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture. Journal of Rheumatology, 23 (4), 633-638.
Denton, C.P., Black, C.M., Korn, J.H., De Crombrugghe, B. (1996). Systemic sclerosis: Current pathogenetic concepts and future prospects for targeted therapy. Lancet, 347 (9013), 1453-1458. doi:10.1016/S0140-6736(96)91687-6

1995

Denton, C.P., Bickerstaff, M.C.M., Shiwen, X., Carulli, M.T., Haskard, D.O., Dubois, R.M., Black, C.M. (1995). Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. BRITISH JOURNAL OF RHEUMATOLOGY, 34 (11), 1048-1054.
Black, C.M., Denton, C.P. (1995). The management of systemic sclerosis. Rheumatology, 34 (1), 3-7. doi:10.1093/rheumatology/34.1.3

1994

Denton, C.P., Sweny, P., Abdulla, A., Black, C.M. (1994). Acute renal failure occurring in scleroderma treated with cyclosporin a: A report of three cases. Rheumatology, 33 (1), 90-92. doi:10.1093/rheumatology/33.1.90

1993

Ostlere, L.S., Harris, D., Denton, C., Williams, J., Black, C., Rustin, M.H.A. (1993). Boxing-glove hand: An unusual presentation of dermatitis artefacta. Journal of the American Academy of Dermatology, 28 (1), 120-122. doi:10.1016/S0190-9622(08)80853-5

1900

Nikitorowicz-Buniak, J. (1900). Abnormally Differentiating Keratinocytes in the Epidermis of Systemic Sclerosis Patients Show Enhanced Secretion of CCN2 and S100A. doi:10.1038/jid.2014.253
Donovan, J., Denton, C., Norman, J., Abraham, D. (1900). Analysis of cutaneous wound healing in a Platelet-derived growth factor receptor alpha knockout mouse. Presented at: 12th International Workshop on Scleroderma Research Cambridge.
Donovan, J., Xu, S., Denton, C., Norman, J., Abraham, D. (1900). Analysis of specific PDGFRα and PDGFRβ signal transduction pathways in SSc fibroblasts and examination of cutaneous wound healing in a PDGFRα knockout mouse. Presented at: 2nd Scleroderma World Congress Madrid.
Evans, I.C., Barnes, J.L., Garner, I.M., Pearce, D.R., Maher, T.M., Shiwen, X., ...Laurent, G.J. (1900). Epigenetic regulation of cyclooxygenase-2 by c8orf4 in patients with pulmonary fibrosis.
Derrett-Smith, E.C. (1900). Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors. Rheumatology, doi:10.1093/rheumatology/ket213
Donovan, J., Xu, S., Rajkumar, V., Denton, C., Norman, J., Abraham, D. (1900). Selective targeting of the Platelet-derived growth factor ligand-receptor pathway – relevance to the pathogenesis of Systemic Sclerosis. Presented at: 11th International Workshop on Scleroderma Research Boston.
Saracino, A. (1900). The molecular aetiopathogenesis of adult morphoea. (Doctoral Dissertation). University College London.
Quillinan, N.P. (1900). Treatment of Diffuse Cutaneous Systemic Sclerosis with Hyperimmune Caprine Serum. (Doctoral Dissertation). UCL (University College London).